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Thymus-maturated lymphocytes (T-cells) provide the immune system with the 
ability to appropriately detect and respond to diseases through a unique receptor.  These T-
cell receptors (TCRs) differentiate between self and foreign peptide antigens and form by 
hypervariable gene rearrangement and imprecise recombination, both of which can 
potentially generate upwards of 1018 unique TCRs in humans.  Our work focused on 
characterizing the chicken ovalbumin (OVA) antigen specific parent hybridoma DO11.10 
T-cell with (1) high-throughput sequencing, (2) structural analyses, and (3) TCR 
reconstitution into T-cells to determine the important factors linking TCR sequence, 
structure, and function.  The repertoire of TCR sequences generated in mice immunized 
with OVA antigen were sequenced using a novel mouse TCR gene primer set.  Using high-
throughput sequencing, we determined the relative gene and hypervariable sequence 
frequencies in the repertoire.  Based on our results in these experiments, no significant 
repertoire differences were found between mouse treatment groups.  Additionally no 
sequences with similarity to previously studied OVA-specific T-cell clones were 
recovered.  The antigen binding loops of TCRs have a high degree of structural similarity 
across diverse receptor sequences.  Key residues in the complementarity determining, 
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antigen-binding regions of TCRs form conserved canonical loop structures.  Here we 
evaluated 249 TCRs and TCR-like antibodies to determine the prevalence of these key 
residues.  Expanding on previous work, we found four new canonical class conformations 
and validated the key residues for these classes.  Finally, we report our work to reconstitute 
engineered TCRs onto the TCR-deficient mouse 58-/- hybridoma line.  We modified an 
existing antibody expression system to display the engineered TCRs in the hybridomas for 
activation assays.  Expression of the TCR was found to be highly sensitive to the N-
terminal signal sequence on each receptor chain.  Additional work began to examine how 
these signal sequences alter stable expression and surface display of these TCRs.  This 
work is important for the discovery of new methods and biological agents to target and 
respond to designed antigens, especially in the context of altering and engineering TCR 
specificity for therapeutic purposes.  
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Chapter 1:  Introduction and Background 
1.1: OVERVIEW OF THE ADAPTIVE IMMUNE SYSTEM 
The innate and adaptive immune systems consist of a complex cellular network to 
identify, signal, and neutralize antigens through a generic primary response and a more 
specific secondary response. Coordination of these highly evolved systems can provide 
protection against common pathogens, generating unique cellular and molecular responses 
to protect against the myriad of encountered antigens from the environment. The innate 
immune system provides an initial non-specific defense against infection by identifying 
foreign material, initiating the complement cascade, and activating the adaptive immune 
system. While this first response can protect against a variety of common pathogens it fails 
to keep pace with and incredibly diverse and often mutating array of antigens and 
pathogens present in the environment. Approximately four days after the innate response 
begins, the recruitment of immune cells and activation of the adaptive immune system 
initializes the generation of a more specific secondary response to the infection. 
The activated adaptive immune system provides a pathogen-specific, long-lasting 
response generated from naïve and effector lymphocytes (white blood cells). The two main 
cell types within the specific lymphocyte response involved in adaptive protection are B-
cells and T-cells. These two major cell types fill distinct and important immunological roles 
by using both antibody and cell-mediated responses to neutralize pathogens and target 
infected cells for removal. Within these lymphocyte cell types are additional cell subsets, 
which function to monitor, regulate, and remove cells as well as provide long-lasting 
immunological memory.  
After maturation in the bone marrow and thymus respectively, naïve B-cells and T-
cells produced during the initial adaptive immune response are clonotypic effector cells, 
meaning each cell type produces a unique protein construct in the form of an antibody or 
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membrane-bound T-cell receptor (TCR) to target the pathogen. This complex maturation 
process generates receptor diversity of approximately 1013 – 1018 for antibodies and TCRs 
respectively in humans, which is explained more in Chapter 1.3. The cells successfully 
targeting the infectious antigens, and/or pathogens are activated and stimulated further to 
help clear the infection from the host. 
Once the adaptive immune system resolves the infection, the majority of the 
activated effector cells are cleared by phagocytosis after death by neglect. A small fraction 
of the effector cells are reserved and recruited as memory cells to guard against future 
infections from the same pathogenic material. The maintenance of these memory cells 
allows individuals to build a cellular repertoire which can more rapidly respond and 
proliferate in the case of repeat exposure. The failure to convert effector cells to memory 
cells or the loss of memory cells in general can lead to immune disorders. 
The critical job of the adaptive immune system is the generation of an enormous 
diversity of antibodies and T-cell receptors which can theoretically respond against any 
antigen. Proper immune function requires the coordination of a complex network of genes, 
chemicals, proteins, receptors, and cells. Deficiencies in the adaptive immune system are 
characteristic of a variety of serious conditions including autoimmune disease, persistent 
infections, and severe combined immunodeficiency.  
1.2: LYMPHOCYTE MATURATION AND DEVELOPMENT 
1.2.1: B-cell Maturation 
Progenitor lymphoid cells in the bone marrow committed to becoming B-cells 
undergo somatic recombination and gene rearrangement to form an antigen binding 
clonotypic B-cell receptor (BCR). Negative selection deletes any immature B-cells with 
self-antigen reactivity the population. The remaining B-cells emerge from the bone marrow 
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and migrate to peripheral lymphoid organs where they wait for an activating signal. 
Thymus-dependent B-cell maturation requires two signals: first, binding of the BCR by a 
specific antigen, and second, interaction with an activated helper T-cell which is displaying 
a peptide from the same antigen. Alternatively, B-cell activation can occur in a T-cell 
independent manner for common antigens such as bacterial lipopolysaccharides (LPS). 
After receiving the activation signal, the mature B-cell undergoes somatic 
hypermutation and class switching to differentiate the cell further into either plasma or 
memory B-cells. Somatic hypermutation mutates antibody genes to increase the antigen 
affinity and specificity. Activated plasma B-cells proliferate and produce large quantities 
of secreted antibodies containing the antigen-binding domain of the BCR with a different 
constant domain for altered functionality and processing by effector molecules and cells. 
Memory B-cells have a prolonged life for future encounters with its cognate antigen. 
Succeeding antigen interactions reactivate the memory cells causing proliferation and 
further affinity maturation through somatic hypermutation in germinal centers. The 
maturation process rapidly responds to clear infections and provide a means to produce 
more effective immune responses over time with additional interactions with cognate 
antigens or pathogens.  
1.2.2: T-cell Maturation 
 Similar to B-cells, T-cells begin as progenitor lymphoid cells in the bone marrow 
which migrate to the thymus through the blood for thymic-specific maturation. This 
thymic-dependent maturation is how T-cells get their designation as thymic lymphocytes. 
T-cell maturation involves a series of steps within the thymus (Figure 1.1) as a progressive 
migration within sections of the thymus before moving to peripheral tissues and sites of 
infection. These maturation steps control the affinity and activity of the clonotypic T-cell 
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receptor (TCR) responsible for recognizing foreign antigens and delivering activation or 
kill signals to other cells. 
 
 
Figure 1.1: Diagram of T-cell development in a thymus capsule.  
T-cell precursors enter the thymus at the cortico-medullary region and migrate through the 
cortex then medulla for positive and negative selection respectively before leaving as naïve 
T-cells ready for antigen activation in the peripheral lymphoid tissue1. 
Upon arriving to the thymus, T-cell precursors enter a capsule within the thymic 
cortex to undergo somatic rearrangement to assemble the TCR genes. The imprecise 
recombinations generated during somatic rearrangement also cause the majority of gene 
products to fail from out-of-frame recombinations or undesirable stop codons. Cells with 
productive, in-frame TCRs then move through the cortex space for positive selection. 
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Positive selection sets the lower threshold affinity so the TCR can bind the MHC strongly 
enough to interrogate bound peptide. Cells failing to bind cortical epithelial cells during 
positive selection do not receive survival signals and die by neglect. Positively selected 
cells then migrate through the cortico-medullary junction into the medulla for negative 
selection where they interact with dendritic cells (DC) and medullary thymic epithelial 
cells (mTECs). Negative selection removes strongly binding TCRs providing central 
tolerance of self-peptides to prevent autoimmune disorders from self-reactive T-cells.  
 After negative selection, the non-self-reactive T-cells become naïve T-cells and 
leave the thymus for peripheral lymphoid organs in search of cognate antigen. The stringent 
affinity maturation process allows T-cells to screen cell surfaces rapidly to increase the 
probability of engaging cognate antigen. When a T-cell binds and activates from 
interactions with an antigen presenting cell (APC), the T-cell ceases lymphoid tissue 
migration, proliferates by clonal expansion, and differentiates. Activated T-cells 
differentiate into effector and memory cells capable of regulating other T-cell responses 
and have a prolonged life to ward off future infections. The scale of the cellular surfaces to 
monitor through one-to-one interaction with a recognized antigen requires the immune 
system to generate a diverse repertoire of TCRs and save the effective antigen engaging 
cells for immune memory.  
1.2.3: Antigen presentation  
T-cell mediated activation requires proper antigen presentation on the APC within 
the MHC binding groove. As the antigen loads into MHC, peptide residues interact with 
hydrophobic pockets in the binding groove (Figure 1.2) anchoring the peptide in place and 
exposing alternate residues for TCR interaction2. Modifying the anchoring and exposed 
residues in the peptide antigen has been shown to change the TCR-pMHC interaction and 
subsequent T-cell activation3. Antigen presentation allows T-cells a method to screen the 
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contents of cells or extracellular proteins collected from the environment for pathogenic 
material. The different processes for collecting endogenous and exogenous material also 
determine the MHC class molecule presenting the peptide and the types of responding T-
cell types. Endogenous peptides presented in MHC-I are interrogated by CD8+ T-cells and 
exogenous peptides in MHC-II by CD4+ T-cells. 
 
 
Figure 1.2: MHC binding groove with peptide anchoring pockets.  
This image shows the peptide (gray) loaded in the MHC binding groove flanked on either 
side by the α-helices with anchoring residues protruding into downward into the 
hydrophobic pockets of the MHC molecule. 
Nearly all cells in the body regularly present endogenous peptides regardless of 
infection status. Intracellular proteins are digested and transported to the endoplasmic 
reticulum (ER) where the peptide fragments load into MHC-I molecules. The peptide-
MHC then moves to the cell surface for recognition by cytotoxic CD8+ lymphocytes 
(CTLs). If an activated CTL recognizes the presented endogenous antigen it releases a 
focused blast of cytotoxins to kill only the neighboring infected cell. This controlled 
method to kill cells stems the spread of infection while preserving the health of surrounding 
cells and tissues. The cytotoxicity of CTLs is so potent and destructive, these cells require 
additional activation signals from either helper (CD4+) T-cells or mature dendritic cells. 
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In order to monitor extracellular material throughout the body, exogenous 
pathogens and materials are internalized through endocytosis. As the endocytic vesicle 
travels deeper into the cell it becomes more acidic and the internalized materials become 
digested by proteolytic activity. The antigen-laden endosomes fuses with other vesicles 
containing MHC-II molecules. Then with the aid of HLA-DM, the antigen-peptide loads 
into the MHC-II binding groove. The MHC-II binding groove has open ends, which allows 
presentation of longer peptide chains. This places fewer restrictions on the alignment or 
register of peptide within the binding groove. The different MHC registers also change the 
exposed peptide residues and subsequent T-cell activity4. Once the peptide loads into the 
MHC-II, the complex moves to the cell surface for presentation and interrogation by CD4+ 
T-cells. 
Unlike MHC-I, only a subset of immune cells are equipped with MHC-II molecules 
for regular antigen presentation. T-cells engaging pMHC-II on APCs are effector CD4+ T-
cells because they mediate the activation of both CTLs to kill infected cells and stimulate 
plasma B-cells to produce antibodies. The cellular coordination of antigen recognition and 
neutralization between B-cells and T-cells allows the adaptive immune system to respond 
appropriately to the many disorders hosts face from viruses, bacteria, and other immune 
diseases. 
1.2.4: The immune complex and T-cell activation 
T-cells provide the body with constant monitoring of self and foreign peptide 
antigens encountered on the surface of APC by a clonotypic αβ TCR heterodimer. The 
central α- and β-chains of the TCR are part of a larger immune complex including three 
dimers of membrane proteins forming a tetramer of dimers around the αβ-chain core 
(Figure 1.3). Two hetero-dimers comprised as CD3δ-CD3ε and CD3γ-CD3ε associate 
with the constant and transmembrane (TM) domains of the α- and β-chains respectively. 
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The third is a CD3ζζ homodimer, which associates with the positively charged arginine on 
the TM domain of the α-chain.  
 
 
Figure 1.3: Diagram of the T-cell immune complex. 
The immune complex on the surface of T-cells includes the αβ chains, CD3γδεζ –chains 
with ITAMs labeled in red, and a CD4 or CD8 co-receptor with Lck as they associate on 
the membrane and engage either MHC-I/MHC-II5. 
These six associated proteins translate the TCR-pMHC interactions into chemical 
signals through activation motifs. Intracellular immunereceptor tyrosine-based activation 
motifs (ITAMs) on these proteins initiate activation signaling though the biophysical 
activity of the αβ TCR chains6. Proteins CD3γ, -δ, and -ε each have one ITAM and CD3ζ 
has three for ten total ITAMs in the immune complex. For stable surface expression of the 
immune complex most of the CD3 proteins must be present in the ER and able to associate 
with the TCR αβ chains through coordinated residue charges in TM regions7. Failure to 
properly express or associate all the CD3 chains can critically diminish TCR surface 
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expression and cripple T-cell activation due to immune complex instability and decreased 
ITAMs8.  
The immune complex has two functionally distinct roles split between the 
extracellular and intracellular domains. The extracellular peptide-antigen recognition 
translates into intracellular cell activation signals through the biomechanical interactions 
between the proteins in the immune complex. Until TCR complexation occurs, the 
sensitive intracellular activation motifs remain occluded from the kinase activity of 
activation enzymes6,9. A current theory on this signal translation involves a two-step, serial 
triggering of TCR-pMHC engagement which coordinates the spatial orientation and 
structural deformations occurring during interaction between these surface molecules10.  
The first step involves the alignment of the TCR over the MHC α-helices in a 
diagonal orientation using MHC residues (α-65, α-69, α-155 for MHC-I and α57, α-61, and 
β-50 for MHC-II) (Figure 1.4) as guides11. The MHC interaction with CD4 or CD8 also 
restricts TCR alignment. The second step is the CDR3 peptide interrogation which either 
pushes or pulls the central strands of the TCR dimer tugging on the F-G loop in the β-chain 
constant domain. The deformation from the binding region through to the constant and TM 
domains reorients the inner-membrane domains of the surrounding accessory proteins in 
the immune complex exposing the CD3 ITAMs12. The piston-like TM translational 
movement of the TCR αβ chains also exposes the CD3ζ ITAMs from their association with 
the inner membrane. The lymphocyte –specific protein tyrosine kinase (Lck) co-receptor 




Figure 1.4: TCR-PMHC contact analysis. 
Alignments of MHC molecules colored based on the number of TCR contacts made using 
rainbow spectrum where blue is minimal contacts and red is the maximum number of 
contacts made for (A) MHC-I and (B) MHC-II molecules. 
The low probability of any given T-cell finding its cognate pMHC within the body 
requires TCRs to scan APC surfaces rapidly. The binding rate kinetics of TCR-pMHC 
interactions allow for rapid pMHC scanning due to a slow kon and rapid koff13. These 
binding kinetics give TCRs weaker but more specific interactions with the pMHC when 
chaperoned by co-accessory proteins in the immune complex. This also allows TCRs to 
quickly recognize antigen, activate, and move aside so another TCR on the same T-cell can 
interrogate the pMHC10. In this way a single pMHC can serially trigger a large number of 
immune complexes on the T-cell, amplifying the overall signal activation. 
During pMHC engagement and immune synapse formation, CD4 or CD8 co-
receptor is recruited futher activating the immune complex. This co-receptor serves to both 
stabilize and orient TCR binding by interacting with the invariant portion of the MHC and 
recruiting Lck to the synapse11. Lck associates with the endodomains of the CD4/CD8 
receptor and phosphorylates exposed CD3 ITAMS. Once ITAM phosphorylation reaches 
high enough levels, another protein molecule, ZAP-70 (CD3ζ-chain-associated protein) 
associates with phosphorylated CD3ζ, which can then act as a kinase to trigger a linker of 
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activated T-cells (LAT) scaffold protein causing further cascades of activation signals. 
Throughout this process, co-stimulatory or inhibitory signals from molecules and receptors 
regulate these T-cell activation molecules. Current technologies are investigating ways to 
utilize these regulatory signals for therapeutic purposes14.   
The functions of activated T-cells depend on their lineages as CD4+ or CD8+ cells. 
Each type is responsible for controlling different aspects of the immune system. Activated 
CD4+ cells release small soluble proteins called cytokines, such as interleukin-2 (IL-2) or 
interferon-γ (INF-γ), which may promote effector cell activation, induce MHC expression, 
or inhibit cell growth. Activated CD8+ cells or CTLs release cytotoxic proteins including 
perforin or granzyme which induce apoptosis in target cells. T-cells remain activated until 
the loss of activating signals through effector molecules or antigen engagement. 
Additionally without memory cell commitment these activated cells survive for only a few 
days which is long enough to resolve most infections15. 
1.3: LYMPHOCYTE REPERTOIRE GENERATION 
The adaptive immune system utilizes a diverse antigen binding repertoire with 
rigorously selected binding affinities for robust and specific antibody targeting and T-cell 
activation. This diversity in antigen binders is imperative for protecting against the nearly 
limitless variety of pathogens in the environment. Production of this diversity in B-cells 
and T-cells employs several mechanisms including combinatorial gene rearrangement, 
imprecise junctions between those recombined genes, and somatic hypermutation for 
antibody affinity maturation in B-cells. Combined these processes can potentially generate 
over 1013 and 1018 different antibody and TCR sequences respectively in humans16.  
The first level of genetic diversity occurs from gene rearrangements to combine 
different gene regions which generates millions of different gene combinations17. 
Antibodies and TCRs use three segments of genes to produce functional proteins consisting 
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of Variable-, Diversity-, and Joining-region (VDJ) genes. These gene segments recombine 
in two configurations as VJ in light or α-chains and VDJ in heavy- or β-chains in antibodies 
and TCRs respectively. Clusters of these genes are arrayed on the chromosome locus as 
shown in (Figure 1.5A). 
 
Figure 1.5: Diversity generation in the adaptive immune system. 
The immune system generates diversity in three main ways to engage foreign antigens with 
a limited amount of gene information though (A) V-, D-, and J-region gene recombinations 
from the various gene segments on the chromosome, (B) the imprecise junctions with 
formation of palindromic hairpins and N-nucleotide addition in the hypervariable CDR3, 
and (C) somatic hypermutation in the antibody genes to mutate and selectively maturate 
the antigen binding portions of the antibody (Source: The Immune System 3rd and 6th 
editions, Garland Science 2014)18. 
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The second level of diversity occurs in the imprecise hypervariable junctions 
formed between these recombined genes through addition and subtraction of nucleotides 
during rearrangement (Figure 1.5B). Junctional diversification occurs in all recombined 
chains except the antibody light chain. The random addition and subtraction of nucleotides 
at these junctions produces non-productive proteins with out-of-frame mutations or 
premature stop codons in the majority of these hypervariable junctions19. Cells with 
unproductive rearrangements will continue gene rearrangement with the remaining VDJ 
segments until either a functional antibody or TCR chain is produced or the cell dies. 
A third level of diversity in these immune receptors comes from the pairing between 
light- and heavy-chains or α- and β-chains in antibodies and TCRs respectively. These 
pairings can control structural features in the receptor including the binding region 
orientation angles. Theoretically every VJ combination can partner with any VDJ 
combination, but based on sequencing data there is some amount of pairing bias occurring 
possibly due to incompatible interfaces between the two combinations of variable 
domains20.  
Beyond the productive rearrangement of antibody genes, activated B-cells can 
undergo somatic hypermutation wherein the antigen-binding genes randomly mutate to 
select for higher affinity variants (Figure 1.5C). This process occurs in the germinal center 
of peripheral lymphoid organs and allows antibody producing B-cells to evolve more 
effective antibodies. With each succeeding B-cell reactivation, the antibody genes can 
undergo further somatic hypermutation. Unlike antibodies in B-cells, T-cells cannot further 
maturate TCRs after leaving the thymus. 
1.4: ANTIBODY AND TCR STRUCTURES 
TCRs are multi-domain heterodimers with the antigen binding region positioned at 
the N-terminus of the protein chains followed by invariant constant domains (Figure 
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1.6A). Each domain in these receptors consists of two parallel β-sheets linked by a disulfide 
bond between highly conserved cysteine residues to form an approximate β-barrel shape. 
The variable domain of each chain has three pMHC-binding loops known as the 
complementarity determining regions (CDRs) (Figure 1.6B). The third CDR of each chain 
comprises the hypervariable region formed during the rearrangement of the Variable-, 
Diversity-, and Joining-region genes. The antigen binding region of the receptor comprises 
the dimer formed from the α- and β-chains which locates CDR1 and CDR2 peripheral to 
the hyper-diverse CDR3s in a rotationally symmetric orientation. The variable domain is 
linked to the invariant constant and transmembrane domains, which closely associate with 
their complementary chain to stabilize the TCR dimer. 
Antibodies are large (~150 kDa) tetramer structures forming a dimer of light and 
heavy chain dimers. The N-terminus of each chain comprises a variable antigen-binding 
domain and the other domains are invariant constant domains. The variable domains form 
the antigen-binding region with six CDR loops directed towards the antigen interface. The 
CDR3 loops in antibody heavy and light chains are larger and more flexible hypervariable 
junctions, which often provide the majority of the interactions with the antigen. The light 
chain has one constant domain while the heavy chain has three. Heavy chain constant 





Figure 1.6: TCR structure and complex orientation.  
TCRs have a conserved structure including (A) the variable, constant, and transmembrane 
domains with the charged transmembrane residues depicted as black sticks. (PDB: 1BD2), 
(B) the arrangement of the antigen binding CDRs with CDR3 central to the peptide binding 
core and CDR1 and CDR2 on the peripheral interacting with MHC, and (C) the semi-
conserved binding orientation of the TCR-pMHC complex (PDB: 1QSF). 
The peripheral arrangement of germline-encoded CDR1 and CDR2 loops restricts 
interactions to the MHC binding groove α-helices which stabilizes and orients the TCR 
over the pMHC21. The majority of the peptide recognition comes from the CDR3 loop, in 
particular the CDRβ3 due to its longer and more diverse structure. Unlike other types of 
protein-protein interactions, the membrane-bound TCRs bind in a conserved diagonal 
orientation with an average angle of 54.6±20.1° (Figure 1.6C). This measurement 
represents the angle between the linear approximation of the MHC binding groove and line 
through the center of mass of the TCR variable domains. A diagonal orientation allows a 
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mixed interaction between each of the αβ CDR3 to interrogate the bound antigen peptide 
generating the extra specificity and binding affinity22.  
Comparisons of TCR CDR structures and variable region sequences finds 
conserved loop conformations called canonical classes. These structural conformations 
form with the presence of key, shape-defining residues which interact internally or with 
neighboring CDRs23–25. In 2000, Chothia et al predicted the locations and amino acids for 
these key residues in TCR variable regions with a limited amount of aligned sequencing 
data and seven solved TCR structures23. The majority of these key residue and canonical 
class predictions remain accurate with the addition of more TCR structures. Analyzing the 
diverse TCR structures, sequence repertoires, binding kinetics, and functionalities reveals 
how TCRs bind a variety of disease antigens in MHC molecules with low affinity and high 
specificity. 
1.5: PROTEIN ENGINEERING 
Antibodies and TCRs have evolved drastically different binding kinetics due to 
their distinct roles in fighting disease. Soluble antibodies must bind a wide variety of 
antigens with relatively high specificity and affinity (KD << 1 μM). These antigens consist 
of small chemicals, organic molecules, proteins, or whole pathogens requiring a significant 
amount of diversity in the antibody binding regions. Alternatively membrane-bound TCRs 
bind antigens in a highly controlled and stereotyped manner in the context of MHC with 
the coordination of other accessory molecules. TCRs also require high specificity for 
appropriate activation, but the rapid scanning of cell surfaces requires a much lower 
affinity. Biochemically, this results in a slow kon and fast koff with affinities often 200-fold 
reduced relative to antibodies. 
Studying these low affinity (KD ≈ 1 – 100 µM) TCRs and pMHC interactions 
requires a variety of highly sensitive assays able to detect rare and unstable binding events. 
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These assays incorporate methods to increase the signal strength of the TCR-pMHC 
binding by saturating solutions or making multi-mers of proteins. Some techniques for 
measuring TCR binding kinetics include enzyme-linked immunosorbent assay (ELISA), 
phage display, surface plasmon resonance (SPR), flow cytometry, IL-2 release, and 
proliferation assays. Characterizing the binding, structure, and stability of TCRs can show 
us how the proteins function during after receiving activation signals from cognate pMHC. 
Many characterization assays use soluble proteins with variants of the antigen 
binding region fused to different constructs and protein domains. Expressing truncated 
immune-receptors like fragment antibodies (Fab) or single-chain fragments (scTCR) 
reduces the protein complexity and can increase soluble expression levels26. In antibody 
Fabs the heavy chain constant region domains 2 and 3 and the antibody bivalency are 
removed, decreasing the complexity of the protein. Bacteria can express large quantities of 
Fabs and scTCRs, but these soluble variants often require stability mutations27. 
Additionally protein fusions with Fabs provide other formats for characterizing protein-
protein interactions. 
Engineering antibodies and TCRs to modify antigen-binding domains has shown 
particular efficacy in generating novel specificities to antigens28. Full-length monoclonal 
antibodies and other soluble protein constructs can serve as therapeutics for protecting 
immunocompetent hosts. Currently, the FDA has approved over 40 monoclonal antibodies 
for therapeutic use amounting to over $100 billion worldwide market sales. Antibodies, 
TCR, and other co-receptor proteins leveraged from the adaptive immune system have 
advanced the capabilities of biotechnology and medicine. For example, chimeric antigen 
receptors (CARs) link antigen binding domain of an antibody with functional signaling 
domains from other immune receptors to stimulate cellular activity.  
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1.5.1 Directed evolution of TCR affinity and specificity 
The process of engineering proteins function involves generating a library of 
mutated DNA templates for the protein, expressing the protein product of each library 
member such that the DNA sequence of each variant is specifically recoverable, and 
screening each library member for altered function. Because of the large amount of 
degeneracy typically required to find significantly altered mutants, high-throughput 
screening methods are often required. In this manner directed evolution and library 
screening can select for higher binding affinity variants28, map binding epitopes29, assay 
enhanced enzymatic activity30. 
For example, scTCR C-terminal fusions to bacteriophage surface coat proteins 
provide a method to rapidly screen and select billions of receptor variants31. While phage 
libraries can rapidly produce and test libraries in the billions of variants the stability of the 
displayed proteins often varies dramatically from protein to protein and can bias results to 
more stable, lower affinity variants. Additionally the resulting library selection and protein 
assays can vary depending on which phage coat protein is fused to the scTCR31. 
Depending on the complexity of the protein to test, the overall size of the library, 
and the parameters of the binding assay several systems are available for producing and 
screening libraries including (in order of increasing complexity) selection screens, 
ribosomal display, bacteriophage display32, spheroplast display33, yeast display34, or 
mammalian cell surface display35. Library screening should involve a compartmentalized 
system enabling the testing and selection every protein variant generated in a timely 
manner. Selection of the preferred trait or activity is also imperative for the screening 
process. For example with displayed proteins one can use a simple binding assay to select 
higher binding proteins and recover the genetic material linked to that phenotype. 
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1.6: CHICKEN OVALBUMIN REACTIVE DO11.10 T-CELLS 
In the 1980s, many studies attempted to identify the various lymphocyte lineages 
in the immune system and determine the peptide-antigen recognition mechanisms involved 
with adaptive immunity. The simplest form of these studies involves  dosing mice with 
antigen peptides then characterizing the activated T-cell populations with cognate 
pMHC36. In this way, the chicken ovalbumin (OVA) antigen became one of the more 
studied antigen models. In particular the DO11.10 and OT-II T-cell CD4+ hybridoma 
clones recognizing peptide OVA323-339 when presented by I-Ad and I-Ab MHC molecules 
respectively were well characterized37.  
While the DO11.10 and OVA323-339 antigen model provides robust protein binding 
characterization and T-cell activation data its functionality depends on the register of 
buried and solvent exposed OVA residues along the MHC binding groove38,39. While there 
is some overlap of TCR recognition between different register presentations, these 
alterations are mostly deleterious to the overall T-cell activity. Of the 4 verified register 
presentations of OVA323-339 : I-Ad in the DO11.10 system register 2 appears to be the active 
register for optimal T-cell activity38. 
The majority of the work described throughout this text specifically involves the 
analysis and characterization of the DO11.10 TCR. This includes high-throughput 
sequencing studies, structural comparison, and thymocyte reconstitution of affinity 
maturated TCR variants.  
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Chapter 2:  High-throughput sequencing of TCR repertoires  
2.1: CHAPTER SUMMARY 
In recent years, high-throughput sequencing (HTS) technologies have accelerated 
our ability to analyze heterogeneous DNA samples with many millions of sequence reads 
per reaction. A few applications of HTS include quantifying the diversity of a prokaryotic 
microbiome40, detecting proliferating leukemia cells41, and repertoire focusing from 
chronic infections42. HTS studies have shown the relationships between TCR repertoire 
diversity and the relative amount of protection provided against antigens and diseases43. 
By linking specific generation of certain TCRs in terms of VDJ-gene utilization or CDR3 
sequence variations, we can better understand of how repertoires shift and expand for 
inclusive antigen recognition and protection. With the availability of this technology, we 
sought to analyze the TCR repertoire for antigen-specific sequences resulting from 
immunization with the well-studied antigen chicken ovalbumin (OVA). 
In this experiment, TCR gene repertoires were sequenced from mice immunized 
with OVA. This antigen challenge is similar to the an initial Kappler and Marrack et al 
study which produced the well-studied DO11 and OT-II T-cell lines44,45. The goal of the 
experiment was to determine if the OVA responding T-cells that were the focus of the 
original Kappler and Marrack study are highly represented across individual mice exposed 
to OVA37,39,45. We focused on the CD4+ T-cell response more than the CD8+ T-cell 
response because OVA antigen presentation should occur on MHC class-II molecules 
through exogenous means described in Chapter 1.2.3. 
Harvested T-cells were sorted into CD4+ and CD8+ pools then TCR mRNA was 
reverse transcribed and amplified using a set of designed oligo primers for mouse T-cell 
Receptor α Variable (TRAV) and T-cell Receptor β Variable (TRBV) genes. These primer 
sets amplified cDNA spanning the TCR gene signal sequence through the constant domain. 
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The amplified TCR genes were sequenced using 454 pyrosequencing to produce over 
460,796 sequence reads with 276,508 TCR sequences identified by IMGT/HighV-Quest 
alignment processing.  
From these sequence data, we determined there was not a strong repertoire OVA-
specific response signal. The probability of producing and detecting over background 
sequences shared (public) and unique (private) TCR repertoire from a single immunization 
is low. This expectation is due to the total predicted number of antigen-specific T-cells 
produced in a single immunization46. Even analyzing the sequences for TCR gene and 
CDR3 sequence similarities to other well-studied OVA-specific T-cells did not find any 
strong candidates within these current data.  
2.2: INTRODUCTION 
Technological progress in both HTS and big data analytics has allowed the deep 
sequencing of diverse polyclonal genes within immune repertoires. HTS can elucidate how 
the modern immune system has evolved whether through co-evolution with common 
diseases and viruses or through other mechanisms. Previously, TCR binding affinity was 
thought to moderate T-cell commitment to regulatory47 or memory cells48.  Some deep 
sequencing studies have found identical TCRs across T-cell subsets meaning TCR affinity 
and development may rely on more nuanced regulation49,50. Early work on immune 
repertoires in mouse found an increased utilization of TRBV13 with many autoimmune 
responses51. Deep sequencing studies of T-cell repertoires can further characterize chronic 
illnesses which cause skewed clonal populations with memory inflation as found in some 
CMV infected individuals52,53. 
Prior to this technology, repertoire analysis could not be performed to any high 
capacity or repertoire sequence depth. Studies instead used less qualitative methods of PCR 
and spectratyping to analyze polyclonal T-cell samples54. These methods can detect a level 
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of clonal population bias, variable region gene presence, and CDR3 length distribution, but 
cannot link variable-region utilization to CDR3 sequence and their frequency in the 
reperotire55.  
With human T-cell repertoires estimated to number 108 different TRBV sequences 
alone, these less qualitative methods lack the ability to thoroughly discriminate between 
the various subsets of clonal populations and truly unique sequences56. Deep sequencing 
of antibody and TCR repertoires gives a glimpse at the frequency and distribution of the 
clonal populations in an individual suggestive of the overall health of the adaptive immune 
system. The total number of sequences required to accurately measure the repertoire 
depends on the cell samples and biological question which some studies put at 
approximately 106 sequences57. 
By using the well-studied DO11.10 model we can determine the peptide-specific 
TCR sequences by removing sequences shared among both the healthy and OVA 
challenged mice45. In this way, we can see if there is a subset of shared sequences either 
similar in sequence to DO11.10 or a subset not found in the control repertoire. Exposing 
mice to particular antigens and finding TCR repertoire changes could find the antigen-
specific sequences and degree of TCR cross reactivity generated during an adaptive 
immune response. 
2.2.1: High-Throughput Sequencing technologies 
Traditional Sanger sequencing with the multi-step process of random nucleotide 
incorporation into elongating strands combined with gel filtration to separate DNA by 
length has been the predominant method for sequencing. This technique requires 
homogeneous purified samples and considerable amount of DNA which often requires 
additional cloning for gene detection or screens. While this method is still predominantly 
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used for general sequencing applications, it is unable to efficiently analyze DNA libraries 
or gene expression patterns in heterogeneous samples. 
In the 1990s, a new application combining pyrophosphate chemistry and 
microfluidics generated a new sequencing technology called pyrosequencing which could 
sequence large quantities of heterogeneous DNA samples. In 2000, 454 Life Sciences 
licensed this technology and was later purchased by Roche in 2007. 454 pyrosequencing 
involves the real-time elongation and detection with pyrophosphate substrate linked 
nucleotides58. Incorporation of these nucleotides results in the oxidation of luciferin by 
luciferase to release discrete photons (Figure 2.1A). Set up of these reactions involves oil-
water emulsions with beads containing the sequencing DNA and a massive array of 
detectors to analyze the photons produced by each of the individual bead reactors able to 
read greater than 107 bases per hour59. These pyrosequencing experiments can also process 
DNA sequencing read lengths of up 450 bases which is long enough to accurately read a 
TCR variable region through to the constant region. In 2013, Roche announced the 
discontinuation of the 454 pyrosequencing technology as much of the HTS experiments 
moved to newer technologies licensed by Illumina. 
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Figure 2.1: Diagrams of the HTS technologies  
(A) 454 pyrosequencing occurs through several steps of DNA modification and enzyme 
chemistry. DNA fragments are ligated to adapters and fused to beads for clonal 
amplification. The beads are then distributed to a picotitre plate and sequenced using 
pyrophosphate chemistry and luciferin oxidation60 and (B) Similar to 454 sequencing, 
Illumina technology uses a DNA adapters, but to hybridize template DNA to a flow channel 
surface instead of beads. Template DNA is clonally amplified and the sequence is read by 
fluorophore cleavage from the nucleotides60.  
In recent years, a second-generation HTS technology licensed by Illumina has 
replaced 454 pyrosequencing. Illumina sequencing uses different chemistry and sample 
processing to collect many millions of sequence reads with similar sequence quality to 
prior technology61. Sequence reads for Illumina are shorter than other technologies so 
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additional sample processing is required if the DNA sample is longer or if sample coverage 
is necessary for both forward and reverse directions59. 
To set up reactions, transposons add adaptors for flanking index motifs to template 
DNA using reduced cycle amplification. Next, the DNA samples are added to a flow 
channel to hybridize with complementary oligo adapters on the channel surface. Bridge 
amplification between nearby complementary adapters clonally amplifies the DNA as 
clusters of reactions. The 3’ ends are then blocked and sequences are read using 
fluorescently labeled nucleotides which emit discrete wavelengths of photons based on the 
incorporated nucleotide base (Figure 2.1B). The light emitted by each clonal cluster during 
sequencing is collected using a fiber optic bundle monitoring the entire flow cell. This is 
called sequencing by synthesis since the sequence is read during second strand synthesis. 
Sequence clusters are read for the desired length before further processing to read the 
reverse direction of the template DNA. After sequencing in the forward direction, the 
template DNA is bridge amplified to a nearby complementary adapter and the sequence is 
read in the reverse direction. Processing and aligning the two read directions for each DNA 
amplification cluster allows a sequence validation as each read direction should be 
complementary of one another if the template DNA is the appropriate length.  
These high-throughput technologies have dramatically increased the variety of 
analyses available to scientist including measuring gene expression with cDNA libraries 
from mRNA, the diversity of the microbiome using ribosomal DNA40, and diverse cellular 
systems with polyclonal repertoires. Aside from the shorter read length from HTS, the error 
rate is also higher than for older Sanger technologies. These technological shortcomings 
are mitigated by the overwhelming amount of sequence coverage. The sheer number of 
total sequences that are read allow sequencing overlap to identify erroneous data60. 
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2.2.2: Ig/TCR repertoire analysis 
HTS studies of gene repertoires provide scientists with deeper insight into the 
mechanisms generating the diversity found in the adaptive immune. The sequences found 
in productive and non-productive TCR chains show the probability of certain gene 
rearrangements and junctions occurring with success during lymphocyte maturation 
selection62. Before HTS analysis became more prevalent, immune repertoire studies 
consisted of relatively small (<100) sample sizes of selected or sorted populations which 
comprises a minuscule fraction of the total expected diversity in an actual repertoire63. 
After genome sequencing of humans, mice, and other species with adaptive 
immune systems, scientists could study the genes and mechanisms which generate 
antibody and TCR diversity. Compiling this genetic information into a database which 
could model the gene rearrangements, Lefranc et al, constructed the IMunoGeneTics 
(IMGT) database64. This database can identify the genes and PN-junctions from both single 
entries and high-throughput data for DNA and protein sequences. The expanding number 
of repertoire analyses from other studies have begun to roughly define the TCR background 
repertoires65. This background repertoire in mice has helped elucidate mechanisms which 
produce inherent biases within the genetic rearrangements and junctional CDR3 
sequences19,66,67.  
While sequencing and analysis of B-cell and T-cell repertoires is now a standard 
method, identifying TCR-antigen specificity requires additional considerations. The highly 
regulated T-cell maturation process selects for a degree of cross-reactivity within foreign 
antigen identification from the low affinity binding kinetics68. The cross-reactive nature of 
TCRs against a particular antigen suggests proper protection requires recognition by 
multiple antigen receptors. This requirement for polyclonal TCR recognition may also 
mitigate antigen escape, providing antigen mutation tolerance69.  
27 
TCRs interact with antigens processed and presented by MHC molecules, which 
vary between individuals. Therefore describing the TCR repertoire response for any 
antigen requires an additional analysis of the pMHC generating that response. MHC 
molecules are highly polymorphic between individuals and the variations in both the α-
helices and the β-sheet binding groove floor can cause differential presentation of disease 
antigens and TCR recognition4. For example certain human leukocyte antigen genes which 
recombine to form the MHC can provide enhanced protection against diseases like HIV 
due to antigen presentation compatibility70.  
 Antigen specific TCR sequences shared across multiple individuals are known as 
public sequences. These types of sequences can occur with some frequency due to a 
stereotyped antigen interaction or from higher probabilities of generation during gene TCR 
gene rearrangment71,72. Both types of shared sequences occur by different immune 
mechanisms in normal and diseased populations. Individuals with public sequences have 
identical receptors thought to interrogate the MHC and particular peptide antigen nearly 
identically. These shared TCR sequences are found with diseases such as Epstein bar 
virus73, CMV72, and multiple cancers74. Identified public TCR sequences highlight the 
propensity to form particular receptors from the possible pool of gene combinations and 
junction rearrangments74,75. Public receptor sequences could also help develop new 
vaccines and therapeutics to target specific disease antigens with enough MHC tolerance 
shared across a broad population with limited nonspecific interactions.  
Natural immune processes such as aging can also lead to biased T-cell repertoires. 
In these repertoire biases, an initially small portion of highly active disease-specific 
thymocytes proliferate until they comprise a much larger portion of the population termed 
memory inflation. Specifically the process of aging slows thymic output of naïve cells 
placing a higher burden and responsibility to protect on existing T-cells leading to 
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stagnating or decreasing receptor population diversity62.  These more homogenous 
thymocyte populations lack the repertoire diversity necessary for proper protection and can 
cause complications similar to being immunocompromised.  
In order to determine a peptide-derived basis for autoimmunity, cancers, and other 
T-cell mediated diseases, we need a better understanding of TCR VDJ-region gene 
utilization, hypervariable junction diversity, prevalent structural conformations in the TCR 
binding region, and receptor functionality. With recent protein developments utilizing 
TCRs as therapeutics against cancerous and viral targets, mapping the repertoires will 
identify those effective TCR gene segments frequency and CDR3 sequences to engineer 
increased antigen-specificity76. 
2.3: METHODS 
2.3.1: Primer set design and validation 
 Using the IMGT database to identify the TCR variable region genes in the mouse 
genome, a primer set was designed to amplify the expected TCR sequences produced in 
the mouse repertoire77. The sense strand primers were designed to anneal within the signal 
sequence of each functional variable region. The antisense strand primer for TCR gene 
amplification was designed to anneal 12 nucleotides into the respective constant domain.  
To reduce the number of primers in this set a degree of nucleotide degeneracy was used to 
combine similar signal sequences. This way a single degenerate primer could contain up 
to 4 different sequences. The average melting temperature of the primer set was 55°C with 
an overall range of 51.5 – 59.2°C. The exception to these design parameters was TRBV13, 
which was instead used to target a more conserved sequence within the framework of the 
variable region. The mouse TCR primer set (Table 2.1) includes 29 and 19 primers for 
TRAV-regions and TRBV-regions respectively. Similar design principles have been used 
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to generate a primer set for the amplification of 83 mouse TCR genes from the more 
conserved region, but were not able to successfully target all the TRAV and TRBV genes78. 
 




















TRAV01 1 52.7 GGT TTG TTC TCT ATC TCT TCC TG  X 2 5 
TRAV02 2 53.7 ATG AAG CAG GTG GCA AAA G   0 5 
TRAV03 3-1,3,4; 3D-3 54.3±0.4 GAC CTT TGT TSC TGT GCT TC X X 0 2 
TRAV04 4-3,4; 4D-3,4 55 GCT GTG CTG GGG ATT CT X  2 5 
TRAV04-2 4-2 59.2 CTG CTG TTG GTG CCG CT X  4 2 
TRAV05-1 5-1 54.8 CTT CTG GCT ACA GAT GGA CT X  0 5 
TRAV05x-4 5-4;5D-4 51.5 ATT ATT CAT GTT TCT ATG GCT GC   0 5 
TRAV06-1 6-1:3; 6D-3 53.8 GCT TTA GTG ACT GTG ATG CTG X  2 2 
TRAV06-4 6-4; 6D-4 56.5±2.1 GTT TTA GTR ACT GYG ATG CTG CTG X  3 4 
TRAV06x-5 6-5; 6D-5 55.4 CCT GAA CTG GGK ATT CTA CTC TTC - - - - 
TRAV06-6 6-6; 6D-6 54.4±0.8 CTY TTC TCC AGG CTT CGT G X X 2 5 
TRAV06-7 6-7; 6D-7 52.5±1 ATG AYT GTG ATG CTC CTC AT X  0 5 
TRAV07 7-1:5; 7D-2:5 54.3±0.3 CTA GTG GTC CTG TGG CTY  X  2 5 
TRAV07x-6 7-6; 7D-6 52.2 CTA GTG TTC CTC TGG CTT C   0 4 
TRAV08x-1 8-1; 8D-1 53.9 GGT TGT TGA TGG TGT CAC TG X X 2 3 
TRAV08x-2 8-2; 8D-2 52.8 GGA ATA TCT TTG GTG ACT CTA TGG  X 0 2 
TRAV09x-1 9-1; 9D-1 54.3 TCG TTC CTC GGG ATA CAT TTC X  0 5 
TRAV09x-2 9-2:4; 9D-2:4 53.7±0.5 CAG TSC TGG GGA TAC ACT X X 0 5 
TRAV10 10; 10D 54.5 ACA TCC CTT CAC ACT GTA TTC C X  0 5 
TRAV11 11; 11D 57.9±1.5 GCC TKA GTG CCT GCT GG X  2 3 
TRAV12 12-1:3; 12D-1:3 56.5±1.2 SCT CAG TTC TYG TGC TCC TC X  0 5 
TRAV13 13-1:5; 13D-1:4 56.9±2.6 TCT CTG YTG GGG CTY CTG X  5 5 
TRAV14 14-1:3; 14D-1:3 54.5±1.5 GAC AMG ATC CTG ACA GCA WC X  3 5 
TRAV15 15-1:2; 15D-1:2 57.1±0.3 ATG CCT CCT CAS AGC CTG X  3 4 
TRAV16 16; 16D 54.2±1.1 CTG ATT CTA AGC CTG YTG GG X  2 4 
TRAV17 17 55 AGT GAC CAT TCT GCT GCT C X  0 4 
TRAV18 18 54.5 ATG CTC CTG AAA CTC TCT GTG  X 2 4 
TRAV19 19 54.4 GCC TTG CTG TTG GTT CTG   3 5 
TRAV21 21 54.1 GAT GTG TGA GTG GAA TTG CC  X 0 5 
TRBV01 1 56.6 TTC TGT GCC TCT GTG TAC TCA T  X  0 0 
TRBV02 2 56.6 GGC TCC ATT TTC CTC AGT TGC X X 0 0 
TRBV03 3 53.9 CTG GCT TCT AGG TTG GAT AAT TTT TAG X  0 3 
TRBV04 4 56.6 GCT GTA GGC TCC TAA GCT GT   0 4 
TRBV05 5 55.4 GCA GGC TTC TCC TCT ATG TTT C X X 0 4 
TRBV12 12-1:2 56.4±1.5 CTG CTA TCT TGG GTT RCT STC TTT C X  0 3 
TRBV13 13-1:3 56.2±2 RCA AGG TGR CAG TAA CAG GAG X X 2 0 
TRBV14 14 56.7 CTT GGC TGG GCA GTG TTC X  2 0 
TRBV15 15 54.2 AGA CCC TCT GTT GTG TGA TC X  0 0 
TRBV16 16 56.4 CTT TTC TGT CTG GTT CTT TGC TTC  X 0 0 
TRBV17 17 55.4 CTA GAC TTC TTT GCT GTG TGA TCT TC X  0 3 
TRBV19 19 56.1 ATG AAC AAG TGG GTT TTC TGC TG X  2 4 
TRBV20 20 55.2 ATG TTM CTG CTT CTA TTA CTT CTG G X X 0 0 
TRBV23 23 53.7 CAC GGC TCA TTT GCT ATG TAG   1 0 
TRBV24 24 55.4 CAA GAC TGC TCT GCT GTG TAG   1 0 
TRBV26 26 56.7 ATG GCT ACA AGG CTC CTC TG X  2 5 
TRBV29 29 56.6 TTA GGC TCA TCT CTG CTG TGG X  2 2 
TRBV30 30 53.5 GAC ATT CCT GCT ACT TCT TTG G X X 2 4 
TRBV31 31 56.5 TGC TGT ACT CTC TCC TTG CC X X 2 4 
Table 2.1: Primer set for mouse TRAV and TRBV genes.  
The TRAV6-5x primer was added Detailed list of the V-region primer set used to amplify 
the cDNA. The columns are primer name, V-region gene targets, melting temperature, 
nucleotide sequence, validated with TOPO cloning, and amplicon quality at 50°C and 53°C 
annealing temperatures respectively. 
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 These primers were validated by amplification and sequencing of mouse lymph 
node (Figure 2.2A) and T-cell hybridoma (Figure 2.2B) cDNA from mRNA. Individual 
amplifications for each primer are shown below (Figure 2.3 A and B), all showed 
appropriate bands at the expected size except TRBV23. Samples of α and β bands were 
purified and subcloned with a topoisomerase vector for sequencing to confirm the targeted 
amplification of the TCR gene. These confirmations are reported in Table 2.1.  
 
 
Figure 2.2: Amplified TCRs from mouse and hybridoma cDNA. 
When the primer set are pooled and used to amplify cDNA from the treated groups of mice 
the products looked (A) similar to a combination of all the bands in (Figure 2.3.1.2A and 
B). Additionally these pooled primer sets worked on DO11.10, HEL, and 172.10 





Figure 2.3: TCR V-regions amplified by the primer set. 
PCR amplifications for the mouse TCR primer designed to optimize reaction conditions to 
amplify and prepare the samples for sequencing: (A) TRAV-regions, (B) TRBV-regions.  
To optimize the cDNA PCR annealing temperatures were tested for each TRAV or 
TRBV primer from pooled mouse mRNA. The reaction quality is scored based on the 
resulting band(s) when run on an agarose gel (Figure 2.3 A and B). A strong single band 
received a (0), a weak single band (1), a doublet (2), a triplet (3), four or more bands (4), 
and a smear received the worst score of (5). This method found the most primers could 
successfully amplify the TCR sequences using an annealing temperature of 50°C. 
2.3.2: Mouse inoculation 
Four healthy 25-27 week old BALB/C (C57/BL6) mice immunized with 100 µg of 
OVA. Two weeks after inoculation, the mice were sacrificed and their spleen and lymph 
nodes were harvested collecting approximately 335 mg of organ material per mouse, which 
was then placed in a solution of RNAlater for one hour. The organ tissue was then 
homogenized the using a sonicator at the highest setting for 1 minute to suspend individual 
cells. The suspended cellular solution was then sorted using magnetic Dynabeads 
(Invitrogen #114.45D, 114.47D) for separating CD4+ and CD8+ t-cells.  
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2.3.3: TCR gene amplification 
Total mRNA was purified from the sorted cells. TRIzol (Invitrogen) was added to 
the cell solutions and then lysed with a homogenizer (OMNI GLH) or mechanical sheering 
in a 23-gauged syringe. Following the manufacturer’s protocols, RNA was then isolated 
from the aqueous phase after 1-bromo 3-chloropropane addition and sample centrifugation. 
The RNA samples were purified using QIAgen’s RNEasy kit. Any contaminating DNA 
genomic was digested using a DNA-free DNA Removal Kit (Invitrogen). Purified samples 
immediately used in cDNA preparation or were stored at -80 °C until further use. 
cDNA was generated from purified mRNA using the protocols prescribed 
SuperScript RT II (Invitrogen) with an extension of a PolyA Tail oligo (5’ – [T]23VN – 3’) 
for 50 minutes at 42°C. The resulting cDNA was immediately amplified by the TRAV and 
TRBV primer sets separately mentioned in Chapter 2.3.1 using Accuprime pfx 
polymerase (Invitrogen) with 25-30 PCR cycles with an annealing temperature of 50°C 
and elongation time of 30 seconds. In order to mitigate bias introduced by the primer set 
during cDNA amplification, a reduced number of PCR cycles was used to amplify TCR 
genes before sequencing. PCR samples were purified by gel extraction and either 
subcloned with a TOPO-TA kit (Invitrogen) or submitted to the Genome Sequencing and 
Analysis Facility at the University of Texas at Austin for further processing and sequencing 
with a Roche/454 Titanium Series Instrument. 
2.4: RESULTS 
2.4.1: Data processing with IMGT and SQL 
 The IMGT/HighV-Quest analysis tool was used to examine the sequence data for 
VDJ-region identity, CDR3 sequence, homology to germline sequences, and relative 
amount of error in the data. In a pilot study we performed, the IMGT processing returned 
a larger than expected amount of identifiable but unproductive receptor rearrangements 
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due to either single frameshifts in the coding region or stop codon mutations. Otherwise 
IMGT identified the majority of the gene regions in the sequence data and determined the 
CDR3 sequence errors were below 2% as determined by the total amount of mutations 
found and the anticipated errors per sequence length. We next set up a database using 
Microsoft’s Server Query Language to further process the IMGT sequence data to calculate 
differences in sequence populations. 
2.4.2: Mouse TCR populations 
Two separate sets of sequencing submissions, the first was a pilot study with one 
immunized mouse and the second with two immunized mice and two control mice 
produced 4,882 and 460,796 sequences respectively. The TCR sequences in these studies 
were harvested and synthesized identically, but the smaller sample only included CD4+ 
cells with pooled α- and β-chain amplifications whereas the larger study was sorted for 
both CD4+ and CD8+ T-cells with separate α and β amplifications. After IMGT processing 
and removal of sequences with low quality or truncated length, there were 3,922 (80 %) 
and 276,508 (60 %) identified TCRs in the pilot and second submission respectively. 
In the pilot sequencing experiment with 3922 identified TCRs by IMGT with 55 of 
82 different TCR V-region genes with TRAV-genes 3, 6, 7, 12, and 13 which individually 
appear greater than 5 % with diverse CDR3 sequences and TRAJ genes. TRAV-7 in 
particular comprised nearly 44 % of the data (Figure 2.4A). Further analysis of the TRAV-
7 alleles (Figure 2.4B) identified 1288 unique and surprisingly diverse sequences. 
Additionally all clonal sequences each comprised much less than 1 % of the total sequences 
in the data. The diversity and distribution seen in this smaller sample with only 11 V-region 
genes identified more than 5 times (greater than 0.1 % frequency) also indicated the need 




Figure 2.4: V-region and TRAV7 gene histograms. 
These histograms show the distribution of the v-region gene frequencies for (A) the smaller 
sequencing experiment and (B) the identified TRAV7 genes by allele for the productive 
IMGT-identified sequences. We determined a lack of V-region gene because the 
distribution and primer melting temperature do not correlate. 
For the larger sequencing experiment with 4 mice, 16 DNA samples of PCR 
amplified cDNA were submitted. Samples were distinct for the individual mouse, CD4+ / 
CD8+ sorting, and then separately amplified α- or β-chain samples. This study of four mice 
found 272,508 (60 %) sequences containing an identified CDR3 junction and the IMGT 
analysis returned 87 % of the sequences in the following breakdown: Productive (39.8 %), 
Unproductive (22.8 %), Unknown (30.0 %), and No Results (7.4 %). Our data showed the 
TCR sequence repertoire composition of control and OVA challenged mice are similar 
with approximately 9.7 %, 1.2 %, and 6.4 % being individually unique to each mouse, 
unique to the treatment group, and shared between treatment groups respectively. The 
remaining majority of sequences were shared between one or two mice with no correlation 
to treatment. 
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There were no specific V-regions, CDR3 sequences, or J-regions that were found 
in higher frequency in one mouse treatment group over the other. TRBV amplifications 
had higher rates of productive sequences with 52 % of sequences productive compared 
with 37 % for the α-chain counterparts. In fact, the strongest difference between the two 
sets was a TRBV29 deficiency in the treated mice with a 2.0 % difference between the 
groups. Otherwise, this slice of these mice TCR was too limited in size to determine any 
significant differences between the treatment groups. 
Between the sorted populations of CD4 and CD8 cells, there was little measured 
variation in the utilization of specific TCR genes or CDR3 sequences. Aside from the 
variation occurring from the different sequencing depths, the relative amounts of unique 
and shared gene and CDR3 sequence combinations (Table 2.2) did not indicate the clear 
development of a specific immunization response.  
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Chain Lineage Mouse Total V,J,CDR3 V-J 
α 
CD4+ 
1 46532 28436 2058
2 32777 20622 1921
3 32426 21117 1866
4 22050 15076 1628
CD8+ 
1 5542 4385 1021
2 44963 29100 2017
3 18505 13098 1627
4 19411 13906 1708
β 
CD4+ 
1 5793 4946 135
2 8332 6469 145
3 7664 5900 151
4 9199 7194 174
CD8+ 
1 3301 2665 135
2 7274 5860 171
3 7122 5793 151
4 5617 4532 119
Table 2.2: The total sequences for each sample pool. 
These data show the number of identical sequences found when grouped by the various 
IMGT identified TCR characteristics. The number of TRAV sequence combinations is 
many times larger than the TRBV groups partially due to sample preparation and due to 
the fewer number of V- and J-region genes. 
 There were 1894 identical sequences in all 4 mice with matching V-region, CDR3 
sequence, and J-region returned from the IMGT analysis. Additionally there were 14745 
sequences shared across the pooled treatment groups. Using the three TCR traits this way 
was considered the most effective method to identify duplicate sequences and possible bias 
introduced in the handling of material or processing of the DNA for sequencing 
preparation. Setting a threshold quality score of 200 and combing the identified gene and 
junction information showed a varied amount of identical sequences in the data. Similar to 
the smaller pilot experiment there was a significant amount of TRAV7 gene sequences 
recovered in over 130,000 sequences across all the 16 samples. Additionally there was a 
strong TRAV11 and TRAJ18 combination with over 4,000 sequences found in the 
sequence set. 
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While certain sequences appear in dramatically different amounts in the data this 
does not necessarily mean they reflect a repertoire of the same composition. This could be 
the case if the sequences have increased representation due to PCR bias, but correlating the 
amplified sequence with the corresponding primer melting temperature did not find any 
trend between a lower melting temperature or primer degeneracy and the total number of 
identical sequences in the sample. Compiling the data in a histogram (Figure 2.5) shows 
the degree of sequence repeats fits well to the power law equation shown in the legend 
below. If the model holds for variable depths of sequencing this allows one to calculate the 
total number of sequences required to find a particular sequence of a low frequency.  
 
 
Figure 2.5: Plot of identical TCR sequence occurrence. 
This plot shows the relative amount of identical sequences found within all the sequence 
data. The x-axis is comprised of the number of sequences based on the clones for that 
sequence. The y-axis is the number of clones within a group. From the plot, the x-intercept 
represents the 105,394 unique sequences that only occur once in the data. Similarly, the y-
intercept represents the largest clonal population with 3029 identical TCRs and it occurs 
for one particular sequence in the data. 
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The sequence data showed no statistical difference between our control and 
immunized mice groups in terms of gene usage or CDR3 junction. However there is a 
slightly increased frequency of a few variable-regions in the OVA treated mice, but these 
data do not conclusively show a distinct shift in the overall TCR repertoire. PCR bias in 
the sequencing data could be partially seen in the abundance of the TRAV7 and TRBV13 
gene sequences from all mice (Figure 2.6). Amplifications lacking these primers for these 
two regions still recovered these V-region sequences to a high frequency (Ben Roy, 
personal communication).  
 
 
Figure 2.6: Treatment group V-region frequency  
This graph shows the ratio of frequency for each V-region in the sequenced mice. V-
regions appearing greater than 100 times in the data set (~0.03 % of the total identified 
sequences or ~0.2 % in each mouse) were measured for an increased frequency ratio 
between the treatment groups. A frequency ratio value above 1 means an increased 
frequency of a particular V-region in the OVA-immunized mouse repertoires. 
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The established OVA-specific and DO11.10-like hybridoma sequences were not 
found in any of the mouse sequences45. V-regions expected to have the most similarity by 
analysis using clustalΩ to the DO11.10 sequences include TRAV10 and TRBV29. A V-
region gene analysis for  Searches using Markov sorts measuring amino acid residue 
similarity of the V-region, J-region, and CDR3 sequence showed no strong similarity to 
the model hybridomas either.  
Of the 61 identified TRAJ genes, 21 are non-functional, either as pseudogenes, 
vestigial genes, or open reading frames. Most have multiple errors in recombination 
sequences and elsewhere such that they do not seem to be able to recombine. Of 9 that 
appear to possibly be capable of recombination, IMGT predicted they would not form 
productive genes. For example TRAJ-36, -54, -55, -60, and -61 have stop codons leading 
to nonfunctional rearrangements, but appear in 320 sequences.   
Additionally TRAJ-7, -44, and -47 which appear in over 5000 sequences, are is not 
recognized by IMGT as a functional TCR sequence from a lack of the conserved amino 
acid sequence motif of F (or W) followed by G-X-G, where X can be any amino acid. In 
the case of TRAJ47, our sequences conform to the consensus sequence. Instead of 
matching the reference sequence CGLG, our sequences are FGLG. This means that either 
their reference sequence is wrong or we have identified a distinct allele, TRAJ47*02, that 
is functional. The case of TRAJ-7 and -44 is a bit more interesting. Again, we have a 
sequence discrepancy. However, their reference sequences show LGAG for TRAJ44, while 
our results are LGTG. TRAJ7 matches in both our sequences and the IMGT reference. In 
other words, while there is a discrepancy, our genes still do not fit with the conserved 
FGXG motif.  
As a result of this mismatch with consensus sequences, we cannot definitively claim 
that TRAJ7, -44, -47 are functional genes, but we can provide evidence that they might 
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be. We have over 5000 sequences that include TRAJ7, -44, -47 regions, but we haven't 
found a single productive TRAJ-4, -36, -54, -55, -60, or -61. If all of these genes are non-
functional, we might expect them to show up occasionally, just as we accurately predict 
that CDR3s with stop codons show up occasionally, as excluded alleles. The fact that there 
are none, and numerous TRAJ7 and TRAJ44 containing sequences indicates this gene 
selected as functional over and over again. The occurrence of these genes has also been 
found in other HTS studies with mouse repertoires67. 
Based strictly on the IMGT analysis we have 272,508 sequences, of which there 
are 170,184 unique V-Region-CDR3 pairings and 114,791 unique CDR3 sequences (when 
grouped solely by CDR3). This means there are 55,393 CDR3s shared by more than one 
V-region. The total number of identified productive CDR3s available to us could be 
theoretically increased with an additional analysis of the identified TCR sequences in our 
data to parse the CDR3 errors as they appear in large abundance as frameshift mutations 
or stop codons. We might be able to remedy these incorrect bases by identifying if the 
originates from the native gene sequence or formed in the PN junction during gene 
rearrangement. 
 To do this analysis we modified the CDR3 analysis to isolate the junction 
rearrangement using the most likely V-region and J-region sequences, which occur in the 
appropriate order. The program searches for either α or β CDR3 with the flanking 
conserved Y–[YFLI]–(C104) and F118 (or W)–G–X–G motifs. We could 
determine the accuracy of our filter since both chains have these highly conserved residues 
and because the 3’ primer used to amplify the variable region sits at nearly the exact same 
location at the C-terminal end of the translated gene. Some determined junctions had 
obvious deficiencies in that they were too long or short. The average productive junction 
length for both CDRα3 and CDRβ3 was approximately 15 amino acids between IMGT 
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residues 104 to 118. The distributions of CDR3 lengths also matches previous 
spectratyping estimates of for the hypervariable loop. Monitoring these estimated junction 
lengths can limit the amount of error in the IMGT analysis, which from this limited data 
set appears to be a significant portion of the returned sequences. 
2.4.3: DO11.10 and OT-II similar TCR sequences 
In an effort to find OVA specific sequences in a high background of nonspecific T-
cells in the sequenced samples, the data were passed through a filter for DO11.10 
homology. The DO11.10 TCR consists of gene regions TRAV5D-4 and TRBV13-2. This 
assumes the single OVA immunization would be enough to generate both a stereotyped 
DO11.10-like sequence complete with gene regions and CDR3 sequence as well as produce 
this antigen specific response in a measurably significant number of sequences. To do this 
analysis, all the mouse V-regions were sorted through the residue homology analyzer 
clustalΩ79. Sequences with over 90% sequence homology were then analyzed for either 
CDR3 residue sequence conservation or similarity to published OVA-specific T-cells45. To 
measure the residue similarity we generated a Markov scoring algorithm to measure and 
compare the sequences for amino acid similarity or a consensus or to a particular sequence 
of interest80. Sequences with length differences greater than two residues from the average 
or published sequence were penalized. Results from the Markov algorithm are shown as 
the Markov score versus the ranked sequences based on that score (Figure 2.7A). There 
were few results or generalities gleaned from the scoring partially because of the variable 
CDR3 lengths shown as a histogram below (Figure 2.7B). 
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Figure 2.7: Markov scoring and CDR3 length histogram 
(A) Plotting the ranked Markov scores shows the low frequency of DO11.10 like sequences 
in the data set and the overall abundance of diversity in CDR3. Additionally the (B) length 
distributions within the data showed no differences between samples or between different 
genes. 
2.4.4: α-chain variant TCRs  
While the sequenced repertoire was not expected to produce an identical TCR 
sequence to the well-studied DO11.10 or other OVA-specific T-cells it was surprising to 
find no sequences with TRAV5D-4. It was also unexpected to have none of the many 
TRBV13 sequences close to the DO11.10 β-chain sequence. As such, the data was then 
analyzed to find similar sequences based on homology found by clustalΩ and an increased 
frequency in the treated mice. Examining the sequence data for TRAV regions found more 
frequently in the treated mice than the untreated found the TRAV3-3 and TRAV7-3 genes 
with increased frequency usage across the other allele in the TCR gene in the treated mice 
when compared to the average in control mice.  
Sequences with increased frequency were then cross-referenced with a clustalΩ 
analysis of TRAV-regions to measure the similarity to the DO11.10 CDRα3 sequence. 
Compilations of the CDR3 sequences and J-regions in V-region genes were further 
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examined to determine the most frequent residues in the CDR3 sequence and J-regions 
associated with the TRAV3-3 and TRAV7-3 gene sequences in each mouse. These TRAV-
region, CDRα3 sequence, and TRAJ-region combinations from the treated mice are 
reported in Table 2.3. The CDRα3 sequences calculated this way had a high degree of 
similarity to wildtype DO11.10. Since the sequencing data provides information on α- and 
β-chain frequencies independent of each other this analysis focused on finding a relevant 
α-chain while holding the DO11.10 β-chain constant.  
 
 V-region CDR3 J-Region 
WT TRAV 5D4 CAASPNYNVLYF TRAJ 21 
1 TRAV3-3*01 CAVMPNYNVLYF TRAJ 21*01 
2 TRAV3-3*01 CAVSRNNNNRIFF TRAJ 31*01 
3 TRAV7-3*01 CAVSGPNYNVLYF TRAJ 21*01 
4 TRAV7-3*01 CAANNYAQGLTF TRAJ 26*01 
Table 2.3: scTCR variants cloned for expression  
V-regions found with higher frequencies in the treated group were cloned into the well-
expressing DO11.10 scTCR construct replacing the wildtype α-chain. The CDR3 
sequences were additionally compiled from the most frequent CDR3 length and amino 
acids at particular positions. 
With the data set analyzed, we decided to test if these sequence candidates obtained 
from the challenged mice could be both cloned into protein expression and bacteriophage 
constructs for further characterization. Since these candidates showed the highest 
frequency of utilization in the data, they were cloned using a combination of overlap 
extension PCR and specific V-region amplification from the pooled mRNA. The α-chain 
in the DO11.10 scTCR variant was exchanged with these 4 variants and cloned into 
MoPAC24 and pAK400 as a M13 pIII fusion construct for phage display and soluble 
expression using the high-yield DO11.10 β-chain variant27,81.  
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Phage displayed and soluble scTCR variants were tested for binding a clonotypic 
anti-DO11.10 antibody using an enzyme-linked immunosorbent assay (ELISA), but these 
assays failed to produce stable scTCR fusions on the phage. Additionally the soluble 
scTCR variants did not express to a high degree and when purified by periplasmic 
expression did not yield measurable quantities of the expected protein size from size 
exclusion chromatography in an FPLC S75 purification (ELISA and FPLC S75 trace data 
not shown). Based on the low protein yields and the lack of clear antigen specific sequences 
in the data set we did not perform further characterization and scTCR combinations. 
2.5: DISCUSSION AND CONCLUSIONS 
From the 460,896 sequences collected across the four mice and two control groups 
in larger run of this experiment, IMGT identified the V-region, CDR3 sequence, and J-
region for 276,508 sequences. Similar to our analysis with the smaller sequencing 
experiment there were no sequences with a strong DO11.10 similarity. While this 
experiment does not guarantee recovery of sequences identical to the previous DO11.10 
and OVA-specific T-cell work, there was the expectation of some consensus sequences 
shared in only the treated mice as a public sequence74. Additionally sequences both shared 
and unique to each mouse between the α- and β-chain amplifications and CD4+/CD8+ 
sorted T-cells did not contain measurable differences between treatments or cell lineages. 
Without a larger distinction between the treatment groups in terms of gene region 
frequency or CDR3 sequence bias, the sequence data may have too many background 
nonspecific sequences masking the immune repertoire signal.  
The results of these experiments show the necessity of additional immunizations in 
the challenged mice to promote the proliferation of antigen-specific cells. Without these 
additional immunizations, the total number of responding cells cannot be determined 
through HTS alone. With only a small fraction of the total T-cells expected to respond to 
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initial antigen challenges, sequencing depths less than 106 sequences per mouse are not 
able to effectively realize the repertoire, especially from cell samples lacking additional 
processing with pMHC or activation sorting82. A combination of additional immunizations, 
sorting, and deeper sequencing should overcome the incredibly low frequency of 
responding specific T-cells over the background repertoire variation within individual mice 
and treatment groups.  
Processing the data to identify more frequently used genes or CDR3 sequences in 
the treated group found four possible candidate sequences. These four α-chain sequence 
candidates were fused with our well-behaved DO11.10 β-chain single chain construct for 
binding assays using phage display techniques. These variants were unstable, as indicated 
by low soluble expression yields when compared to other scTCRs. Additionally ELISA 
and western blot methods found the α-chain variants unable to bind the clonotypic 
DO11.10 antibody. These selected TRAV genes and CDR3 sequences may be 
incompatible with the particular DO11.10 β-chain as seen in other studies with 
combinatorial fusions of antibody and TCR chains83.  
Cloning novel TCRs from T-cell pools requires methods to screen libraries of TCR 
α and β chain combinations for pMHC binding. Since the TCR mRNA in this experiment 
is pooled from the dissociated T-cells, the repertoire analysis must consider the two α- and 
β-chain TCR sequence set independent of one another. These independent amplifications 
prevent the linking of clonotypic α and β chains. This limits our analysis since half the 
receptor repertoire analyzed is performed independently of the other chain and both are 
shown to play an important and shared role in pMHC interactions. One method to 
overcome the independence of each chain population links the two chains using gene 
assembly with a linker region to generate a random library of scTCR or bicistronic 
constructs84. These gene assemblies from amplified variable domains can produce libraries 
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of greater than 107 bypassing the problem of mismatched TCR chains when paired with a 
rapid screening method like phage display. 
Determination of the four genes (TRAV, TRAJ, TRBV, and TRBJ) and junction 
sequences (CDRα3 and CDRβ3) for individual T-cells is important for finding the 
complete diversity and frequency of sequences in the T-cell repertoire. Previously, HTS 
and single-cell studies have been unable to obtain gene and junction data for both TCR 
chains from T-cell clones on a high-throughput basis. The single cell studies use RT-PCR 
techniques to obtain both α- and β-chain sequences using nested PCR reactions. Until 
recently, these single cell studies were time consuming, labor intensive, and could not scale 
to the depths necessary for repertoire sequencing.  
In the last few years, new developments in microfluidics have dramatically 
increased the scale of single cell sequencing analysis. Two new HTS methods using 
different techniques generate isolated single cell reactors for cloning the two immune 
receptor chains. The first involves sorting and sealing individual cells into 125 pl wells on 
a printed microscope slide85. Thermocycling the slide then amplifies and links the receptor 
sequences for downstream HTS. This process works on scales of 1.7 x 105 well per slide 
and can generate sequences for more than 5 x 104 cells per experiment. The second method 
uses single cell emulsion droplets to isolate cells instead of the pl well slide for downstream 
gene amplifications and chain linkages86. This method reports sequencing rates between 3 
x 105 – 1.2 x 106 quality, paired in reads per emulsion reaction. Implementation of these 
methods with other polymorphic or hypervariable sets of genes can measure natively 
unlinked diversity in a myriad of new applications. Coupling increased sequencing depths 
with the ability to sequence both chains of sorted cells would have greatly increased the 
utility of our experiment, allowing us to accurately pair TCR chains for antigen specific 
cells above the background repertoire. 
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In conclusion, supplemental experiments to pursue antigen-specific sequences in 
mouse TCR repertoires should take additional steps to increase the in vivo of OVA-specific 
T-cells in the mouse by giving the mice an additional immunization one to two weeks after 
the initial exposure. The use of Illumina technology will also require a redesign of the TCR 
primer set for the shorter sequencing read lengths used in this process. A more interesting 
question may be how the repertoire expands and contracts with time before during and after 
encountering various disease antigens. Characterization of the antigen-responding cells 
from HTS alone was hampered by non-specific background. A more extensive study of the 
repertoire either by single cell assays or with antigen stimulation and sorting would more 
easily identify the antigen specific T-cells.   
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Chapter 3:  Evaluation of canonical loops in TCRs 
3.1: CHAPTER SUMMARY 
Canonical CDR loops in the majority of TCR and antibody variable regions have 
well-defined key residues that play an important and conserved role in loop structure. 
Previous work by Chothia et al with seven unique TCR structures predicted the presence 
of several canonical classes for each CDR loop, based on preexisting antibody canonical 
loop analysis23.  Increased interest in analyzing TCR binding kinetics has motivated the 
ongoing investigation of canonical loop structures in TCRs23,87,88.  The ability to accurately 
predict TCR CDR structures will aid in the effort to design functional TCRs against target 
peptide-MHC complexes and engineer specific immune responses89,90.  
In this study, we expanded Chothia’s work and evaluated CDR loops from 249 
solved TCR and TCR-like antibody structures deposited in the Protein Data Bank (PDB). 
Loops were grouped into canonical classes based on a pairwise root mean squared distance 
(RMSD) of ≤1.5 	 and	 analyzed	 the	TCR-pMHC binding orientation and interfacial 
properties. This analysis found classifications for the majority of CDR loops, 70% and 81% 
in the α- and β-chains respectively and structures for 3 new canonical classes in CDR1 and 
CDR2. CDR structure prediction from sequence data provides insight into TCR-pMHC 
interactions. Protein modelers can use sequence data to design mutations to alter the CDR 
loop structure to change the TCR function. This TCR structural prediction analysis from 
sequence data has implications protein and immune-receptor engineering. Engineering 
receptors for affinity and specificity is important for immunotherapies and many biological 
processes. Antibody and TCR models can use key residues similar to this study to predict 
the general structural conformation and surface characteristics.  
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3.2: INTRODUCTION 
The adaptive immune system plays a critical role in the recognition and 
neutralization of diseases with a complex network of chemicals, proteins, receptors, and 
cells. T-cells in particular are tasked with discerning between self and foreign antigen 
peptides presented by other cells in a rapid, robust fashion with a clonotypic T-cell receptor 
(TCR). Successful antigen peptide recognition by the TCR initiates a signaling cascade via 
a series of stereotyped events including T-cell differentiation, cytokine expression, and 
targeted cell lysis depending on T-cell type.  
TCR/ pMHC function 
To generate the level of binding diversity required to target the myriad of foreign 
peptides in the body, TCRs rely on genetic recombination and imprecise junction 
formation. The resulting diversity in the structure of CDR3 allows the fine distinction of 
the numerous self-peptides from the nearly infinite number of foreign antigen peptides 
indicative of illness. While TCR peptide-MHC (pMHC) interactions are more often 
considered homologous to antibody-antigen interactions generated in B-cells, several 
major differences warrant attention. Unlike high affinity soluble-antigen binding 
antibodies, TCRs engage pMHCs as membrane-bound molecules with a more constrained 
interaction. B cells further maturate stronger antibody binding affinities by somatic 
hypermutation for improved function while TCRs undergo no further mutations upon 
exiting the thymus91,92. As opposed to antibody-antigen interactions, the structural and 
kinetic mechanisms governing TCR/pMHC interactions are less well understood. T-cell 
maturation involves a coordinated selection of TCRs with a narrow binding affinity range 
balanced between no binding and cross-reactive aberrant MHC binding. Many TCR-
pMHC kinetic studies describe the receptor’s specificity as driven by a slow kon and a rapid 
koff13,93. A current hypotheses for high specificity and low affinity of this peculiar protein-
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protein interaction results from the plasticity of all the interacting components wherein 
proper TCR deformation exposes internal co-receptor ITAMs for downstream signaling 
activation94. 
TCR/ pMHC structure 
The surface TCR complex involves a  host of accessory proteins (CD3-γ, -δ, -ε, & 
-ζ, CD4, CD8, etc.) to guide and stabilize pMHC interrogation95. As mentioned above the 
flexibility, low affinity and generally soluble-format instability of the TCR and pMHC has 
prevented a more thorough analysis and fewer solved unique TCR structures of these 
immunologically important proteins.81,96,97 TCRs are structurally homologous to 
antibodies, with an α/β hetero-dimer, each having a constant and variable domain. The 
variable domain consists of an immunoglobulin (Ig) β-sheet barrel structure with three 
CDRs comprising the binding paratope, responsible for pMHC ligand interaction. The third 
CDR on both chains forms by the gene combinations and imprecise hypervariable junctions 
generating considerable sequence and structural diversity required to recognize the vast 
array of potential antigen peptide. MHC molecules are polygenic and highly polymorphic 
hetero-dimers with two structurally conserved α-helices atop a β-sheet “floor” forming a 
peptide binding groove to accommodate a myriad of short peptides (8-17 amino acids in 
length), lipids, and other small molecules depending on the MHC class. The polymorphic 
MHC molecules require a custom repertoire of TCR αβ-chain combinations and CDR3 
sequences to engage this antigen presenting protein. 
Biochemical studies suggest TCR-pMHCs interactions occur as a two-step process, 
with αβ CDR1 and CDR2 first engaging the MHC α-helices peripheral to the CDR3s and 
antigen peptide to stabilize the recruitment of accessory receptors and TCR deformation 
interrogation95,98–100. Many TCR-pMHC structures show a mostly conserved and concerted 
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diagonal engagement with the binding groove forming a pocket for the CDR3s to directly 
interrogate the peptide, giving the CDRs specific and stable binding99,101.  
Canonical Structures in Antibodies and TCRs 
Previous work by Chothia et al identified, in both antibodies and TCRs, conserved 
Ig CDR residues predicted to make canonical structural conformations underscoring the 
balance in the variable domain’s conserved framework structure and variable CDR 
loops23,80,88,102,103. While the variable genes in the entire Ig repertoire contain considerable 
sequence diversity, the majority contain key canonical loop forming residues in CDR1 and 
288,104. These key residues and subsequent canonical classes were initially identified by 
structural comparison and sequence alignment of antibody CDR loops and flanking 
frameworks. The hypervariable CDR3 loops, which vary significantly in length and 
sequence, have so far defied structural classification and prediction due to the dramatic 
structural deformations between bound and unbound states105. This early work identified 
multiple classes for each CDR1 and 2 loops, as well as key residues in the majority of 
variable gene regions. Ward et al later solved the structure for the predicted α1-4 canonical 
class, from an isolated α-chain homodimer with shorter CDR than observed in most other 
TCRs24. The utility of canonical classes, apart from describing structural diversity and 
predicting specificity-determining residues, allows engineering of CDR grafts on chimeric 
TCRs and the development of more accurate algorithms to predict CDR structure, residue 
interactions, and hypothesize specificity and function from sequence data87,103,106,107.  
In the years since the Chothia et al study, the TCR structural database has expanded 
significantly from the seven initial structures to over 200 today (Figure 3.1). TCR 
structural analyses has proceeded more slowly than antibodies due to the lack of TCR 
diversity in the solved structures with less than 100 novel TCRs defined on IMGT and 
PDB. This stems from difficulties in the production of soluble, recombinant TCR protein, 
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as TCRs have evolved for stable expression at the outer membrane surface. Recent 
advances in recombinant TCR expression technology resulted in an increase in the 
available TCR structures, providing a larger data set for a statistically significant analysis 
of TCR canonical classes. TCRs are structurally analogous to antibodies, but functionally 
distinct immunological receptors, and are more difficult to study biochemically. 
 
 
Figure 3.1: Published TCR structures in the PDB over time. 
Starting from the initial discovery of thymocytes in 1985 the number of solved TCR 
structures remains only a fraction of the total antibody structures due in part to the 
instability of soluble receptors and the low affinity interactions with pMHC which can 
make complexation difficult. 
For example, characterization of the 179 pMHC-bound TCRs have yet to elucidate 
a clear role for the conserved diagonal binding footprint and whether the orientation is 
forced by the co-accessory proteins in the immune complex or if the angle is  a genetically 
encoded “interaction codon” or opposing charged residues key to regulating TCR-PMHC 
specificity100,108. The conserved interrogation of the MHC by CDR1 and CDR2 may cause 
the high amount of structural similarity between the various TCRs regardless of sequence. 
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3.3: STRUCTURAL ANALYSIS METHODS 
TCR data set 
In this study, we analyzed the prevalence of canonical classes in the available αβ, 
γδ, and TCR-like Ig structures, consisting of 249 PDB structures and 64 uniquely paired 
TRAV/TRBV TCR structures. Discussion of α- and β-chain properties applies to the 
respective chains of γδ TCRs and the Light/Heavy chains of antibodies. On March 12, 
2015, all 249 available αβ and γδ TCR and TCR-like antibody structures were retrieved 
from the PDB in their various complex configurations (unbound, pMHC bound, IgG 
bound, single-chain variant, super-antigen bound, etc.). The CDR locations and sequences 
within each TCR chain were identified using the IMGT unique numbering system for Ig 
and T-cell receptors77. This work used slightly modified loop selections to give additional 
structural context to the loops within the Ig structure. CDR1 loops were expanded to 
include residues from the conserved cysteine at IMGT position 23 to the tryptophan at 
position 41. CDR3 loops also spanned from the conserved cysteine through to the aromatic 
-FG or -WG groups on the carboxyl-terminal end of the loop. CDR2 identification was 
slightly modified from prior rules established for antibody and TCR canonical loops. The 
variation in the CDR2 locations required additional modifications to the selected definition 
of CDR2. To overcome the possible variability of the loop location in the chains the CDR2 
the loop was isolated using the residues of the C’ and C’’ β-sheet strand flanking the CDR 
approximately 20 residues after the C-terminal Trp41 residue of CDR1 and 36 residues 
before the conserved Cys104 in CDR3 on both chains.  
CDR alignment comparison script 
A program (Align.py) to align and measure the structural similarity between every 
identified CDR loop was written for pyMOL (The PyMOL Molecular Graphics System, 
Version 1.7.4 Schrödinger, LLC.) using a python-based scripting language. For each TCR 
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structure, the program isolates the CDR main-chain backbone atoms (N, Cα, C, & O) with 
the CDR identification parameters established above to remove the flanking framework 
residues. If PDB contained multiple identical TCR structures within the unit cell the 
program (Aligned Unit Cells.py) then compared each loop for its variability measuring 
the average distance between each backbone atom along the loop backbone. Often, the 
CDR3 loops varied significantly between identical chains within a unit cells. Additionally 
if the PDB structure contained atoms with alternate location indicators the program 
considered the atom listed first in the further analysis. After isolating one of the six sets of 
CDRs from all the TCRs in this fashion, the script performed a pairwise superposition 
alignment to calculate the root mean squared difference (RMSD) used to measure the 
aggregate structural difference between individual backbone atoms. If the alignment 
function excluded backbone atoms in this way, a further analysis was performed to 
determine if the exclusion loses integral structural information and the RMSD penalty that 
should be associated with the exclusion. Similarly this alignment program compared loops 
between the six regions for any structural similarity, but with lowered atomic exclusion 
parameters to allow for differences in loop sizes between the mobile and reference objects. 
Identification of canonical classes and key residues 
With all the RMSD values calculated between every individual CDR loop in a 
diagonally symmetric pairwise table, another program (Data Processer.py) minimized the 
distance between clustered loops by their mutual RMSD values excluding loops with 
RMSD values larger than 1 Å to any other clustered loop. Groups lacking a plurality of 
variable regions were rejected as definitive clusters since sequence and structural identity 
is not necessarily indicative of a canonical class. Any remaining loop structures not 
clustered or classified were considered unclassified. In most cases, CDR loops from 
identical TCRs fit into the same cluster except for a few exceptions for point mutations or 
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peculiar complexation configurations. To determine and verify the structural role of key 
residues as defined by Chothia et al (2000) the CDR sequences of clustered structures were 
aligned as seen in Table 2 showing the conserved physiochemical residues. Additionally 
alignments of the clustered CDRs showed definitively how the key residues had an 
incredibly low amount of structural variability in both the mainchain backbone and their 
orientation of the sidechain.  
Comparisons between interaction codon 
Structural co-variation with combinations of multiple CDRs used a similar 
alignment script as above but with expanded region selections. These combinations (α1α2, 
β1β2, α1α2+β1β2, or α1α2α3+β1β2β3) illustrate the conserved and coordinated nature of 
the CDR loop structures in the V-region sequences since certain key residues and canonical 
classes co-vary as features in their shared function and pMHC interactions. 
TCR-pMHC structural interactions 
To analyze any structural trends in the orientation and spatial arrangement of TCR-
pMHC complexes CCP4 subroutines AREAIMOL, SC, and CONTACT calculated the 
buried surface area, shape complementarity, and the atomic contacts respectively. Another 
script (Docking.py) calculated the TCR-pMHC docking angle and spatial orientation 
between the long axial MHC binding groove and the line between the TCR α and β chains. 
This binding geometry was found between each TCR chain CDR mainchain atoms reduced 
to centers of mass and the linear and planar approximations for the peptide and MHC 
binding groove. The coordinate system centered on the flanking α-helices with the x- and 
y-axis parallel and perpendicular to the linear approximation of the peptide respectively 
the positive z-axis extends into the complex of the TCR. While the TCR chain centers of 
mass may be biased by the size and arrangement of the CDRs it more accurately 
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representatives the TCR footprint because it is closer to the actual pMHC contacts. This is 
varies from previous calculations that used the line through the center of the di-sulfide 
bonds for each chain by differing amounts based on the TCRs orientation in relation to 
MHC plane96. An alternative method for determining the crossing angle described as a 
residue-specific definitions of the TCR-pMHC binding-angle by identifying 
complementary opposing charged residues between the TCR CDRs and MHC alpha 
helices108. Surprisingly the separate linear approximations of both the peptide antigen and 
the α-helices showed little variability as linear vectors.  
3.4: CANONICAL STRUCTURE RESULTS 
The percentages of classifiable TCRs and their miscellaneous properties are 
summarized in Table 1. The overall average RMSD values for the 17 classes reported in 
Table 3.2A-D are based on comparisons to the average loop conformation depicted in 
Figure 3.2A-D compiled from all the TCR structures within the class. Within each class, 
the RMSD of the backbone alpha carbons position varied less than 1.5 Å, with each CDR 
having 3-6 observed classes104,109. Of the total CDR1 and CDR2 loop structures analyzed 
76% fit into canonical classes with 82% and 73% for human and mouse TCRs respectively. 
The percentage of classified pMHC-bound TCR and unbound structures was 77% and 60% 
respectively with an additional 33 loops in Ig or super-antigen bound complexes classified. 
Many previously proposed canonical classes based on the seven original structures (PDBs: 
1AO7, 1BD2, 1BEC, 1KB5, 1NFD, 1TCR, & 2CKB) and limited number of known human 
and mouse TCR v-regions had additional structures added in this analysis. Most classified 
structures maintained the proposed key residues and conformations predicted by Chothia 

















































































































































































































































0.55±0.01  75 25 12.5 87.5 1AC6; 2PXY; 2Z31; 2Z35; 3C5Z; 
3C60; 3RGV; 4QRP 
A2‐2c  2  14 
RA14 (50.0); SB47 (50.0)  LFVLLSNGAVKQEG (50.0), 
LFVMTLNGDEKKKG (50.0) 






























































0.95±0.14  86.7 13.3 13.3 86.7 1G6R; 1I9E; 1MWA; 1TCR; 2CKB; 
2E7L; 2ICW; 2OI9; 3E2H; 3TF7; 
3TJH; 3TPU; 3VXM; 4H1L; 4NHU 
A2‐new2  3  14  9C2 (66.7); MICA (33.3)  FLIRQGSDEQNAKS (100.0) H‐VD1 (66.7); H‐VG4 (33.3)  0.05±0.02  33.3 66.7 100 0 3OMZ; 4LFH; 4LHU 





























































































































































0.01±0.001  25 75 100 0 1TVD; 4MNG; 4MNH; 4NDM 
B1‐new2  4  15 








0.91±0.19  50 50 100 75 1HXM; 1W72; 3CVI; 3UBX 
















































































































































0.68±0.27  85.7  14.3 100 0 3MV7; 3MV8; 4E41; 4E42; 4JRY; 4PRH; 4PRI; 4PRP
Table 3.1D: Summary table for CDR 
Summary tables for the canonical classes found in this study including the number of PDB structures in each class, the CDR 
length, the specific TCRs, CDR residue sequence, variable region, RMSD score to the central average structure, the percent of 




Figure 3. 1: Aligned CDR classes  
Class and subclass alignments between the average structures compiled from the classified 
loop in each CDR show how similar the flanking positions of the loops are in CDR1 and 
more variable in CDR2. Average alignments for the loops include: (A) CDRα1, (B) 
CDRβ1, (C) CDRα2, and (D) CDRβ2. 
The majority of loops in each CDR had similarity with at least one member of a 
different V-region leaving a minority of unclassified structures with 14%, 45%, 11%, and 
23% unclassified for CDR α1, α2, β1, and β2 respectively. These unclassified loops are 
summarized in Table 3.1A-D. With additional solved structures, these distinct structures 
will be shared additional V-regions and possibly become a canonical class. While α loops 
had more canonical classes than β loops, the β structures had fewer unclassified structures, 
which is similar to the diversity of canonical classes found in antibody structures110. Due 
to the very different variable domain arrangements of the β-sheets no canonical classes 
were shared between antibodies and TCRs. There were 46 loop structures with identical 
chains in the unit cell, which did not converge on a single conformation. These structures 
were not included in subsequent analysis. 
Previously established and predicted canonical classes with only one TCR type 
were further scrutinized to determine if the structures are a distinct canonical class. For 
example, the N15 TCR (PDB: 1NFD & 3Q5Y) α-chain was established as the 
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conformation for class α1-3 and had two solved structures forming distinctly different loop 
conformations. Although the N15 structures didn’t agree on a similar conformation there 
were 21 other structures with those proposed key residues which now form the expected 
structural conformation for this canonical class. 
Key residues, CDR length, and framework β-sheet arrangement all play an 
important role in the stabilization and conformation of the backbone loop in its interaction 
with other CDRs and the pMHC. The additional solved structures found 3 new canonical 
classes based on their dissimilarity to other clusters of structures and unique set of V-
regions. In the structural comparisons, we noticed the occurrence of slight structural 
variations from canonical loops that also maintained the key residues. These groups while 
distinctly different from the canonical class were similar enough to warrant definition as a 
canonical subclass. The analysis determined a new set of 16 subclasses indicated in 
summary Table 3.1A-D, defined by identical and spatially overlapping key residues with 
backbone variations between residues. For example, the main conformation for α1-1 class 
had three mostly similar subclasses with an RMSD less than 1.5 Å.  
Structures compared  
By generating alignments by CDR sequence, key residues, V-region, or TCR 
identity, or CDR3 sequence showed the prevalence of certain loop conformation occurring 
and the slight variations occur between the bound and unbound receptors. As expected, the 
amount of backbone variation between these alignments increased as the grouped property 
became less specific. Alignments between identical V-regions and CDR sequences in both 
bound and unbound configurations showed low mainchain variation as seen in the 
differences between blue and red loops in figure 2. Coupled with the amount of structural 
similarity found in the β-sheet barrels comprising the V-region framework indicates a more 
conserved structure outside the hypervariable CDR3 region on both chains. This is an 
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interesting since other studies have found a higher degree of paratope plasticity expected 
from TCRs.69,111,112  
The majority (72%, 179/249) of the solved TCR structures are bound to MHC 
molecules, with 83% (148/179) in complex with MHC class-I. TCR derived from either 
CD4+ or CD8+ T-cells have been shown to bind the pMHC differently between what MHC 
α-helix residues are contacted and the TCR affinity based on orientation over the pMHC 
and the lineage’s function in the immune system. Several studies have noted the TCR 
affinity differences in CD4+ and CD8+ T-cells due in part to the need for the TCR to either 
specifically target an infected cell or serially scan for more peptide antigens for the two 
lines respectively, which may in fact be impacted by the binding of the CD4/CD8 co-
receptor to the pMHC113,114.   
Predicted Key Residues 
The previously predicted key residues were predominately accurate in nearly all 
classified structures between a variety of CDR sequences and V-regions. The key residues 
in many classified structures were functionally conserved, with physiologically similar 
amino acids, and pointed either into the CDR loop to contact or interlock with one another 
or towards a neighboring CDR loop. Loops without exactly matching key residues as 
defined by Chothia, had a similar functioned residue in their place, which did not seem to 
affect the overall conformation. The key residues predicted for classes TRBV1-5, TRBV2-
4, and TRBV2-5 were not found to any structural relevance in this study did not cluster 
with any V-regions outside identical structures or sequences.  
Note on mouse TRBV-13 with other V-region classes  
The most prevalent V-region genes used in many TCR structures is mouse TRBV13 
found in 62 structures, all of which were in the same CDR1 and 2 classes. The TRBV13 
increased representation could be attributed to a more prevalent β-chain rearrangement 
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with this gene or due to the biased usage in cloning because its stability as a soluble protein 
in high quantities in E. coli or possibly the bias of this V-region found in mouse TCR 
repertoiress27.  
The α1 hypervariable regions 
The CDRα1 domain has five canonical classes incorporating 31 V-regions 
disregarding the myriad of other polymorphisms. Of the 235 α1 structures analyzed 86% 
were classified. 
 
Figure 3. 2A-F: CDRα1 class alignments 
Canonical loops with key residues shown for classes (A) α1-1, (B) α1-2, (C) α1-3, (D) α1-
4, (E) α1-5, (F) α1-6. 
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Figure 3.2G-K: CDRα2 class alignments  
Canonical loops with key residues shown for classes (G) α2-1  (H) α2-2 with two 
subclasses, (I) α2-3 with two subclasses, (J) α2-4 with three subclasses, and (K) α2-5. 
α1-1 
From the 3 original structures in the class 60 more had the same CDRα1 
conformation all within 0.31 Å of the average structure. The α1-1 class has the largest 
amount of genetic variability of the other α1 classes with 8 TRAV regions used (h-TRAV-
1, -12, -13, and -29 and m-TRAV14) TRAJ region usage was also the most variable in this 
class using 19 gene regions. Residues important for the structure consist of residues 25 and 
39, the majority of which are Tyr and Phe respectively. These two residues point inwards 
of the loop and if both are aromatic they stack. Residue 36 may also have structural 
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significance with either a Ser or Phe pointing into the loop as seen in Figure 3.2A causing 
an indent in the peptide backbone towards its center at that residue. 
α1-2 
The original CDRα1 TCRs 1AC6, 1TCR, and 2CKB barely fit into this class with 
an overall RMSD average of 0.793 Å for these three structures alone. The 29 new TCRs in 
class α1-2 all had a length of 13 residues with an overall average RMSD of 0.38±0.60 . 
This class contains 3 6TRAV-regions (human TRAV3, -8, & -9 and mouse TRAV6, -9, & 
-12) and uses 12 TRAJ-regions. The key residues in this class include inwardly pointing 
Tyr25, Pro37, and Lue39 which interact with one another with an approximate distance of 
2.0 and 2.6 Å between the closest atoms of Try25:Pro37 and Try25:Leu39 respectively. 
The kinked and slightly variable structure in the loop apex highlighted in Figure 3. 2B is 
caused by a combination of Pro37 and it pushing against the side chain at position 27 out 
of the plane of the loop setting it apart from other canonical classes. Contained in this class 
are three subclasses which have matching positions at the key residues but very slightly at 
residue positions 27-36.  
α1-3 (With novel subclass recognized as α1-5) 
The initially proposed α1-3 conformation using the N15 (PDB: 1NFD) CDRα1 loop 
did not have any additional structures added in this expanded set of TCRs even though 21 
other structures had the prescribed key residues. These other loops also formed two 
subclass structures with a loop length of 14 residues and an average RMSD value of 
0.05±0.03 Å and 0.82±0.14 Å respectively. The N15 in structure 1NFD might be a 
structural anomaly because it is IgG-bound possibly altering the CDR structures since 
antibody affinities are much higher than pMHC interactions. This class contains 7 V-
regions (human TRAV14, -19, -26, human TRDV1, human TRGV4, mouse TRAV16, and 
-21) and 11 TRAJ-regions. The subclasses split and for a different configuration at residues 
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28 and 29 with the human TRAV26 and mouse TRAV21 regions using Ile at residue 29 to 
interact with the other key residues instead of Thr28 in all the other classified structures. 
Many of the residues in this group are either charged or polar allowing various intra-loop 
interactions shown in Figure 3.2C and E. The second subclass shown on the right has 
residue 30 interacting with the nitrogen of residue 27, bringing the top portion of the 
backbone into a hairpin turn. Variations between the two subclasses occur at residue 
positions 26 and 28-30 while all the other loop positions and key residues are in nearly 
identical positions.  
α1-4 
This class was originally predicted based on the following the 12 residues sequence 
pattern found in 5 V-region sequences:  
C-X-S-S-X-X-[FL]-X-X-[VLIW]-X-W23. 
Ward et al then solved the first structure with a similar sequence motif with mouse 
TRAV4-4/DV10 (PDB: 1H5B).  The α1-4 class contains 8 different CDR sequences and 6 
TRAV-regions (human TRAV22, -27, -35, -39, mouse TRAV4, and -13) and 11 TRAJ-
regions. The overall average RMSD value for this class is 0.05±0.04 ,	the	lowest	of	all	
the	 classes. The three key residues in this class all strongly associate and cause the 
distinctly square loop shape seen in the Figure 3.2D.  
α1-6 (New canonical class)  
This new conformation with an average RMSD value of 0.59±0.67Å includes many 
structures with class α1-1 key residues, but has an incredibly different backbone shape well 
beyond what could be considered a subclass. There are 4 unique V-regions in this class 
(human TRAV1, -10, -11, 20, and mouse TRAV11) and 8 TRAJ-regions. Looking at the 
α1-1 and α1-5 average structure in Figure 3.2F for these loops shows a large deformation 
between residues 27 – 29 and 36 with a maximum distance of approximately 3.4 Å at 
 68
residue 28. The key difference of this class to the α1-1 structure is the small residue at 
position 29 allowing a sharper turn and increasing the gap at that location. 
The α2 hypervariable regions 
Just over half (54%) of CDRα2 loops fit into a canonical class, with the largest 
amount of unclassified loops of all the CDRs. This CDR showed the largest amount of 
structural diversity with higher average RMSD values and the most classes and subclasses 
likely due to the variability caused by the location of the CDRα2 loop at the far end of the 
2 sets of parallel β-sheets and the size of the residues oriented into the loop. In this study 
the CDRα2 loop consisted of the residues between flanking β-turns on either side of β-
sheet strands C’ and C’’. 
α2-1  
The α2-1 class includes 27 human TCR loops 12 residues in length and an overall 
average RMSD of 1.35±0.66 Å. The majority (96 %) of the TCRs utilized human TRAV12 
except ELS4 (PDB: 4GRM) which used human TRAV39 and 6 TRAJ-regions. The Lys66 
residue points towards the C’ β-strand where it pushes between residues 55 or 57. The loop 
apex flattens at the top with the residue side chains pointing nearly perpendicular (see 
Figure 3.2G) to the plane of the loop, which is interesting since this occurs in both bound 
and unbound structures in this class.  
α2-2  
The α2-2 class includes 36 structures in three subclass conformations 13 residues 
long and higher average RMSD values of 1.48±0.06 Å, 0.55±0.01 Å, and 1.33±0.04 Å 
respectively. The α2-2 class had 6 TRAV-regions (human TRAV9, -11, -24, -39, mouse 
TRAV6, and -11) and 8 TRAJ-regions. Alternating, inwardly pointing, medium-sized 
residues (54, 56, 58, 64, and 66) in this class help give this loop its almost zipper-like shape 
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in subclass α2-2a. The Lys66 in α2-2a subclass further brings the two sides of the loop 
together with a hydrogen bond with the carboxyl oxygen on residue 55. The variations 
between the three classes occur in the different sizes of the residues at these positions, 
which slightly alter the distance between the flanking ends of the loops shown in Figure 
3.2H.  
α2-3  
The α2-3 class includes 29 structures and has 2 nearly identical subclasses which 
only vary at the C’’ strand by a distance of 1 Å. This class has 5 different TRAV-regions 
(human TRAV10, -17, -21, -29, and mouse TRAV14) and 12 TRAJ-regions with an overall 
average RMSD of 1.14±0.26 and 0.53±0.24 Å for the two subclass structures respectively. 
The bulky residues positioned at the apex cause greater deformation of the backbone which 
allows the charged or polar residue at position 66 to  point into the loop to form hydrogen 
bonds with the backbone carboxyl group of residue 55. This structure is visualized in 
Figure 3.2I.  
α2-4 
The α2-4 canonical class was proposed by Ward et al (S Ward) containing Vα11 
(1H5B). Class α2-4 has 17 TCR structures, a length of 11 residues, and comprises two 
slightly varying subclasses Figure 3.2J with overall RMSD averages of 1.20±0.31 and 
0.16±0.10 Å respectively. There are 3 TRAV-regions (human TRAV22, -26, and mouse 
TRAV4) and 14 TRAJ regions. This class is structurally similar to α2-3 class with residue 
66 pointing toward the backbone of residue 55 forming a bond if the residue is long enough 
as in the case of a Lys66 in mouse TRAV4. Residues at positions 54, 56, 66, and 68 
alternately almost stack beside one another to help give the loop a planar shape. 
α2-5 (New canonical class) 
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This new class conformation found in 15 structures was the only new unique 
conformation found in CDRα2 using 2 TRAV-regions (human TRAV8 and mouse 
TRAV9) and 4 TRAJ-regions and an overall RMSD average of 0.95±0.14. The Tyr56 in 
this class pushes itself within the apex of the loop forcing residues 57-59, 62, and 63 to 
arrange themselves away from the loop center with help from the kink provided by residue 
63 shown in Figure 3.4.2K. The hydrophobic residues at 54 and 65 additionally narrows 
the distance between the flanking ends of the loop. Based on these structural features 
described the key residues for this class include hydrophobic residues at 54 and 65, a large 
aromatic residue at 56, and a small to medium-sized amino acid at position 63.  
 
The β1 hypervariable regions 
CDRβ1 had the highest number of classified structures of all CDRs with 86% of 
structures analyzed fitting into the two established classes. Additionally there was another 
new conformation with 4 structures found in human TRDV-regions. Similar to antibodies 
there was less structural variability in CDRβ1 and β2 possibly because evolutionary 
pressure has focused on CDRβ3 since it has a much larger diversity generated during VDJ 
gene rearrangement. CDRβ1 classes 3-5 that were initially proposed in 2000 did not have 
any structures cluster beyond identical TCRs even though there are now over 14 TCR 
structures with TRBV-regions.  
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Figure 3.3A-G: CDRβ class alignments 
Alignments for the CDRβ1 and CDRβ2 classes show the majority of structures conform to 
a single class. Canonical loops with key residues shown for classes (A) β1-1, (B) β1-2, (C) 
β1-3, (D) β2-1, (E,F) β2-2 with two subclasses, and (G) CDRβ3 alignments showing the 
high structural diversity these loops. 
β1-1 
As predicted by the key residues in CDRβ1, the majority (68%) of the β1 structures 
examined were classified as β1-1 loops. This class had 13 V-regions from human, mouse 
and rat TCRs (human TRBV4, -5, -6, -10, -19, -25, -27, -28, mouse TRBV12, -13, -19, -
29, and rat TRBV5) and 20 TRBJ-regions, a 12 residue length, and an overall average 
RMSD of 0.07±0.13 Å. The β1-1 class is one of the most structurally consistent classes, 
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seen in Figure 3.3A, even with so many different TCRs, structures, and sequences. This 
consistency hinges upon the close interactions between residues 25, 27, 29, and 32.   
β1-2 
This CDRβ1 class also contains a large number of structures with 42 (17 %) loops, 
9 TRBV-regions (human TRBV5, -7, -9, 11, -12, -14, mouse TRBV3, -12, and -26), 11 
TRBJ-regions, and an average RMSD value of 0.66±0.33 Å. The key difference of this 
loop from β1-1 is the Pro25 residue which varies the backbone at residues 25-28 shown in 
aligned classes of Figure 3.3C. This backbone alteration narrows the loop at residues 26-
29 with close interactions between 26 and 29 shown in Figure 3.3B. Outside of this 
variation, the remainder of the loop residues are nearly identical to β1-1.  
β1-3 (New canonical class) 
The previously proposed β1-3 class is structurally most likely unique to its variable 
region since the 10 structures with matching β1-3 key residues (PDB: 1FO0, 1KB5, 1KJ2, 
1NAM, 2OL3, 3HG1, 4JFD, 4JFE, 4JFF, and 4JFH) failed to form any structural consensus 
seen by Figure 3.3C. Instead of a third β1 class around mouse TRBV1 another smaller set 
of 4 TRDV-region structures (human TRDV1 and -3), 14 residues long, and an average 
RMSD value of 0.01±0.01 Å showed a distinctly unique and interesting conformation. This 
class has residues 25, 27, 37 and 39 all pointing into the center of the loop in direct 
opposition to one another. The loop apex also has residues 29 and 30 oriented either 
perpendicular to the plane of the loop or directly away from the base of the loop. With only 
two CDR sequences in this class the key residues are not especially distinct.  
The β2 hypervariable regions 
Similar to CDRβ1, this analysis found larger but fewer β2 classes than originally 
proposed in the 2000 canonical study with only two classes with well-defined 
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conformations. CDRβ2 found classifications for 75% of the loops. The remaining smaller 
groups of unclassified CDRβ2 loops lacked diversity within the groups to be definitive 
classes. Similar to CDRα2 loop, this loop is the antigen engaging portion between β-sheet 
strands C’ and C’’ which can vary depending on the β-chain sheet composition or α-chain 
V-domain interaction.  
β2-1 
As expected based on the co-variation of classes, most of the TCRs classified as 
β1-1 had β2-1 CDRβ2 loops. This class had 159 structures in it with 11 TRBV-regions 
(human TRBV5, -6, -10, -19, -25, mouse TRBV12, -13, -19, -29, and rat TRBV5), 22 
TRBJ-regions, a length of 13 residues, and an average RMSD of 0.94±0.47 Å. All the loops 
have a Ser56 in the same orientation forming hydrogen bonds with the backbone carboxyl 
oxygen in residues 58 and 65 labeled in Figure 3.3D. These hydrogen bonds help fold the 
loop apex into the center of the β-chain and orient the side chains of residues 55, 57, 65, 
and 67 into solvent exposed positions near CDRα3.   
β2-2 
Similar to the previously mentioned classes formed around TCR N15 there were no 
additional structures added to its particular loop conformation. The key residues proposed 
for the β2-2 class otherwise had 24 structures in 2 subclasses 7 TRBV regions (human 
TRBV 5, -7, -9, -11, -12, -14, and mouse TRBV14) and 7 TRBJ-regions, all 12 residues 
long, and an average RMSD values of 0.92±0.44  and 0.68±0.27  for each subclass 
respectively. This loop class is tightly bound with 5 sets of hydrogen bonds connecting the 
backbone nitrogen and carboxyl oxygen atoms in residues 55, 57, 64, 66, and 67 indicated 
in Figure 3.3E & F. Similar to β2-1 the side chains at residues 55, 57, 66, and 67 into 




We performed the same structural analysis with CDR3 and found the loops mostly 
unclassifiable due in part to the substantial variability in length, sequence, and structure. 
Depending on the complex conditions, the longer and often structurally ambiguous CDR3 
structures are either solvent exposed or pressed against the pMHC causing a high degree 
of structural variability between the solved structures of nearly identical TCR complexes. 
The only consistent feature of CDR3 structures was the conserved framework and take-off 
portions highlighted in Figure 3.3G, which contrasts with the central pMHC-interrogating 
portion that contains a large amount of variability. Studies attempting to obtain parameters 
for CDR3 structural predictions have found limited success in both TCR and antibody 
hypervariable regions102,105.  
γδ CDR Loops 
γδ TCRs comprise a small minority of lesser studied structures with 7 γδ dimers 
(G115, G8, and MICA-specific human delta scFv) (PDBs: 1HXM, 3OMZ, 4LFH, 4LHU, 
4MNG, 4MNH, and 4NDM) and one δ chain fragment (PDB: 1TVD) analyzed similarly 
to αβ TCRs for possible canonical structures. Due to the different overall framework 
structure of these γδ TCRs only 3 CDR structures fit into established canonical classes.  It 
could be the different functional role of γδ TCRs binding to a variety of antigens, MHC-
bound or otherwise, could give them CDR conformations similar to both αβ TCRs and 
antibodies. 
Antibody Comparison 
After establishment of these detailed canonical classes, they were then compared 
to known antibody classes110. The two sets of canonical classes had no overlapping 
similarities even though both are structurally similar. It could be the higher binding 
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affinities in antibodies change the framework and CDR backbone structure when compared 
to TCRs. TCR-like antibodies have only been reported for a few pMHC molecules, 25-
D1.16 in particular binds to pOV8-Kb with nearly the same orientation as its TCR 
counterpart KB5-C20 (PDB: 1KB5)115,116. Even with the nearly identical epitope found 
between the two proteins none of the CDR loops of the 25-D1.16 overlapped with the KD5-
C20 TCR. 
3.5: DISCUSSION AND CONCLUSIONS 
With the advancement of technology in high throughput sequencing and increased 
reliability of protein modeling and structural prediction algorithms, protein engineers can 
more accurately hypothesize the TCR structures capable of involvement in specific antigen 
interactions. The hypervariable CDR3 regions defy conventional means of determining 
their structure and predicting their antigen engagement, limiting the accuracy of these 
structural models. While this study confirmed these challenges for CDR3, the strong 
prominence of key residues in the conformations of the other CDRs in TCRs allowed us to 
describe the canonical loops of TCRs as has previously been done for antibodies. 
In this study with 249 TCR and TCR-like structures it was shown the majority of 
TCR CDR conformations correlate with a set of proximal key residues. These residues tend 
to provide either structural stability when they point inwards or a packing stability 
involving hydrogen bonds with other residues or with the loop backbone. Additionally 
three new canonical class conformations not previously proposed were found in the larger 
dataset. The original de novo predictions of canonical classes from the V-region sequences 
available in 2000 provided a limited insight into the various key residues found in total 
TCR gene repertoire. Many of the class predictions have not been tested from a lack of 
solved crystal structures for respective V-regions. Of the 18 classes proposed based on the 
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sequence and structure data, 12 had accurately unique conformations with the remaining 
needing either additional solved structures or reevaluation with an updated V-region gene 
repertoire.  
The total number of TCR canonical classes still lags behind the number of diverse 
structural classes in antibodies (a total of 42 classes across all the heavy and light chain 
CDRs110). A recent examination of antibody CDR clustering in over 12,000 loops found a 
clustering rate of over 90% for all CDRs except H3, similar rates may be expected with an 
increasing diversity and number of solved TCRs117. In antibodies approximately a fifth to 
a third of the CDR residues participate in antigen binding, where van der Waals radii atomic 
contact is designated by a distance of 0.5 Ǻ107. Antibody structure modeling using solved 
structures and established canonical class templates have increased the theoretical accuracy 
of structural and functional experiments118. 
Homogeneous β-chain structures  
The predictions for the TRAV-regions were not as accurate as for the TRBV-
regions. Different attributes of the two chains may cause these phenomena such as the β-
chain’s larger reliance on the VDJ junction to generate the necessary the TCR structural 
diversity. Since most bound TCR structures indicate a shared pMHC engagement with the 
TCR αβ chains the structural differences between the chains may be more nuanced. The 
increased structural homology found in the large canonical classes in the β-chain may 
indicate some sort of evolutionary bias either in the TCRβ structure. Rearrangement and 
stable membrane display of the β-chain occurs with a generic pre-TCR α-chain (pTα). The 
pTα when associated with the β-chain does not interact with the TRBV-domain selecting 
for more stable soluble TRBV-regions119.  
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Unclassified and other overlapping loops   
While the large majority of the loops were classifiable, 14%, 45%, 11%, and 23% 
of CDR α1, α2, β1, and β2 loops remained unclassified. Many of these unclassified loops 
were slightly above the RMSD threshold required for clustering or involved smaller, single 
V-region groups and a few truly distinct structures when compared to identical TCRs such 
as 1NFD. Certain V-regions had a majority represented in a canonical class with a few 
remaining structures left unclassified or in another class with an alternative conformation 
such as human TRAV39 with 2 loops in α1-1 and 22 loops in the new α1-5 class. These 
exceptions were in the minority such as CDRα1 in TCR 2C where 3 of 7 loops diverged at 
residues 28, 29, and 36 by 4.3 Å generating the subclass structure in α1-2.  
Affinity matured TCRs  
Affinity maturated TCRs have engineered pMHC interactions for altered affinity 
and specificity and while these mutations usually occur at the interfacial positions they do 
not always significantly alter the structure of CDR loops. Most TCR engineering aimed at 
increasing TCR affinity without cross reactivity focuses on CDR3 mutations to increase 
antigen interactions. For example, the well-studied 1G4 has undergone several studies to 
increase the TCR affinity from ~15 μM to less than 10 nM120. The α-chains vary in CDRα2 
with the point mutations of S58P and S59W in structures 2P5E and 2P5W causing the loop 
apex to fold further upon itself. The solved structures for these mutations show slight 
(~1.15 Å between 2F54 and 2P5E) CDRα2 alterations from the wildtype structure and 
more significant loop changes in CDR3 structure121,122.  
Mouse versus human?   
The percent of human and mouse CDR structures classified was roughly the same 
at 73% and 82% respectively based on the current analysis. Humans have a larger number 
 78
of variable region genes than mice which could lead to increased structural variability. 
Mice also have a limited pool of T-cells at any given time which could restrict the diversity 
found in their TCRs. Conclusions about the differences between species remains fairly 
limited because the data set encompassing unique TCRs was generated from high-affinity 
variants, autoimmune models, or soluble-engineered and solvable proteins. Additionally 
the TCRs of many predominant disease models like multiple sclerosis are extensively 
studied and comprise many of the solved TCR crystal structures in protein databases123,124. 
TCRs that have increased soluble stability or express in higher concentrations may be 
overrepresented in the available PDB structures due to relative ease of crystallization, and 
any bias of this type would carry over into our analysis. 
Structural Mechanisms 
There are various theories about the evolution of T-cell maturation and how 
germline VDJ-regions have evolved their specific function and sequential order on the 
chromosome100 . Determining correlations within TCR rearrangement events and V- and 
J-region combinations by analyzing their sequences may shed insight into the co-evolution 
of diseases and cellular immune systems. The pMHC interaction may play a distinct role 
in determine the whether a TCR’s CDR fits into a class because over twice as many 
classified structures come from pMHC-bound TCRs than unbound. While some loops 
change conformation significantly when pMHC-bound (B7 with structures 1B2D and 
1BWM having RMSD values 1.01, 1.70, 0.98, & 1.39  for CDRs α1, α2, β1, & β2 
respectively), most others show little to no structural change between the pMHC-
bound/unbound structures seen in many TCRs like 2C for example. Using these TCR CDR 
conformations, the pMHC interacting residues can be determined similarly to studies of 
antibody  specificity-determining residues. These are identified by combining consensus 
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sequence data with structurally important  positions in CDRs and neighboring key 
residues107. The TCR-pMHC contacts analyzed in this study found a set of focused contacts 
on the binding groove MHC α-helices as reported in previous studies, but no strong 
correlation of contacts with canonical classes11,111. Additional studies with HTS and 
restricted pMHC sorting molecules could determine if these canonical classes are 
stereotyped to particular pMHC epitopes. This analysis could show if there is a limited 
sequence space generated from the same structural epitope. 
Analysis of TCR canonical loop classes enable prediction of TCR structure from 
sequence data, which will be particularly useful in conjunction with HTS of in vivo TCR 
repertoires. This study with an expanded set of TCR structures validated 12 of the 
conformations proposed in the initial Chothia et al study and 3 new classes not previously 
proposed. While this work helps to further characterize the structures of TCRs there are 
still considerable gaps in our structural modeling capability. There are a couple factors 
limiting the expansion and accuracy of these structural models from V-region sequences 
including conformational difference between pMHC-bound/unbound structures, TCR-
pMHC contacts, and predominantly CDR3 sequence and structure variability   
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Chapter 4: Structural repertoires for de Novo antibody engineering 
4.1: CHAPTER SUMMARY 
In a similar application of immune-receptor and CDR structural analyses described 
in Chapter 3, we used existing loop conformations and key residues in antibody and TCR 
structures for structural predictions in a de novo structure. This study used OptCDR a 
structure predicting algorithm for proposing a novel antibody sequence and structure for 
interacting with a flag-peptide tag103. In vitro characterization of these antibodies proved 
difficult due to low expression yields and binding affinity with the flag peptide. Here we 
detail the use of an antibody structural repertoire to predict and analyze the inherent 
feasibility of generating the model antibody structures.  
The designed set of single-chain antibody structures used a common framework 
mouse IGHV1-82*01 and mouse IGKV1-117*01 with CDR sequence variants to bind a 
flag-peptide (Figure 4.1). By aligning the either the framework structure or the framework-
CDR loop interface between the many available structures the variability between loops 
and structures was measured and compared to the de novo models originally proposed in 
the antibody study. Searching the much larger repertoire of antibody structures found the 
conformational loop limits and sequence variability permitted in these structures on this 




Figure 4.1: Overview of the OptCDR model. 
(A) Depiction of the model generated for the OptCDR structure’s binding groove with the 
heavy, light, and flag-peptide colored blue, red, and gray respectively. Binding distances 
between peptide and scFv of 2-, 3-, and 4-Å contacts highlighted in yellow, orange and 
black respectively. (B) Alignment of the 14 antibody structures predicted to bind to flag 
peptide showing the consensus framework with the more variable CDR loops. 
 
These structural comparisons helped determine why the single chain variants from 
these models failed to express or bind as predicted. The structural analysis on the structures 
in the PDB measured the sequence diversity in compared variable domain frameworks 
which maintain the overall shape and framework/CDR interface position, orientation, and 
arrangement predicted in the model. Variable domain frameworks matching the model 
were then found, and the binding region CDR loops for conformation and sequence 
diversity were analyzed. Finally, we compared the flag-peptide structure with other 
peptides and peptide binding antibodies to characterize the interactions between peptide 
and antibody. This analysis was performed over all the OptCDR models to understand the 
experimental results showing poor expression and peptide binding. The results proposed 
specific CDR changes to leverage the known structural repertoire for these de novo models. 
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4.2 METHODS 
The OptCDR model system uses a framework input to generate an interface, 
between the variable region framework and CDRs, to fix the orientation and position of 
CDR loop termini. CDRs from existing PDB structures are grafted in situ to the framework 
and residues are assigned, rotated, and tested for possible clashes to determine the best 
surface complementarity and local chemistry to encourage peptide binding. Within the 
CDR fitting the rigid flag peptide input is probed along the surface of the paratope 
searching for the highest binding energy.  
Based on analysis from TCR canonical structures it was hypothesized this 
modelling system makes a few assumptions which may overlook some key features 
common to antibody CDRs and canonical loop structures. First, main-chain loop structures 
are highly variable even with fixed N- & C- termini. Second, slight CDR sequence 
variations can have a significant effects on loop conformation as shown in studies of 
affinity maturated structures and key residues.23,87,105,125 CDR key residues usually point 
internally or towards other CDR loops for stabilizing overall structure. Finally, peptide 
binding occurs cooperatively when both the antibody and peptide interact which alters the 
structure of both. Antibody CDR deformation to surround the much smaller peptide within 
a binding groove come at too high an energetic penalty between bound and unbound 
structures126. 
4.3: RESULTS AND DISCUSSION 
A search of PDB associated with the search terms ‘antibody’ and ‘TCR’ found 3056 
structures of antibodies (2844) and TCRs (212) to compare to the modeled complex. We 
aligned these structures with the proposed framework input for the model. Aligned PDB 
structures with RMSD values less than 1Å were further compared to a set of 36 residues 
comprising the framework/CDR interface (residues: H 24-26, 37-39, 53-55, 65-67, 102-
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104, & 118-120; L 24-26, 39-41, 53-55, 66-68, 102-104, & 118-120). Three residues were 
used at the N- and C-termini of each CDR to help guide the alignment program to orient 
the compared structures. Alignment calculations were allowed to reduce the overall 
number of atoms up to half the total residues in the reference framework. Any reduction in 
the compared number of atoms was also factored into the alignment metric score (RMSD 
/ (% of framework atoms aligned)). The alignments were labeled partial and full if the 
framework or both the framework and interface had RMSD values less than 1Å 
respectively. The program then isolated the CDRs from the matching structures to analyze 
the compatible CDR loop structures and sequences for comparison to the predicted model 
structure and sequences. Additionally the depth of the flag binding peptide into the VH/VL 
interface was measured as the z-axis distance from the plane made from the N and C 
terminal residues of the heavy and light CDR3s. This analysis was also run with the total 
distance from the centroid of the four residues, but was considered less informative than z-
axis depth due to the variable orientation of the rigid flag peptide over the paratope. 
4.3.1: Structural repertoire analysis 
Of the 3056 structures analyzed, 326 had a similarity to the framework and 42 had 
a full framework/CDR interface compatibility with the predicted flag peptide-binding 
model. RMSD scores showed a distinct gap between aligning and dissimilar frameworks 
shown in Figure 4.2A and Figure 4.2B below. The input framework is distinct in shape 
and highly represented in the PDB structures with over 10% of the total structures having 
RMSD values <1Å. The 326 candidate structures were then analyzed for their CDR 
similarity, length, sequence, and key residue variation. Additionally the 42 interface 
compatible structures were analyzed for their CDR similarity to the models and general 
alignment overall (Figure 4.3A) 
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Figures 4.2: Alignment to model framework  
From the screen of PDB frameworks (A) the RMSD alignment scores to the entire 
candidate framework used in the OptCDR model and (B) the subsequent alignment score 
to only the interfacial residues, shown as spheres, describing the arrangement of the CDRS. 
4.3.2: Light chain 
There were 45 light chain CDRs with at least one of the model’s proposed sequence 
including two antibodies with all 3 matching light CDR sequences (PDB: 3NN8 and 
4NKD), both being from previous flag peptide structure work within the Maynard Lab. 
These matches on CDRs L1, L2, and L3 have limited mainchain loop structural variability. 
Light chain CDR lengths were more limited in conformation (Figure 4.3C) with many 
compared structures having the same CDR length. For example, the majority of the L2 
loops had 3 residues, which is probably an artifact of L2 in general. Further analysis found 
the majority of the models predicted a greater interaction of the light chain with the peptide 




Figure 4.3: Alignments to framework interface. 
(A) For the EEh14.3 parent model, three residues at N- and C-termini of the 
framework/CDR interface for all six CDRs (inset) were compared to all antibody-related 
PDB structures. 58 structures possessed interface alignment RMSD values <1 Å. (B) This 
subset shows low overall variability in the framework light chain (red) and heavy chain 
(blue), excluding the CDRs shown at the top. (C) Isolated light chain CDRs of the 
interface-aligned structures, shown from above, show low structural variation, and 
EEh14.3 parent model CDRs (black) exhibit similar conformations. Interface residues used 
for alignment are shown as black spheres. (D) Isolated heavy chain CDRs, rendered 
similarly, show large structural and length variability, and EEh14.3 parent model CDR1 
and CDR2 show distinctly different conformations from the interface-aligned population. 
4.3.3: Heavy chain 
While the heavy chain framework and interface is maintained in many other solved 
antibodies, the model’s CDRs themselves are unique in sequence, length, and structure 
(Figure 4.3D). The heavy chain had no identically matching CDR sequences for any of the 
regions, indicating OptCDR may have attempted to create and fit de novo sequences and 
structures to the framework. The design of the heavy chain may have had a much larger 
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influence on the overall performance of the antibody compared to the light chain. As 
modeled, the heavy chain contributes closer, but fewer contacts to the flag binding than the 
light chain. Additionally the gap in the heavy chain required for flag binding may be 
leading to the overall instability of the antibody.  
CDR length also plays an important role in the ability of the antibody to interact 
effectively with the peptide. Compared to other peptide binding antibodies the 14a complex 
may have CDR3 lengths well outside of the stable range for the framework (Figure 4.4A). 
 
 
Figure 4.4: CDR length variations and flag peptide depth 
Calculations of the average CDR length for the structurally similar candidates and the 
lengths for the proposed 14a structure showing the variations of CDR lengths outside of 
the average may contribute to the instability and (B) a plot of the variation of z-axis distance 
from the interfacial core of the complex along with the minimum and maximum distances. 
4.3.4: Peptide Binding 
The depth of the peptide when penetrating the antibody structure may be the largest 
difference of the model to other PDBs. The majority of the antibodies with framework 
matches have CDRs stably filling the gap wedged between the H/L domains. The H/L 
interfacial domain opens very wide for flag peptide interaction with the majority of the 
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deformation occurring in the Heavy chain. It was indeterminable if the residues comprising 
the binding interface were stable enough to tolerate solvent exposure during peptide 
binding. It is possible the groove can stably open wide enough to accept the peptide, but 
this would probably reduce the overall efficiency of the binding kinetics even if it binds 
tightly. Surprisingly when compared to the other models the average flag peptide depth 
was the deepest for complex 14 (Figure 4.4B). Looking at highly variable rigid flag peptide 
arrangements over the paratope 15 predicted complex structures it is clear the peptide 
structure should have been allowed to flex or been modelled along with the CDRs to further 
minimize the binding energy and increase the model accuracy.  
4.4: DISCUSSION AND CONCLUSIONS 
In the future, library screening efforts may be more successful if the sequences are 
capable of conforming to a canonical CDR structure typical of peptide binding and the 
statistical makeup of beta-turns potentials in terms of the probability of having a certain 
amino acid in the turn position is taken into account. Altering the structures of solved 
antibodies may provide the best insight when grafting new sequences and arrangements. 
Antigens that bury deeper into the chain may be tighter binders if the antibody can stably 
expose the interface between the chains to form the binding groove. Finally, rigid peptides 
should not be considered accurate unless they have additional structural context excluding 
the antibody.   
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Chapter 5:  Activation studies of engineered TCRs 
5.1: CHAPTER SUMMARY 
Here we report our work to generate a surface display system for testing the 
activation of engineered TCRs on mouse α-/β- T-cells. These affinity maturated engineered 
TCRs were generated in two separate bacteriophage display studies by other members in 
the Maynard lab. Complete TCR surface expression in eukaryotic and thymocyte cells will 
also verify the in vitro binding assays by mitigating any biases occurring in soluble 
bacterial expression and phage display122,127. Affinity maturation of TCRs using phage 
display or soluble expression systems has shown to have variable effects on activation and 
antigen specificity when reconstituted on accepting thymocytes13. While in vitro assays 
can measure altered antigen specificity, determination of differences in T-cell activation 
requires the reconstitution of the engineered receptor into a T-cell immune complex. 
Progress for collecting display and activation data for these TCRs confronted multiple 
problems including receptor stability, transfection efficiency, and the improper trafficking 
of the protein to the outer membrane. Additional work is ongoing to collect T-cell 
activation data for the TCR variants and to test variant signal sequences for intracellular 
trafficking and display. 
The discovery of the improper TCR trafficking due to the antibody signal sequence 
on the expression vector led to a brief investigation of how these N-terminal peptides 
influence TCR expression and trafficking. This study varied the signal sequences on full-
length TCRs as individual chain plasmids, a bicistronic IRES, a single transcription 2A 
peptide, or a CAR. The sequence variations examined how residue mutations in the 
hydrophobic (h) and the peptidase cleavage (c) regions alter the display stability and 
secretion of proteins trafficking through the secretion pathway. 
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5.2: INTRODUCTION 
Mutations in TCR CDRs can modify the receptor’s overall activity through slight 
secondary structural alterations carried through to the bound CD3 proteins in the immune 
complex128. To test variant TCRs generated in vitro we developed an expression system to 
display full length TCRs including the variable, constant, and transmembrane domains129. 
TCRs displayed this way can bestow activated α-β- T-cells with additional antigen 
specificity and activity dependent on the formation of the immune complex with the CD3 
co-receptors130. TCR display and activity was measured by transfecting these constructs 
into the TCR deficient 58-/- thymocyte cell line. This immortalized cell line was derived 
from the BW5147 murine T-cell line and has non-functional α- and β-chains131. The TCR 
chains tested in this display and activation study included DO11.10, 172.10, and TRBV5 
(Table 5.1). The mouse TRBV5 chain was unexpectedly recovered from the DO11.10 and 
BW5147 hybridoma fusion132,133.  
 
TCR Leader/Signal Sequence V region gene CDR3 sequence D J C
DO11.10 MKTYAPTLFMFLWLQLDGMSQ mTRAV 5D-4 AASPNYNVLY - 21 1
172 MDKILTASFLLLGLHLAG mTRAV 14-3 AASANSGTYQR - 13 1
DO11.10 MGSRLFFVLSSLLCSKHM mTRBV 13-2 ASGSGTTNTEYF 1 1-1 2
172 MGSRLFFVLSSLLCSKHM mTRBV 13-2 ASGDAGGGYEQY 2 2-7 1
BW5147 MGSRLLLYVSLCLVETALM mTRBV 5 ASSQITSNQDTQYF 2 2-5 2
Table 5.1: TCR constructs tested in this display study. 
The TCR chain compositions for this study included DO11.10, 172.10, and mouse TRBV5. 
The signal sequence oligo was also able to subclone a functional mouse TRBV5 gene from 
the BW5147 hybridomas with the genes and CDR3 sequence. Since the DO11.10 and 
172.10 β-chains are so similar, the mouse TRBV5 construct was used as a negative control 
when transfected with different α-chain. 
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5.2.1: Phage display directed evolution and affinity maturation 
Previous work with the directed evolution and affinity maturation of a DO11.10 
single-chain TCR using phage display found two CDRα3 variants with higher binding 
affinities to a clonotypic antibody specific for the anti-mouse DO11.10 TCR (clone: KJ-
26, BD Biosciences). The two higher affinity TCRs had CDRα3 sequences varying slightly 
from the wildtype DO11.10 sequence by only a few residues (Table 5.2). Each variant was 
selected as a fusion with different M13 phage coat proteins.  
 
          Randomized residues       
  Fusion  104 105  106  107 108 109 113 114 115 116  117  118 
WT  ‐  C  A  A  S  P  N  Y  N  V  L  Y  F 
176  pIII  C  A  A  S  T  N  W  H  N  L  Y  F 
817  pVIIIo2  C  A  A  S  P  R  F  D  V  L  Y  F 
Table 5.2: Sequence data for DO11α-chain variants 176 and 817. 
The two DO11.10 variants were selected from a CDRα3 library using different C-terminal 
fusions on different M13 bacteriophage coat proteins. The expected scTCR local 
concentration on these different coat proteins alters the binding through relative avidity 
affects. 
The M13 phage used in this experiment has 5 coat proteins with different 
arrangements along the shaft and termini of the phage (Figure 5.1A and B)134. Fusing 
scTCR constructs to these coat proteins allows the rapid screening of libraries in excess of 
1010 variants135.The two higher affinity variants called 176 and 817 were selected on coat 
proteins pIII and pVIII respectively (Figure 5.1C and D). These coat proteins have 
strikingly different roles and arrangements on the phage and as such, screening of scTCR 
fusions to these coat proteins can lead to different binding kinetics based on avidity affects. 
Characterization of the two selected variants also found differences in the expression 
yields, stability, and binding kinetics of each protein.  
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Figure 5.1: M13 phage with coat proteins labels.  
(A) M13 is a filamentous bacteriophage with (B) 5 coat proteins encasing its single 
stranded genomic DNA. Affinity maturation with scTCR C-terminal coat protein fusions 
found two DO11.10 CDRα3 variants with higher binding compared to the wild type TCR. 
Variant 176 (C) is a pIII fusion found in 1-5 copies at the end of the bacteriophage and 817 
(D) is a pVIIIo2 fusion found in several thousand copies comprising the central shaft of 
the phage. The difference in copy number and arrangement on the phage selected for 
different secondary binding properties in each variant.  
5.2.2: Eukaryotic protein expression 
Expression of engineered proteins in eukaryotic cells requires many complex 
techniques and genetic components. First, the genetic material must become transfected 
into both the cell and the nuclear envelope. Transfection techniques for eukaryotic cells are 
more complex than for bacterial transformations due to less permeable cell membranes and 
resistance to foreign genetic material136. Depending on the cell type, a transfection 
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method’s efficiency can vary dramatically. Several transfections techniques include viral 
transduction, lipofection (Invitrogen and others), nucleofection (Lonza), electroporation, 
or calcium phosphate precipitation. Additionally the cell only transiently maintains and 
expresses the introduced DNA unless additional selection pressures, such as antibiotic 
resistance selection for example, force the cell to integrate the material into its 
chromosome.  
Depending on the cell assay or protein expression system, transient transfection or 
stable cell line generation may be necessary. For example, small-scale antibody expression 
in CHO cells often uses transient transfection to produce large quantities of antibodies 
without the more involved, lengthy stable selection process. Transient transfections only 
last for a few cell generations because the plasmid DNA is not maintained in the nucleus 
and becomes diluted with every cell replication. Alternatively, some assays require a stable 
homogenous population selected from a single cell to guarantee uniformity in the results. 
Stable cell lines take weeks to months to generate, as the desired gene must stably 
incorporate into the genomic DNA followed by single cell or polyclonal selection to 
remove cells lacking the desired phenotype. 
After transfection into the nucleus, transcription factors transcribe the genetic 
material into mRNA. Next, the mRNA processing removes any introns and adds stabilizing 
components including a 5’ mRNA cap and 3’ polyA tail before transport out of the nucleus 
into the cytoplasm. A ribosome next associates with the processed mRNA, recognizing the 
Kozak sequence immediately 5’ of the first start codon in the open reading frame before 
beginning translation of the genetic information into a polypeptide sequence137. As the 
nascent peptide chain emerges from the ribosome, it acts as a signaling mechanism to direct 
the trafficking of the synthesizing protein-ribosome complex to the proper receptors and 
organelles in the cell for further post-translational modifications.  
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5.2.3: Signal sequence in protein trafficking 
This signal sequence N-terminal to the gene of interest serves a critical role in 
secreted or displayed proteins requiring transport through the ER, Golgi, and eventually 
the outer cell membrane. Signal sequences while diverse share 3 distinct peptide regions 
designated the n-, h-, and c-regions138. These regions are responsible for the recruitment of 
the signal recognition particle (SRP) and after translocation into the ER, encourage signal 
peptide peptidase activity.  
For secreted and transmembrane proteins destined for the ER, the signal sequence 
recruits an SRP by a coordinated interaction with a conserved central h- region of the signal 
sequence and a cluster of methionine residues on the SRP139. Recent work has shown the 
interaction between the SRP and signal sequence h-region is aided by a series of suboptimal 
amino acid codons approximately 40 – 60 residues after the nascent chain first emerges 
from the ribosome. These codons slow translation to allow time for proper interaction 
between the SRP and signal sequence and proper trafficking to the ER140. The SRP changes 
shape after binding to the signal sequence and guides the nascent chain-ribosome-mRNA 
complex to the SRP-receptor on the outer surface of the ER for translocation of the 
synthesizing protein.  
 During protein translocation into the ER, the signal sequence can remain anchored 
within the ER membrane where it awaits cleavage by signal peptidase141. Signal sequences 
with weak or cryptic cleavage regions become unstable and targeted for degradation as 
incompletely processed proteins142. Signal sequence cleavage in general is thought to occur 
as the protein translocates into the ER, but this varies between proteins. Depending on the 
protein’s final destination, this ER anchoring and cleavage event may cause downstream 
effects in expression. 
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Antibodies and TCRs alike both use strong signal sequences imperative for proper 
folding and incorporation into the ER membrane for eventual transport to the Golgi and 
outer membrane. Each variable region gene has a corresponding signal sequence which 
follows the n-, h-, and c-region motif with some clear distinctions between antibody and 
TCRs signals. Comparisons of the signal sequences for these secreted and membrane-
bound proteins in humans and mice using weblogos of sequences 19 residues long show 
the slight variations the signal sequences of these classes of proteins (Figure 5.2), which 
may give some insight into their functionality as soluble proteins and membrane-bound 
receptors143. The noticeable occurrence of cysteine residues and more variable hydrophobic 
region of the TCR signal sequences are curious as aberrant di-sulphide bond formation 
could significantly influence overall expression of the receptors. The ClustalΩ web server 
compiled consensus signal sequences generated from all functional antibody and TCR V-
regions are reported in Table 5.3. Surprisingly there is no overlap in signal sequences 
between antibodies and TCR and each consensus sequence is 21 residues long.   
 
 
Figure 5.2: Weblogos for antibody and TCR signal sequences. 
Signal sequences from human and mouse (A) antibodies and (B) TCRs 19 residues long 
were aligned to show the n-, h-, and c-regions along with the variations between the two 
protein classes. These variations involve a very hydrophobic h-region in the antibody signal 
sequence and an interesting number of cysteine residues in the h-region of TCRs. 
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 Consensus Signal Sequence Genes Range Mean StDev 
Ig MGWSWIFLFLVAAPTGVHSLS 390 16-24 19.46 1.02 
TR MLMGTRLLCWVALCLLGAGHV 256 14-39 20.06 2.97 
Table 5.3: Ig and TCR gene consensus signal sequences. 
Compiling all the signal sequences for antibody and TCR genes for humans and mice using 
the ClustalΩ web server found two distinctly consensus sequences79. The h-region in the 
consensus signal sequences is in bold, red text and the cysteine residues in the TCR peptide 
are underlined. The Genes column reports the total number of functional gene alleles with 
unique signal sequences. 
The critical signal sequence components required for proper display have been 
vaguely described for several protein models without a more knowledgeable understanding 
of the mechanisms involved144. Analysis of many signal sequences in immune-proteins 
(Table B.4) found an incredible diversity of sequences to convey the level of variability in 
length and sequence for leaders among different secreted vs membrane bound proteins. 
A review of different TCR display constructs finds most use the cognate signal 
sequence for each variable TCR gene without modification122,127,136,145–149. Rarely are these 
sequences modified in expression vectors unless it is, for example, to use engineered signal 
sequences such as the mouse H2-Kb signal sequence to control stoichiometric compilation 
and targeting to the ER microsomes150. Another examination of CARs found constructs 
using human CD8α signal sequence for protein expression151,152 or the Gaussia luciferase 
signal sequence from Vargula luciferase to maximize the soluble protein secretion153.  
5.2.4: T-cell activation and the 58-/- cell line 
As mentioned before in Chapter 1.2.4, T-cells use clonotypic receptors to 
recognize and respond to disease antigens presented on the surface of other cells. When a 
TCR interacts with its cognate antigen the receptor initiates an activation cascade through 
peripheral receptors in the immune complex. During T-cell activation, early activation 
marker CD69, a C-type lectin protein becomes highly expressed on the cell surface. This 
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increased receptor expression down-regulates Sphingosine 1-Phosophate Receptor-1 
(S1P1) to prepare the cell for proliferation and further activation in the context of APCs, 
pathogens or apoptotic cells154. As an early indicator of T-cell activation, CD69hi cells can 
be stained for cytometry to show the relative reactivity of the TCR-pMHC interaction. The 
induced CD69hi expression can occur in as little as 2 – 4  hours depending on the antigen 
peptide12,155. 
An alternative method to detect T-cell activation involves measuring the 
concentration of the activation cytokine, IL-2. The production of IL-2 in activated T-cells 
can be measured directly using intracellular staining of permeabilized cells or indirectly by 
an ELISA of the activated cell culture supernatant. The predominant method to measure 
T-cell activation levels is the IL-2 ELISA. For activation assays involving polyclonal or 
transient TCR transfections, the cytokine concentration in the supernatant may be below 
the sensitivity of ELISA, in which case the intracellular IL-2 staining or early activation 
marker CD69 staining should be an appropriate substitute.  
5.3: METHODS 
5.3.1: Expression vector constructs for TCR display 
The vector used in this study is derived from a κ-chain antibody expressing system 
with a CMV promoter, cloning sites EcoRI and AgeI before and after the signal sequence 
respectively, a HindIII site 3’ of the stop codon, and a SV40 PolyA tail signal 3’ to the 
coding region156. These vectors also have a CMV promotor for immediate early expression 
of proteins compatible with many eukaryotic cell types. A Kozak sequence with an optimal 
ribosome binding site was used in these vectors as well. To make cassette vectors for testing 
different combinations of TCR α and β chains, we cloned restriction sites SspI and 
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EcoO109I for each chain respectively into the linker between the variable and constant 
domains. 
The genetic material for the constant and transmembrane regions was amplified 
using the RT-PCR method described in Chapter 2.3.3 from the DO11.10 and 172.10 
immortalized hybridomas in the lab. Additional CD3 and CD28 receptors were recovered 
from these mRNA samples in the same way. Point mutations for the different TCR variants 
were generated using the Kunkel mutagenesis protocol from single stranded DNA 
described by (Sidhu and Weiss)157.  
5.3.2 Lipofectamine transfection protocol for CHO cells 
This is almost identical to the standard protocol with the Lipofectamine 2000 reagent. 
Note: this transfection reagent does not work with the immortalized T-cells 58-/- 
 
Day 1- Plate cells for transfection. 
1. Trypsinize and count cells from a previously growing CHO cell culture. 
2. Seed the plate with the appropriate number of cells (Table 5.4) with the normal media 


















24-Well 1.0E+05 0.5 mL 0.4 mL 50 ul 0.6 ug 1.5 ul 100 ul per well
12-Well 2.0E+05 1 mL 0.8 mL 100 ul 1.2 ug 3 ul 200 ul per well
6-Well 5.0E+05 2 mL 1.5 mL 250 ul 3 ug 7.5 ul 500 ul per well
Table 5.4: Lipofectamine transfections materials. 
This table lists the amounts of cells, DNA, Lipofectamine and culture volumes required for 
the different CHO transfections used in this study. 
 
3.  Return the plates to the incubator to sit overnight. 
Day 2- Transfection. 
4. Remove and discard media from cells. Replace with the appropriate volume of media 
with low IgG FBS, no antibiotic (Table 5.4).  
5. Prepare 2 tubes with the appropriate amount of Opti-MEM reduced serum media.  
6. To one tube add the appropriate amount of DNA (0.5-5 ug/ul solution) and mix. 
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7. Add to the second tube the appropriate amount of Lipofectamine-2000 reagent and mix. 
8. Add the diluted DNA to the tube with Lipofectamine and vortex to mix. 
9. Let the DNA-reagent complexes form for 15 minutes at room temperature. 
10. Add the appropriate amount of complex to each well or flask and tilt gently to mix. 
11. Return plates to incubator. 
5.3.3: Electroporation of Hybridoma Cells 
*Protocol adapted from Nath Shubhankar from the Martin Ponie lab  
This protocol is for transient or stable selection of eukaryotic cells using a ratio of 
DNA and selection vector. For each cell type and antibiotic used a kill curve must be 
generated to determine the amount of time required to kill cells lacking the selection vector.  
Materials: 
 4mm electroporation cuvette (BD Biosciences) 
 2 x 107 healthy cells for transfection 
 15µg DNA with the antibiotic resistance gene 
 Pre-warmed Opti-mem (Life Technologies) 
 10 ml warmed culture without antibiotics in a T75 flask 
 Selection antibiotic 
Protocol: 
1. Rinse cells in Optimem with at least ½ volume of medium with a final volume of 400 
µl (do not exceed the metal plates of the cuvette. 
2. Add DNA to the cell sample and incubate at room temperature for 10 – 15 minutes. 
3. Electroporate cells using the parameters 250V and 950 µF which should have a ~27.5 
ms time constant. 
4. Let the cells rest for 2 – 3 minutes, dead cells will float to the top of the sample and 
cling to the sides.  
5. Carefully remove the cells in solution to avoid the aggregate floating dead cells. 
6. Gently pipette cells into the T75 flasks and place the cells in the incubator for 24 – 48 
hours before adding the antibiotic to begin selection. 
7. Check cell counts over the next few weeks depending on the strength and stringency 
of the antibiotic based on kill curves. 
8. Maintain the concentration of dead cells at a minimum to promote cell growth. 
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5.3.4: Peptide antigen presentation and T-cell activation 
Activation assay for DO11.10 hybridomas and OVA323-339 presented by A20 cells. 
T-cell IL-2 activation assays secretion and immunofluorescence staining combined 
(Combined from Ben, Jamie, Edith) 
 
Materials 
 OVA whole protein solution in RPMI (200 μg/ml) 
 OVA peptide in RPMI (20 μM or 3.55 μg/ml) for a MW of 1774 g/mol 
 96-well plate 
Solution Prep 
 Dissolve the protein and antigen peptide in RPMI and filter sterilize.  
Make only enough for the study. 
Cells (use >90% confluent cells) 
 A20 cells (15,000 cells/well) 
 DO11.10 Hybridoma cells (15,000 cells/well) 
 Transfected 58-/- cells (15,000 cells/well) 
Controls 
 A20 and DO11.10 s cells without peptide  
 DO11.10 cells with peptide 
 A20 cells incubated with peptide for ≥12 hours 
Protocol 
1. Put 75 μl containing 2 x 104 A20 cells into each well of a 96 well plate. 
2. Add 25μl of RPMI or protein solution to the respective wells. 
3. Incubate cells and protein in the Euk incubator for 12 hours. 
4. Add 100 μl containing 3 x 104 Tcells to the respective wells. 
5. Incubate cells in the Euk incubator for the necessary amount of time for the assay. 
 
IL-2 release assay with ELISA 
1. Coat a 96-well plate with the IL-2 capture antibody from the ELISA kit with 
the configuration required based on the samples and standards. 
a. Use a 1:250 dilution of the Capture antibody in the Coating buffer 
(100 μl/well) and incubate ON at 4°C 
b. Rinse with wash buffer before use and allow the plate to come to RT. 
2. After 24-48 hour incubation of Tcells with APCs harvest 100 μl of sample 
well supernatant by spinning plates. Immediately freeze the supernatant or 
begin ELISA. 
3. Add the samples to the coated plate and incubate for 2-4 hours. 
4. Wash plate and add 100 μ of detection mix (detection antibody at 1:1000 and 
SA-HRP 1:250). 
5. Incubate for 1 hour then thoroughly wash 
6. Add 100 μl substrate solution and incubate until color change occurs. 
7. Add 100 μl stop solution and read plate at 450 nm. 
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Surface and intracellular staining (~8 hours) 
1. 4-6 hours before cell staining add an appropriate amount of Brefeldin A such 
that the final concentration in the well is 5 μg/ml (for the 1000X stock of 5 
mg/ml) 
2. Pellet cells and wash in PBS 
3. Stain samples for surface markers for <60 min with: 
CD69 –APC-Cy7 (Ex640nm, Em660nm), (clone FN50, BD BioLegends) 
KJ-26-PE (Ex561nm, Em575nm) (clone KJ1-26 Biosciences), and  
mTCR-Cβ-FITC (Ex488nm, Em530nm) (clone H57-597, BD Biosciences) 
4. Stain for 1 hr then pellet cells, remove SN, add 100 μl Fixation buffer, 
incubate for 20-60 min 
5. Wash cells and add 100 μl Permeabilization buffer, incubate for 20 minutes 
6. Stain with intracellular antibody for 30 min with: 
IL-2 – APC (Ex405nm, Em450nm) (clone JES6-5H4, BioLegends) 
7. Add 450 μl PBS and run sample on the cytometer with the correct detection 
parameters. 
5.4: RESULTS 
5.4.1 TCR reconstitution 
 To reconstitute TCR on a T-cell for measuring receptor-mediated activation, we 
generated a TCR display system by cloning full-length αβ TCR genes into a eukaryotic 
expression vector previously used for antibody expression in CHO cells. Initial transfection 
tests with these expression vectors in CHO cells failed to display the receptor even with 
positive controls which had transfection efficiencies of greater than 50 % of live cells. After 
a more detailed examination of the vector construct components and comparing these to 
literature, we discovered most TCR display studies use the native signal sequence 
associated with TCR variable region gene. The signal sequences for these constructs were 
then swapped from the mouse IgHV antibody signal sequence to the native TCR peptide 
for additional transfection experiments.  
With this single change, CHO cell transfections with these new constructs had 
nearly 20 % positive staining for antibodies specific for both the DO11.10 epitope and the 
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TCR β-constant domain (clone H57-597, BD Bioscience) indicating surface display of the 
DO11.10 TCR. Contrary to previous reports, the charged residues in the TM domains of 
the α and β chains did not prevent TCR display on the surface of CHO cells which lack the 
charge-balancing CD3 co-receptors imperative for proper receptor display on 
thymocytes158. Additionally, the positively transfected CHO cells had higher surface 
concentrations of receptor than DO11.10 hybridoma cells based on MFI values from flow 
cytometry with KJ-26 staining in the positive transfected populations (Figure 5.3A). This 
display difference between DO11.10 hybridomas and CHO cells may be a result of the 
more regulated TCR display in thymocytes due to immune complex formation and receptor 
recycling mechanisms to control surface receptor concentration149. 
 
 
Figure 5.3: Surface concentrations of displayed TCR 
(A) Transient transfection of the DO11.10 TCR on CHO cells shows a range of receptor 
concentrations. (B) Dramatically reduced overall display for a transfection of DO11.10α 
+ mouse TRBV5 indicated by low staining with the anti- mouse TCRβ-constant domain.  
CHO transfections with mismatched α and β chains (i.e. DO11.10α + 172.10β, or 
DO11.10α + TRBV5) showed decreased display of the receptor as measured by staining 
 102
of the TCR β-constant domain (Figure 5.3B). This result was expected as several studies 
have reported the interfacial instability occurring between non-native TCR chains similar 
to what was described in Chapter 2.4.4 which attempted express novel pairs of TCR 
chains83. 
After the success of CHO cells to transiently display the various TCRs, we next 
tried to replicate this display on the 58-/- T-cells. This proved harder than expected due to 
thymocytes being highly resistant to lipofection, the method successfully used for CHO 
cells. After many attempts to transfect cells with the TCR constructs, we determined 
generation of stable cell lines using electroporation and antibiotic selection would likely 
be necessary (Nath Shubhankar, personal communication).  
For stable selection, the TCR chains were cloned into the antibiotic selection 
vectors using G418 and puromycin resistance genes. These vectors, pEGFP-N1 (GenBank 
Accession #U55762) and pIRESPURO (Clonetech Cat. #631619), were a generous gift 
from the Martin Poenie lab (Appendices B.1.2.2). Additionally these vectors were 
modified to replace EGFP with CFP, YFP, mCherry, or to remove the fluorescent protein 
fusion. Similarly, the pIRESPURO vector was modified for our purposes to display TCRs. 
After cloning full-length TCRs into the new plasmids for stable selection, electroporations 
were performed with the DO11.10α-EGFP or DO11.10β-EGFP. These cells grew well 
under selecting conditions and tracked to a two-phase selection kill curve (Figure 5.4 




Figure 5.4: Selection curves for stable cells. 
Compiled data from multiple cell selections details the expected kill curve and resistant 
population growth in antibiotic medium. Sorting for positive cells through either the 
fluorochrome fusions or antibody staining occurs once cells reach confluence and the 
expected positive population is over 106 total cells, which is approximately 3-4 weeks after 
initial electroporation.  
After 28 days under G418 antibiotic selection, EGFP+ cells were sorted with a BD 
FACSAria cell sorter. Stable populations continued to grow in the presence of antibiotic 
and maintained EGFP expression (Figure 5.5A). Additionally genomic DNA 
amplifications showed the TCR construct remained intact during selection as seen by the 
strong bands corresponding with TCR DNA (Figure 5.5B). With these encouraging 
results, the second chain on a plasmid with a puromycin resistance gene for each respective 
TCR fusion was additionally electroporated into the EGFP fusion cell lines to generate 
stable cell lines with both chains. Antibiotic selection tracked nearly identically to the first 
round of selection (Figure 5.4 red dashed line) with slightly lower cell counts during the 
selection process possibly due to puromycin toxicity. After an additional 28 days under 
selection with both G418 and puromycin, the cells were stained with KJ-26 to test for TCR 
display (Figure 5.5C). These samples also failed to stain for CD3ε indicating a lack of 


















Figure 5.5: Stable cells generation and tests 
(A) Flow cytometry plot of the transiently electroporated cells displaying the DO11.10 
TCR as stained by the anti-DO11.10 antibody. The overall TCR display is limited to the 
expression of the chain fused to the EGFP (α-chain-EGFP fusions have a lower stability 
than the β-chain). (B) Tests for the presence of the DO11.10 TCR genes in purified 
genomic DNA in the antibiotic resistant samples showed positive amplification of each 
TCR chain. The gel image shows plasmid controls, each TCR-EGFP fusion, and a β-actin 
control. (C) After antibiotic selection with both G418 and Puromycin for selection of both 
TCR chains, the cell cultures failed to display TCR in concentrations similar to the 
DO11.10 hybridoma cells. 
The lack of proper TCR display on stably selected cells indicated either a problem 
with the antibiotic selection or the some other problem in the proper transport of the 
receptor and immune complex to the receptor to the surface. Western blots with cell lysate 
of these populations also indicated proper formation of the TCR dimer at the 100 kDa band 
for the non-reduced lanes for stably transfected cells with EGFP-3X-Flag tag fusions 
(Figure 5.6A). The 58-/- cells failed to display the receptor even with both genes thought 
to be stably transfected based on antibiotic selection, protein expression, and TCR 
heterodimer formation.  
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Figure 5.6: Cell lysate western blot and CD3δζ gene detection 
(A) Cell lysate from stable cell cultures was run in a 12 % SDS-PAGE gel and transferred 
to a nitrocellulose membrane for a western blot detection with anti-flag peptide. The 
presence and size of the bands indicate the TCR αβ chains (100 kDa band in non-reducing 
lanes) are forming the TCR. (B) Comparing the presence of the CD3 mRNA between 
mouse T-cells and the 58-/- hybridoma cells shows a distinctly lower amount mRNA for 
expression of CD3δ and CD3ζ. 
The TCR αβ dimer should increase the stability of the chains to aid CD3 association 
and formation of the immune complex for transport to the outer cell membrane. Previous 
studies have mentioned a lack of CD3 co-receptor expression can significantly hinder 
overall display of the TCR on T-cells159. Interestingly Kranz et al. found CD4 and CD8 
receptors did not significantly increase the binding and activation of cloned surface TCR 
to pMHC and in fact in some tests their addition decreased binding as measured by IL-2 
release160. The cells were then tested for the presence of the CD3δ and CD3ζ co-receptors 
by RT-PCR (Figure 5.6B) (amplifications of CD3γ and CD3ε not shown). The 58-/- cells 
lacked these CD3 mRNA sequences which suggest these genes may have been crippled 
during the generation of the cell line. Additional work is required to determine if 
 106
transfecting these two chains will reconstitute surface display in the antibiotic selected cell 
lines. 
5.4.2 Signal sequence for receptor display and secretion 
Based on BCR and TCR cellular display experimental data in the Maynard lab, it 
appeared that signal sequences play a significant role in both receptor expression and 
trafficking to the cell surface. Initial display experiments with a mouse IgHV signal 
sequence, failed to display BCRs and TCRs on CHO and thymocyte cells161. This could 
have been due to several reasons including: (1) lack of proper translocation to the ER 
lumen, (2) instability due to improper signal peptide cleavage, or (3) instability in the 
transmembrane domain. 
Normally with antibody engineering and expression, the native signal sequence 
should be utilized to prevent complications to re-optimize signal sequences162. Even slight 
changes to this native signal sequences can often cripple expression and secretion of 
proteins (Michael Kaleko, personal correspondence). After the lack of display seen in 
transfected cells, we restored the native signal sequence corresponding to the TCR 
variable-region on the receptor chains, surface display was detected to densities on positive 
cells greater than in the positive control DO11.10 hybridoma cells (Figure 5.3A and 
Figure 5.7A and D). Additionally a heterogeneous signal sequence systems with at least 
one native signal sequence on either TCR α or β chains could properly display the receptor 
(Figure 5.7B and C). From these challenges and observations, we wanted to understand 
what signal sequence characteristics factor into this almost binary expression of membrane 
displayed proteins.  
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Figure 5.7: CHO cell TCR display with Ig/TCR signal sequences 
Flow cytometry plots for staining with mouse TRBC-FITC and anti-DO11.10-PE on CHO 
transient transfections. Each transfection used two plasmids with signal sequences 
according to the labels on the left and top of the plots for the α- and β-chains respectively. 
The sample using the antibody secretion signal sequence (A) for both chains fails to display 
any TCR. All other samples with at least one wildtype signal sequence (B) display TCR as 
expected. 
We designed a set of signal sequences modified from the native TRBV13-2 leader 
sequence with increment point mutations to lower the h-region hydrophobicity or change 
the polarity of c-region residues (Table 5.5). Additionally we fused the consensus Ig and 
TCR signal sequences and a novel sequence called SpMax to the N-terminus of the 
DO11.10 β-chain. The SpMax sequence was designed to maximize the predicted signal 
trafficking and peptide cleavage scores calculated by the SignalP server and reported in 
Table 5.5138,163. Tests with these variant leaders are currently underway. It is hypothesized 
to show decreases in the h-region hydrophobicity will correlate with diminished TCR 
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transport to the cell surface and similarly the loss of polar residues from the c-region will 
prevent signal peptide cleavage and negatively impact protein stability153. If these results 
show increased display in the consensus signal sequences, SpMax or any of the other 
variants, we will test signal sequence fusions with other TCRs and antibodies. This will 
determine if the sequences have utility as more general protein expression and trafficking 






TRBV13 No Leader None 0.099 0.102 
WT MGSRLFFVLSSLLCSKHM 21 0.809 0.693 
WT_1L MGSRAFFVLSSLLCSKHM 21 0.724 0.610 
WT_2L MGSRAFFVASSLLCSKHM 21 0.548 0.465 
WT_3L MGSRAFFVASSALCSKHM 21 0.354 0.311 
WT_4L MGSRAFFVASSAACSKHM 21 0.233 0.221 
WT_C MGSRLFFVLSSLLSSKHM 21 0.740 0.610 
AbVec SS. MGWSCIILFLVATATGVHS 17 0.945 0.814 
Ig_consensus MGWSWIFLFLVAAPTGVHSLS 20 0.952 0.898 
TCR_consensus MLMGTRLLCWVALCLLGAGHV 24 0.954 0.941 
SpMax MLMGTLLLLLLLLLLLLAKHV 24 0.968 0.957 
Table 5.5: Mouse TRBV13-2 leader variants and novel signal sequences. 
This describes the signal sequences generated to test the variability of display when placed 
on the DO11.10 β-chain construct. Variants include a reduced h-region by removal of 
leucine residues, modified polarity with serine substitutions for cysteine residues 
(mutations shown by underline). The Ig and TCR consensus signal sequences were also 
cloned into the construct as well as a variant called SpMax designed to have the best SRP 
recognition and peptidase activity for all Ig and TCR v-region sequences as calculated by 
SignalP138. 
Analysis of signal sequences will help determine the characteristics necessary for 
proper trafficking of secreted and surface displayed proteins. Sequences with less affinity 
for the SRP would not be expected to translocate into the ER membrane as this process is 
highly regulated through both receptor proteins and transmembrane channels141. 
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Additionally proteins tested with weak or cryptic cleavage-regions may cause the retention 
of the protein in the ER lumen if it is not targeted for degradation otherwise164.  
These experiments could also answer how certain signal sequences are selected for 
their capacity to direct the post-translational activities of proteins within the cells. These 
sequences already perform a multitude of roles with stabilizing the nascent protein, 
recruiting trafficking molecules for translocation, and possibly downstream stabilization 
during and after protein translocation through the ER membrane. If tuning the three regions 
of the signal peptide controls additional aspects of expressed proteins then optimization 
may increase the stability and yields.  
5.5: CHIMERIC ANTIGEN RECEPTORS IN T-CELLS 
A new class of engineered proteins called chimeric antigen receptors (CARs) have 
fused domains from various immuno-protein origins altering the protein’s overall 
functionality152. CARs are currently under heavy development as they link the antigen 
binding regions of antibodies and TCRs with other stimulatory or effector domains to 
engineer a particular immune response165. As protein formulation and cellular therapeutics 
have advanced, highly functional immunological receptors comprising fusions of 
antibodies coupled with T-cell activation using CD3ζ ITAMs have proven their efficacy in 
a few trials166. The CD28 domain provides co-stimulatory interactions with CD80 and 
CD86 on the APC and causes the surface display of protein as a disulfide-linked 
homodimer. Additionally most CARs with published signal sequences use CD8 for stable 
display152,167. This preliminary work designed (Figure 5.8A) and expressed a DO11.10 
second-generation CAR on 58-/- (Figure 5.8B) and CHO (Figure 5.8C) cells, but similar 
to previously described results the transiently transfected cells could not be activated. 
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Figure 5.8: DO11.10 CART schematic and surface display. 
(A) Diagram of the DO11.10 CART construct generated with scTCR, CD28, and CD3ζ 
fusion, (B) Histogram of CART display on the surface of CHO and 58-/- cells showing 
proper surface display of the receptor.  
5.6: DISCUSSION AND CONCLUSIONS 
TCR engineering in vitro requires the reconstitution of the receptor onto the T-cell 
surface to test for any alterations in the activation of the receptor. Transient transfections 
with the TCR display constructs showed stable display on CHO cells, but failed to 
transiently transfect 58-/- cells for an activation assay. Antibiotic selection for stable cell 
lines using G418 and puromycin also failed to display TCR at levels comparable to 
DO11.10 hybridomas. This was even after extensive antibiotic selection and subsequent 
sorting. 
A deeper analysis of literature found some problems with the 58-/- cell line which 
may cause the malformation of the immune complex and lack of TCR display seen in these 
tests. There are several conflicting reports about the cell line’s ability to display particular 
TCR constructs as a complete immune complex. One study found CD3ζ-/- mice have 
abolished TCR display shown in a figure that nearly identically matched the flow 
cytometry histogram seen in the DO11.10α-EGFP + β-PURO sample of Figure 5.4.1.2C 
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and other studies have noted the need to co-transfect CD3ζ or CD4 to reestablish the 
immune complex159,168. Meanwhile other researchers have shown in a variety of 
experiments the ability to stably transfect TCRs in 58-/- cells for activation studies similar 
to the one attempted in this report without the additional CD receptor transfections169–171.  
Further experimentation will be required to increase the transfection efficiency for 
more robust TCR display on the 58-/- T-cells. These experiments could include 
transfections with cloned full-length CD3 chains to reestablish the receptor expression 
required for the immune complex172. Additional transfection methods such as 
nucleofection and viral transduction could bypass the low efficiencies seen with 
electroporation. Alternatively, a separate activated T-cell line already expressing an 
immune complex could be transfected with our TCR constructs for duel TCR display, but 
with some complications if there the native TCR interferes with the transfected receptor. 
These efforts to display engineered TCRs on the surface of T-cells for activity assays has 
led to many interesting investigations on the myriad of complicated and important aspects 
for TCR expression in thymocytes and protein production in eukaryotic systems.  
The current understanding of protein expression with SRP-mediated translocation 
is somewhat limited to certain a few classes of proteins and model system. The 
complications with surface display due to the signal sequences in this study show there is 
opportunity to optimize commonly used signal sequences on commercial vectors for 
broader applications with more general proteins. We hypothesize the SpMax, Ig, and TCR 
will increase display but with variability due to the different h-regions, including the two 
central cysteine residues in the TCR consensus variant. Finally, we expect the TRBV13-
2L variants will have diminished display as their signal sequences depart from the 
established n-, h-, c-region motif.    
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Chapter 6: Future directions and concluding remarks 
 In this report, we present evidence linking TCR sequence, structure, and function 
to help elucidate the requirements for the robust recognition and activation that is 
characteristic of these molecules in the adaptive immune system. The high throughput 
sequencing experiments provided an opportunity to understand the types of analytical 
methods needed to probe TCR repertoires for background composition and changes due to 
antigen immunizations (Chapter 2). In addition, an examination of structural repertoires 
in antibodies and TCRs for conserved framework interfaces, CDR loops, aligned residue 
sequences, and key residues found residue sequence-based correlations which can guide 
structure modeling for novel receptor proteins (Chapters 3 and 4). Finally, we applied the 
insights of the sequence and structure analyses from the previous chapters to test the in 
vivo characteristics of reconstituted engineered TCRs (Chapter 5). 
6.1: HIGH-THROUGHPUT SEQUENCING FOR DISEASE RESPONSIVENESS 
While the data from the HTS study described in Chapter 2 did not show a definitive 
antigen-specific shift in the TCR repertoire, this type of analysis to sort and screen 
sequences is important for determining the health of the immune system. In recent years, 
numerous studies have used HTS to study the many facets of the immune system and 
increased its utility as a platform technology41,53,72. Monitoring the development of T-cell 
repertoires and analyzing memory inflation with HTS in chronically infected individuals 
can both identify rare antigen specific T-cells and characterize antigen recognition within 
inflated T-cell populations. Identifying TCR sequences selected for memory cell 
maturation also gives insight into various components of disease progression leading to a 
narrowed TCR repertoire and memory inflation, which decreases immune responsiveness.  
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An investigation by Holtappels et al. showed the accumulation of public CD8+ 
CMV-specific TCRs occurring in multiple chronically infected individuals173. Leveraging 
these public sequences on CD8+ cells and transfecting them into CD4+ cells can enhance 
the overall immune response by recruiting more diverse CMV-specific T-cells to sites of 
infection52. Production of these diverse T-cell responses is imperative for prolonged 
protection against the diverse antigen landscape. Correlating these public TCR repertoires 
with the corresponding MHCs also reveals which HLA genes present antigens to generate 
the best protection against infections72,174. 
While we ultimately chose not to pursue further HTS experiments at this time, we 
have gained the following insights into requirements for any future repertoire sequencing 
efforts. Developing finer cell isolation processes, gene amplification techniques, and 
sequence analysis algorithms will increase the utility of HTS as a platform technology. A 
comprehensive study of repertoire changes due to antigen challenges and environmental 
exposures allows for improved vaccines and immunotherapeutics for initiating proper 
immune responses. These advancements will allow scientists to analyze and characterize 
individual immune systems nearly down to the cellular level to identify and correct for 
gaps in the repertoire.  
6.2: MODELING WITH STRUCTURAL REPERTOIRES 
Characterization of TCR-pMHC interactions provides a quantitative insight into the 
structural mechanisms involved with peptide recognition and downstream activation. The 
conserved structural features described here with key residues and canonical classes, will 
allow us to assign structural meaning to the affinity-maturated variants selected in directed 
evolution studies or from HTS experiments. Structural modeling of antibodies and TCRs 
can help generate more effective vaccines to prevent viral escape as well as 
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immunotherapeutics to direct receptor specificity away or towards self-peptides in cases of 
autoimmune disorders and cancers respectively123. 
While the work discussed in Chapter 3 found structural classifications in TCRs for 
the majority of CDR1 and CDR2 loops, much work remains to delineate the structural 
prediction capabilities for the hypervariable CDR3. This longer and more flexible CDR 
loop provides the majority of the important peptide contacts during TCR-pMHC 
interactions. In addition more structural analysis should be performed to elucidate how 
during pMHC engagement, the CDR3 translates the recognition signal through β-strand G 
to the constant domain and CD3 co-receptors12.  
The supplemental structural analysis in Chapter 4 found potential areas for 
improvement in the modeling capacity of the OptCDR program103. By using a hybrid-
modeling program to build novel CDR loops on a structurally well-defined framework, the 
program treated the CDRs as flexible transposable elements. This study found the modeling 
software should instead leverage key residues and canonical class conformations found in 
the majority of antibodies and TCRs to design the antigen-binding region in silico23,25. In 
this way, with enough engineering to control the chain interfaces and β-sheet composition 
a program could possibly design a universal framework to present, orient, and generate 
most antigen-binding regions. 
6.3: FUTURE DIRECTIONS WITH TCR THERAPEUTICS  
The success of adoptive transfer therapies with the antigen-binding regions of 
antibodies and TCRs  has sparked the development of a suite of new cellular and receptor-
mediated therapies14. These types of treatments use modified T-cells to stimulate the 
activity of the patient’s own immune system. This also has the added benefit of producing 
modified memory cells for prolonged treatment efficacy.  
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Engineered BCRs, TCRs, and CARs combines affinity-maturated receptors with 
the biological activity associated with immunoproteins in B-cells and T-cells. For example, 
transfecting engineered TCRs with cancer specificity into T-cells can bypass negative 
selection since these self-peptide specific receptors are normally removed during T-cell 
maturation167. Another soluble CAR technology uses a single chain protein with both a 
CMV-specific scTCR fused to an IgG1 heavy chain Fc region to label infected cells for 
destruction175. This platform technology could be applied to a variety of soluble CTL 
receptors to target a range pMHCs for an improved ability to treat infections without 
possible harmful side effects. Further engineering of these receptors to fuse various 
domains together for their activities short-circuits signaling pathways to circumvent cell 
regulators that might dampen a desired immune response176. The preliminary work in 
Chapter 5 for displaying engineered TCR constructs to study the effect of in vitro affinity 
maturation on T-cell activity provides deeper understanding into the complex nature 
cellular engineering. In addition, the design of signal sequence variants for tuned TCR and 
CAR display can further modify the activity these receptor-displaying cells.  
6.4: CONCLUDING REMARKS 
 The critical role of TCRs in the immune system makes them an excellent target for 
protein engineering to aid disease response through affinity maturation, chimeric fusions, 
and adoptive cellular therapies. While antibody-based therapies have been the subject of 
research for decades, TCR-based therapies are relatively new and the research landscape 
remains fairly open. Linking the various aspects of TCRs discussed here can allow a more 
comprehensive macro- and micro-analysis of individual receptors and repertoires. With 
this greater understanding of TCR-pMHC complex, advancements in repertoire 
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sequencing, crystallography, and cellular manipulations will continue to allow scientists to 
make new discoveries and develop therapies to tackle challenging immune disorders.
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Appendices 
A: SELECTED METHODS 
A.1: Cell Suspension Preparation 
1. Isolate spleens from mouse. Store in each spleen in 3 ml DMEM-5 on ice 
2. Cut spleens with scissors in several places with EtOH washed scissors 
3. Transport spleens back to the lab on ice 
4. Disrupt tissue structure with the back of a sterile syringe grinding against the petri 
dish until mostly fibrous tissue remains 
5. Draw up cells in media with needle/syringe and expel through a cell strainer into a 
50 ml centrifuge tube 
6. Wash petri dish with ~4 ml of DMEM-5, pass through strainer into centrifuge tube 
7. Centrifuge 5 min at 250 x g, discard supernatant and store on ice until ready for red 
blood cell lysis. 
A.2: M13 Phage Protocols 
Protocols adapted from from	Sidhu	and	Weiss	 2004  
Make sure to use the correct phagemids (MoPAC24) and XL1-Blue or (another F pilus+ 
line) cells cell lines that can produce phage and become infected by the M13 phage used 
in the lab. To further increase yields add %1 glucose to the media to give cells more energy 
as they consume sugar for the lac operon. Create M13 phage displaying the protein of 
interest. Used in studies with TCR:pMHC interactions. MoPAC24 has GP3 linker region 
attached to the scFv, the M13 grabs onto the GP3 and displays up to three scFv proteins on 
the phage surface. Good yields with 100 ml of culture. This protocol is also found in the 
Weiss paper #6. 
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A.2.1: Phage Production 
1. Start an overnight 2 ml culture of either E15 or XL1Blue with the “MoPAC” plasmid 
containing the scFv of interest 
2. Increase the culture to 100 ml and place in the 37°C shaker until an OD of ~0.5 
3. Induce with 1 mM IPTG, incubate at room temperature for 1.5 hours 
4. Add helper phage to final concentration of 1010 phage/ml, incubate at room 
temperature with no shaking for 15’ then incubate for 1 hour with shaking. 
5. Add Kanamycin and place in the 37°C shaker overnight. 
A.2.2: Phage Purification 
Harvest phage particles and determine the titer concentration. 
1. Centrifuge culture for 10’ at 10 krpm and 4°C  
2. Transfer SN to a fresh tube and add 1/5 vol PEG/NaCl solution to precipitate the 
phage and incubate for 5’ at room temperature 
3. Centrifuge for 10’ at 10 krpm and 4°C and aspirate all SN. 
4. Resuspend the pellet in 1/20 volume of PBS.  Pellet insoluble matter by centrifuging 
for 5’ at 15 krpm and 4°C. Transfer SN to clean tube. 
5. Estimate [phage] spectrophotometrically (OD268= 1.0 for 5 x 1012 phage/ml) 
6. Use immediately or store at -80°C 
A.2.3: dU-ssDNA Isolation 
Constructing Phage display libraries by oligonucleotide-directed mutagenesis. Phage 
Display. Eds. Clackson and Lowman 
1. Transfer 1 colony of CJ236 with phagemid to 1mL TB + Amp, incubate at 37°C 
250rpm 6-8h.  
2. Add helper phage to ~1010 virons/mL (10µL at 1013-14 virons/mL).  Incubate at RT 
15min. 
3. Transfer to 30 mL 2xYT + Amp + uridine (0.25µg/mL). Incubate at 37°C 250 rpm 
ON. 
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4. Centrifuge 15,000 rpm 10m in 4°C. Transfer SN to new tube with 1/5th vol. 20% 
(w/v) PEG-8000/2.5M NaCl. Incubate on rotor 4°C 20 min. 
5. Harvest phage at 10k rpm 10min 4°C. Pour off SN and invert on paper towel to dry 
~5min 
6. Resuspend in 500µL PBS (pH 7.4), transfer to tube. Spin max 5min and transfer SN 
to new tube. Repeat to remove all cell debris (1X repeat typically OK). 
7. Add 7µL Buffer MP (QIAgen Spin M13 Kit), mix and incubate at rt 2min 
8. Add to spin column, spin 8,000rpm 15s, discard FT 
9. Add 700µL Buffer MLB, repeat spin and discard FT 
a. Repeat with additional 1min incubation at rt 
10. Add 700µL Buffer PE, repeat spin and discard FT 
a. Repeat and perform final spin 8,000rpm 30s to remove residual EtOH 
11. Transfer to new tube, add 100µL Buffer EB. Incubate at rt 10min. Elute at 8,000rpm 
30s. 
12. Spec to determine concentration and run on gel.  




B: OLIGO-NUCLEOTIDE AND PLASMID SEQUENCES 






180 1.79 * 107 1.6 * 106 
181 2.00 * 107 2.1 * 106 
178 1.45 * 107 1.4 * 106 
200 2.22 * 107 2.2 * 106 
Table B.1: Cell concentrations for the various samples 
T-cell counts taken before and after CD4 and CD8 sorting 
 
Mouse [RNA] (ng/μl) 260/280 260/230
178 Elution 1 475 2.15 1.84 
178 Elution 2 45.2 2.01 0.38 
200 Elution 1 401.3 2.13 1.49 
200 Elution 2 53.7 1.85 0.19 
Table B.2: Amount of sorted cDNA collected from the mice 
After harvesting RNA using Triazol and Qiagen kit the yields are as follows 
 
 CD4+ Sorted Cells CD8+ Sorted Cells 
Mouse tRNA [ng/µl] 260/280 260/230 tRNA [ng/µl] 260/280 260/230 
1 57.7 1.93 0.97 60.9 1.93 1.12 
2 72.3 1.86 0.31 73.1 1.79 0.40 
3 62.8 1.94 0.70 70.1 1.89 0.74 
4 105.8 1.86 0.28 87.7 1.92 0.84 
Table B.3: Amount of sorted cDNA collected from the mice 




B.1.2: Generated HTS Variants 
HTS Variant #1  
     1: G  L  L  L  L  A  A  Q  P  A  M  A  E  A  A  V  T  Q  S  P  R  N  K  V  A  V  T  G  E  K   
        GGATTGTTATTACTCGCGGCCCAGCCGGCCATGGCGGAGGCTGCAGTCACCCAAAGCCCAAGAAACAAGGTGGCAGTAACAGGAGAGAAG  90 
     1: V  T  L  S  C  N  Q  T  N  N  H  N  N  M  Y  W  Y  R  Q  D  T  G  H  G  L  R  L  I  Y  Y   
        GTGACATTGAGCTGTAATCAGACTAATAACCACAACAACATGTACTGGTATCGGCAGGACACGGGGCATGGGCTGAGGCTGATCTACTAT 180 
     1: S  Y  G  A  G  S  T  E  K  G  D  I  P  D  G  Y  K  A  S  R  P  S  Q  E  N  F  S  L  T  L   
        TCATATGGTGCTGGCAGCACTGAGAAAGGAGATATCCCTGATGGATACAAGGCCTCTAGACCAAGCCAAGAGAACTTCTCCCTCACTCTG 270 
     1: E  S  A  T  P  S  Q  T  S  V  Y  F  C  A  S  G  S  G  T  T  N  T  E  V  F  F  G  K  G  T   
        GAGTCGGCTACCCCCTCTCAGACATCAGTGTACTTCTGTGCCAGCGGCTCCGGGACAACAAACACAGAAGTCTTCTTTGGTAAAGGAACC 360 
     1: R  L  T  V  V  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  E  Q  V  E  Q   
        AGACTCACAGTTGTAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCCGGAGGCGGTGGTTCTGGAGGAGGAGGATCCGAGCAGGTGGAGCAG 450 
     1: R  P  P  H  L  S  V  R  E  G  D  S  A  V  I  T  C  T  Y  T  D  P  N  S  Y  Y  F  F  W  Y   
        CGCCCTCCTCACCTGAGTGTCCGGGAGGGAGACAGTGCCGTTATCACCTGCACCTACACAGACCCTAACAGTTATTACTTCTTCTGGTAC 540 
     1: K  Q  E  P  G  A  S  L  Q  L  L  M  K  V  F  S  S  T  E  I  N  E  G  Q  G  F  T  V  L  L   
        AAGCAAGAGCCGGGGGCAAGTCTTCAGTTGCTTATGAAGGTTTTCTCAAGTACGGAAATAAACGAAGGACAAGGATTCACTGTCCTACTG 630 
     1: N  K  K  D  K  R  L  S  L  N  L  T  A  A  H  P  G  D  S  A  A  Y  F  C  A  V  M  P  N  Y   
        AACAAGAAAGACAAACGACTCTCTCTGAACCTCACAGCTGCCCATCCTGGGGACTCAGCCGCGTACTTCTGCGCGGTGATGCCGAACTAT 720 
     1: N  V  L  Y  F  G  S  G  S  K  L  T  V  E  P  A  A  S  G  A  D  H  H  H  H  H  H  *  *  A   







HTS Variant #2 
     1: L  L  L  A  A  Q  P  A  M  A  E  A  A  V  T  Q  S  P  R  N  K  V  A  V  T  G  E  K  V  T   
        TTATTACTCGCGGCCCAGCCGGCCATGGCGGAGGCTGCAGTCACCCAAAGCCCAAGAAACAAGGTGGCAGTAACAGGAGAGAAGGTGACA 90 
     1: L  S  C  N  Q  T  N  N  H  N  N  M  Y  W  Y  R  Q  D  T  G  H  G  L  R  L  I  Y  Y  S  Y   
        TTGAGCTGTAATCAGACTAATAACCACAACAACATGTACTGGTATCGGCAGGACACGGGGCATGGGCTGAGGCTGATCTACTATTCATAT 180 
     1: G  A  G  S  T  E  K  G  D  I  P  D  G  Y  K  A  S  R  P  S  Q  E  N  F  S  L  T  L  E  S   
        GGTGCTGGCAGCACTGAGAAAGGAGATATCCCTGATGGATACAAGGCCTCTAGACCAAGCCAAGAGAACTTCTCCCTCACTCTGGAGTCG 270 
     1: A  T  P  S  Q  T  S  V  Y  F  C  A  S  G  S  G  T  T  N  T  E  V  F  F  G  K  G  T  R  L   
        GCTACCCCCTCTCAGACATCAGTGTACTTCTGTGCCAGCGGCTCCGGGACAACAAACACAGAAGTCTTCTTTGGTAAAGGAACCAGACTC 360 
     1: T  V  V  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  E  Q  V  E  Q  R  P   
        ACAGTTGTAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCCGGAGGCGGTGGTTCTGGAGGAGGAGGATCCGAGCAGGTGGAGCAGCGCCCT 450 
     1: P  H  L  S  V  R  E  G  D  S  A  V  I  T  C  T  Y  T  D  P  N  S  Y  Y  F  F  W  Y  K  Q   
        CCTCACCTGAGTGTCCGGGAGGGAGACAGTGCCGTTATCACCTGCACCTACACAGACCCTAACAGTTATTACTTCTTCTGGTACAAGCAA 540 
     1: E  P  G  A  S  L  Q  L  L  M  K  V  F  S  S  T  E  I  N  E  G  Q  G  F  T  V  L  L  N  K   
        GAGCCGGGGGCAAGTCTTCAGTTGCTTATGAAGGTTTTCTCAAGTACGGAAATAAACGAAGGACAAGGATTCACTGTCCTACTGAACAAG 630 
     1: K  D  K  R  L  S  L  N  L  T  A  A  H  P  G  D  S  A  A  Y  F  C  A  V  M  P  N  Y  N  V   
        AAAGACAAACGACTCTCTCTGAACCTCACAGCTGCCCATCCTGGGGACTCAGCCGCGTACTTCTGCGCGGTGATGCCGAACTATAACGTG 720 
     1: L  Y  F  G  S  G  S  K  L  T  V  E  P  A  A  S  G  A  D  H  H  H  H  H  H  *  *  A  *  P   









HTS Variant #3 
     1: L  L  L  A  A  Q  P  A  M  A  E  A  A  V  T  Q  S  P  R  N  K  V  A  V  T  G  E  K  V  T   
        TTATTACTCGCGGCCCAGCCGGCCATGGCGGAGGCTGCAGTCACCCAAAGCCCAAGAAACAAGGTGGCAGTAACAGGAGAGAAGGTGACA 90 
     1: L  S  C  N  Q  T  N  N  H  N  N  M  Y  W  Y  R  Q  D  T  G  H  G  L  R  L  I  Y  Y  S  Y   
        TTGAGCTGTAATCAGACTAATAACCACAACAACATGTACTGGTATCGGCAGGACACGGGGCATGGGCTGAGGCTGATCTACTATTCATAT 180 
     1: G  A  G  S  T  E  K  G  D  I  P  D  G  Y  K  A  S  R  P  S  Q  E  N  F  S  L  T  L  E  S   
        GGTGCTGGCAGCACTGAGAAAGGAGATATCCCTGATGGATACAAGGCCTCTAGACCAAGCCAAGAGAACTTCTCCCTCACTCTGGAGTCG 270 
     1: A  T  P  S  Q  T  S  V  Y  F  C  A  S  G  S  G  T  T  N  T  E  V  F  F  G  K  G  T  R  L   
        GCTACCCCCTCTCAGACATCAGTGTACTTCTGTGCCAGCGGCTCCGGGACAACAAACACAGAAGTCTTCTTTGGTAAAGGAACCAGACTC 360 
     1: T  V  V  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  E  Q  V  E  Q  R  P   
        ACAGTTGTAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCCGGAGGCGGTGGTTCTGGAGGAGGAGGATCCGAGCAGGTGGAGCAGCGCCCT 450 
     1: P  H  L  S  V  R  E  G  D  S  A  V  I  T  C  T  Y  T  D  P  N  S  Y  Y  F  F  W  Y  K  Q   
        CCTCACCTGAGTGTCCGGGAGGGAGACAGTGCCGTTATCACCTGCACCTACACAGACCCTAACAGTTATTACTTCTTCTGGTACAAGCAA 540 
     1: E  P  G  A  S  L  Q  L  L  M  K  V  F  S  S  T  E  I  N  E  G  Q  G  F  T  V  L  L  N  K   
        GAGCCGGGGGCAAGTCTTCAGTTGCTTATGAAGGTTTTCTCAAGTACGGAAATAAACGAAGGACAAGGATTCACTGTCCTACTGAACAAG 630 
     1: K  D  K  R  L  S  L  N  L  T  A  A  H  P  G  D  S  A  A  Y  F  C  A  V  S  R  N  N  N  N   
        AAAGACAAACGACTCTCTCTGAACCTCACAGCTGCCCATCCTGGGGACTCAGCCGCGTACTTCTGCGCGGTGAGCCGCAACAACAACAAC 720 
     1: R  I  F  F  G  D  G  T  Q  L  V  V  K  P  A  A  S  G  A  D  H  H  H  H  H  H  *  *  A  *   






HTS Variant #4 
     1: L  L  L  A  A  Q  P  A  M  A  E  A  A  V  T  Q  S  P  R  N  K  V  A  V  T  G  E  K  V  T   
        TTATTACTCGCGGCCCAGCCGGCCATGGCGGAGGCTGCAGTCACCCAAAGCCCAAGAAACAAGGTGGCAGTAACAGGAGAGAAGGTGACA 90 
     1: L  S  C  N  Q  T  N  N  H  N  N  M  Y  W  Y  R  Q  D  T  G  H  G  L  R  L  I  Y  Y  S  Y   
        TTGAGCTGTAATCAGACTAATAACCACAACAACATGTACTGGTATCGGCAGGACACGGGGCATGGGCTGAGGCTGATCTACTATTCATAT 180 
     1: G  A  G  S  T  E  K  G  D  I  P  D  G  Y  K  A  S  R  P  S  Q  E  N  F  S  L  T  L  E  S   
        GGTGCTGGCAGCACTGAGAAAGGAGATATCCCTGATGGATACAAGGCCTCTAGACCAAGCCAAGAGAACTTCTCCCTCACTCTGGAGTCG 270 
     1: A  T  P  S  Q  T  S  V  Y  F  C  A  S  G  S  G  T  T  N  T  E  V  F  F  G  K  G  T  R  L   
        GCTACCCCCTCTCAGACATCAGTGTACTTCTGTGCCAGCGGCTCCGGGACAACAAACACAGAAGTCTTCTTTGGTAAAGGAACCAGACTC 360 
     1: T  V  V  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  Q  N  V  Q  Q  S  P   
        ACAGTTGTAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCCGGAGGCGGTGGTTCTGGAGGAGGAGGATCCCAGAATGTGCAGCAGAGCCCG 450 
     1: E  S  L  I  V  P  E  G  A  R  T  S  L  N  C  T  F  S  D  S  A  S  Q  Y  F  W  W  Y  R  Q   
        GAATCCCTCATTGTCCCAGAGGGAGCCAGGACCTCTCTCAACTGCACTTTCAGTGACAGTGCTTCTCAGTATTTCTGGTGGTACAGACAG 540 
     1: H  S  G  K  A  P  K  A  L  M  S  I  F  S  N  G  E  K  E  E  G  R  F  T  I  H  L  N  K  A   
        CATTCTGGGAAAGCCCCCAAGGCACTGATGTCCATCTTCTCCAATGGTGAAAAAGAAGAAGGGAGATTCACAATTCACCTCAATAAAGCC 630 
     1: S  L  H  F  S  L  H  I  R  D  S  Q  P  S  D  S  A  L  Y  L  C  A  A  N  N  Y  A  X  G  L   
        AGTCTGCATTTCTCCCTGCACATCAGAGACTCCCAGCCCAGTGACTCTGCTCTCTATCTCTGCGCGGCGAACAACTATGCGCANGGCCTG 720 
     1: T  F  G  L  G  T  R  V  S  V  F  P  A  A  S  G  A  D  H  H  H  H  H  H  *   
        ACCTTTGGCCTGGGCACCCGCGTGAGCGTGTTTCCGGCGGCCTCGGGGGCCGATCACCATCATCACCATCATTAG 






B.2: Designs for TCR display constructs 
Primers to add the restriction sites (EcoRI/AgeI/HindIII) at either end of the inserts: 
Initial primers to amplify the coding regions of the mRNA include: 











Vα5D‐4	 	 	 http://www.imgt.org/cgi-bin/IMGTlect.jv  AC005855 
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EcoRI site with Kozak sequence as well the start of the murine IgG1 
signal peptide; derived from DEC205/IgG fusion protein in GenBank 
Accession Number DQ407610. This maintains the TCR Signal sequence 
before coding the V-region.  
AbVec     CGA TTG AAT TCC ACC ATG GGA TGG TCA TGT ATC ATC CTT TTT CTA 
    R   L   N   S   T   M   G   W   S   C   I   I   L   F   L    
Va14 EcoRI      GA TTG AAT TCC ACC ATG GAC AAG ATC CTG 
Va14 seq     TTC AGT CTA GGA GGA ATG GAC AAG ATC CTG 
Va5D-4 EcoRI ATT TAA TTG AAT TCC ACC ATG AAA ACA TAC GCT CC 
Va5D-4 seq ATT TAA TTG GGA AGA GCA ATG AAA ACA TAC GCT CCT ACA 
Vb13 EcoRI      GA TTG AAT TCC ACC ATG GGC TCC AGG CTC 
Vb13 seq TGC CTT GGT CCC AAG     ATG GGC TCC AGG CTC  
pEGFP-N1 TAT CGA TGA ATT CTC ACC ATG GGA TGG TCA TGT ATC ATC CTT TTT CTA  
    R   *   N   L   T   M   G   W   S   C   I   I   L   F   L 
 
AgeI site at the end of the murine IgG1 signal peptide; derived from 
DEC205/IgG fusion protein in GenBank Accession Number DQ407610 
AbVec    ACT GCA ACC GGT GTA CAC TCG GAT ATC CAG ATG A 
   T   A   T   G   V   H   S    
Va 14 AgeI      T GCA ACC GGT GTA CAC TCG GTG AGT GGC CAG CAG G 
Va sequence    CTT CTA GGC CTT CAC CTA GCT GTG AGT GGC CAG CAG GAG 
Vb13 AgeI      T GCA ACC GGT GTA CAC TCG     CAC ATG GAG GCT GCA G 
Vb 13-2 AgeI     CTC TCC ACC GGT GTA CAC TCG AAA CAC ATG GAG GCT GCA G 
Vb mRNA seq TG CTC TCC AGT CTC CTG TGT TCA AAA CAC ATG GAG GCT GCA GTC ACC C 
Vb IMGT seq    CTC TCC AGT CTC CTG TGT TCA     CAC ATG GAG GCT GCA GTC 
Va 5D-4 AgeI    TTT CTA ACC GGT GTA CAC TCG GAG CAG GTG GAG CAG CTT CCT TCC A 
Va 5D-4 seq    TTT CTA TGG CTG CAG CTG GAT GAG CAG GTG GAG CAG CTT CCT TCC A 
Vb 5 AgeI     ACT GCA ACC GGT GTA CAC TCG AAC ACT AAA ATT ACT CAG TCA CC 
 
HindIII site C-terminal of the Constant region; derived from DEC205/IgG 
fusion protein in GenBank Accession Number DQ407610 
3’-Vector                             TGA AGC TTG GCC GCC 
Ca sequence ACG CTG AGG CTG TGG TCC AGT TGA GGT CTG CAA GAC TGA CA  
Ca HindIII  CG CTG AGG CTG TGG TCC AGT TGA AGC TTG CAA GAC TGA C 
Ca XmaI  ACG CTG AGG CTG TGG TCC AGT TCC CGG GTG GCC GCC (AbVec)  
VbC*01 seq G GCT ATG GTC AAA AGA AAG AAT TCA TGA AGT CAG ATG TGA A  
Cb01 HindIII  G GCT ATG GTC AAA AGA AAG AAC TCA TGA AGC TTG ATG TGA A  
Cb02 HindIII                        AA AAT TCC TGA AGC TTA CTT TTA TGC 
VbC*02 seq   CAG GTC AAG AAA AAA AAT TCC TGA GAC AAA CTT TTA TGC ATC 
CTG AGC 
Cb02 HindIII      G GTC AAG AAA AAA AAT TCC TGA AGC TTA CTT TTA TGC ATC 
CTG AGC 
Cb XmaI G GCC ATG GTC AAR ARA AAA AAT TCC CGG GTC GAG AAG   
 
377 (same as 378 with one shift ATGAAGCTTG) 
CGGTTCTATCGATTGAATTCCACCATGGGATGGTCATGTATCATCC……TTCTAGTAGCAACTGCAACCGGT
GTACACTCGGATATCC…GAGAGTGTTAGAAGCTTGGCCGCCAT 
Table B.4: Descriptions of the display vector cloning sites.  
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B.2.1: Model TCRs 172 and DO11.10  
172 α sequence (Leader-V-J-Constant): 
 M  D  K  I  L  T  A  S  F  L  L  L  G  L  H  L  A  V  S  G  Q  Q  E  K  R  D  Q  Q  Q  V         
ATGGACAAGATCCTGACAGCATCGTTTTTACTTCTAGGCCTTCACCTAGCTGTGAGTGGCCAGCAGGAGAAACGTGACCAGCAGCAGGTG 
 
 R  Q  S  P  Q  S  L  T  V  W  E  G  E  T  A  I  L  N  C  S  Y  E  N  S  A  F  D  Y  F  P         
AGACAAAGTCCCCAATCTCTGACAGTCTGGGAAGGAGAGACCGCAATTCTGAACTGCAGTTATGAGAACAGTGCTTTTGACTACTTCCCA 
 
 W  Y  Q  Q  F  P  G  E  G  P  A  L  L  I  S  I  L  S  V  S  D  K  K  E  D  G  R  F  T  I         
TGGTACCAGCAGTTCCCTGGGGAAGGTCCCGCTCTCCTGATATCCATACTTTCAGTGTCCGATAAAAAGGAAGATGGACGATTCACAATC 
 
 F  F  N  K  R  E  K  K  L  S  L  H  I  A  D  S  Q  P  G  D  S  A  T  Y  F  C  A  A  S  A   
TTCTTCAATAAAAGGGAGAAAAAGCTCTCCTTGCACATTGCAGACTCTCAGCCTGGAGACTCAGCCACCTACTTCTGTGCAGCAAGTGCA 
 
 N  S  G  T  Y  Q  R  F  G  T  G  T  K  L  Q  V  V  P  N  I  Q  N  P  E  P  A  V  Y  Q  L          
AATTCTGGGACTTACCAGAGGTTTGGAACTGGGACAAAACTCCAAGTCGTTCCAAACATCCAGAACCCAGAACCTGCTGTGTACCAGTTA 
  
 K  D  P  R  S  Q  D  S  T  L  C  L  F  T  D  F  D  S  Q  I  N  V  P  K  T  M  E  S  G  T         
AAAGATCCTCGGTCTCAGGACAGCACCCTCTGCCTGTTCACCGACTTTGACTCCCAAATCAATGTGCCGAAAACCATGGAATCTGGAACG 
 
 F  I  T  D  K  T  V  L  D  M  K  A  M  D  S  K  S  N  G  A  I  A  W  S  N  Q  T  S  F  T         
TTCATCACTGACAAAACTGTGCTGGACATGAAAGCTATGGATTCCAAGAGCAATGGGGCCATTGCCTGGAGCAACCAGACAAGCTTCACC 
 
 C  Q  D  I  F  K  E  T  N  A  T  Y  P  S  S  D  V  P  C  D  A  T  L  T  E  K  S  F  E  T          
TGCCAAGATATCTTCAAAGAGACCAACGCCACCTACCCCAGTTCAGACGTTCCCTGTGATGCCACGTTGACTGAGAAAAGCTTTGAAACA 
 
 D  M  N  L  N  F  Q  N  L  S  V  M  G  L  R  I  L  L  L  K  V  A  G  F  N  L  L  M  T  L          
GATATGAACCTAAACTTTCAAAACCTGTCAGTTATGGGACTCCGAATCCTCCTGCTGAAAGTAGCCGGATTTAACCTGCTCATGACGCTG 
 
 R  L  W  S  S  *   
AGGCTGTGGTCCAGTTGA 
 
172 β sequence (Leader-V-J-Constant): 
 M  G  S  R  L  F  F  V  L  S  S  L  L  C  S  H  M  E  A  A  V  T  Q  S  P  R  N  K  V  A          
ATGGGCTCCAGGCTCTTCTTCGTGCTCTCCAGTCTCCTGTGTTCACACATGGAGGCTGCAGTCACCCAAAGCCCAAGAAACAAGGTGGCA 
 
 V  T  G  G  K  V  T  L  S  C  N  Q  T  N  N  H  N  N  M  Y  W  Y  R  Q  D  T  G  H  G  L          
GTAACAGGAGGAAAGGTGACATTGAGCTGTAATCAGACTAATAACCACAACAACATGTACTGGTATCGGCAGGACACGGGGCATGGGCTG 
 
 R  L  I  H  Y  S  Y  G  A  G  S  T  E  K  G  D  I  P  D  G  Y  K  A  S  R  P  S  Q  E  N         
AGGCTGATCCATTATTCATATGGTGCTGGCAGCACTGAGAAAGGAGATATCCCTGATGGATACAAGGCCTCCAGACCAAGCCAAGAGAAC 
 
 F  S  L  I  L  E  L  A  T  P  S  Q  T  S  V  Y  F  C  A  S  G  D  A  G  G  G  Y  E  Q  Y         
TTCTCCCTCATTCTGGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCTGTGCCAGCGGTGATGCGGGGGGGGGGTATGAACAGTAC 
 
 F  G  P  G  T  R  L  T  V  L  E  D  L  R  N  V  T  P  P  K  V  S  L  F  E  P  S  K  A  E         
TTCGGTCCCGGCACCAGGCTCACGGTTTTAGAGGATCTGAGAAATGTGACTCCACCCAAGGTCTCCTTGTTTGAGCCATCAAAAGCAGAG 
 
 I  A  N  K  Q  K  A  T  L  V  C  L  A  R  G  F  F  P  D  H  V  E  L  S  W  W  V  N  G  K         
ATTGCAAACAAACAAAAGGCTACCCTCGTGTGCTTGGCCAGGGGCTTCTTCCCTGACCACGTGGAGCTGAGCTGGTGGGTGAATGGCAAG 
 
 E  V  H  S  G  V  S  T  D  P  Q  A  Y  K  E  S  N  Y  S  Y  C  L  S  S  R  L  R  V  S  A         
GAGGTCCACAGTGGGGTCAGCACGGACCCTCAGGCCTACAAGGAGAGCAATTATAGCTACTGCCTGAGCAGCCGCCTGAGGGTCTCTGCT 
 
 T  F  W  H  N  P  R  N  H  F  R  C  Q  V  Q  F  H  G  L  S  E  E  D  K  W  P  E  G  S  P         
ACCTTCTGGCACAATCCTCGCAACCACTTCCGCTGCCAAGTGCAGTTCCATGGGCTTTCAGAGGAGGACAAGTGGCCAGAGGGCTCACCC 
 
 K  P  V  T  Q  N  I  S  A  E  A  W  G  R  A  D  C  G  I  T  S  A  S  Y  H  Q  G  V  L  S   
AAACCTGTCACACAGAACATCAGTGCAGAGGCCTGGGGCCGAGCAGACTGTGGAATCACTTCAGCATCCTATCATCAGGGGGTTCTGTCT 
 
 A  T  I  L  Y  E  I  L  L  G  K  A  T  L  Y  A  V  L  V  S  G  L  V  L  M  A  M  V  K  K   
GCAACCATCCTCTATGAGATCCTACTGGGGAAGGCCACCCTATATGCTGTGCTGGTCAGTGGCCTAGTGCTGATGGCCATGGTCAAGAAA 
 




DO11.10 α sequence (Leader-V-J-Constant): 
 M  K  T  Y  A  P  T  L  F  M  F  L  W  L  Q  L  D  M  S  Q  G  E  Q  V  E  Q  L  P  S  I        
ATGAAAACATACGCTCCTACATTATTCATGTTTCTATGGCTGCAGCTGGATATGAGCCAAGGCGAGCAGGTGGAGCAGCTTCCTTCCATC 
 
 L  R  V  Q  E  G  S  S  A  S  I  N  C  T  Y  E  N  S  A  S  N  Y  F  P  W  Y  K  Q  E  P         
CTGAGAGTCCAGGAGGGATCCAGTGCCAGCATCAACTGCACTTATGAGAACAGTGCCTCCAACTACTTCCCTTGGTATAAGCAAGAACCT 
 
 G  E  N  P  K  L  I  I  D  I  R  S  N  M  E  R  K  Q  T  Q  G  L  I  V  L  L  D  K  K  A         
GGAGAGAATCCTAAGCTCATCATTGACATTCGTTCAAATATGGAAAGAAAGCAGACCCAAGGACTCATCGTTTTACTGGATAAGAAAGCC 
 
 K  R  F  S  L  H  I  T  D  T  Q  P  G  D  S  A  M  Y  F  C  A  A  S  P  N  Y  N  V  L  Y          
AAACGCTTCTCCCTGCACATCACAGACACCCAGCCTGGAGACTCAGCCATGTACTTCTGTGCTGCAAGTCCTAATTACAACGTGCTTTAC 
 
 F  G  S  G  T  K  L  T  V  E  P  N  I  Q  N  P  E  P  A  V  Y  Q  L  K  D  P  R  S  Q  D          
TTCGGATCTGGCACCAAACTCACTGTAGAGCCAAACATCCAGAACCCAGAACCTGCTGTGTACCAGTTAAAAGATCCTCGGTCTCAGGAC 
 
 S  T  L  C  L  F  T  D  F  D  S  Q  I  N  V  P  K  T  M  E  S  G  T  F  I  T  D  K  T  V          
AGCACCCTCTGCCTGTTCACCGACTTTGACTCCCAAATCAATGTGCCGAAAACCATGGAATCTGGAACGTTCATCACTGACAAAACTGTG 
 
 L  D  M  K  A  M  D  S  K  S  N  G  A  I  A  W  S  N  Q  T  S  F  T  C  Q  D  I  F  K  E          
CTGGACATGAAAGCTATGGATTCCAAGAGCAATGGGGCCATTGCCTGGAGCAACCAGACAAGCTTCACCTGCCAAGATATCTTCAAAGAG 
 
 T  N  A  T  Y  P  S  S  D  V  P  C  D  A  T  L  T  E  K  S  F  E  T  D  M  N  L  N  F  Q         
ACCAACGCCACCTACCCCAGTTCAGACGTTCCCTGTGATGCCACGTTGACTGAGAAAAGCTTTGAAACAGATATGAACCTAAACTTTCAA 
 
 N  L  S  V  M  G  L  R  I  L  L  L  K  V  A  G  F  N  L  L  M  T  L  R  L  W  S  S  *   
AACCTGTCAGTTATGGGACTCCGAATCCTCCTGCTGAAAGTAGCCGGATTTAACCTGCTCATGACGCTGAGGCTGTGGTCCAGTTGA 
 
DO11.10 β sequence (Leader-V-J-Constant): 
 M  G  S  R  L  F  F  V  L  S  S  L  L  C  S  H  M  E  A  A  V  T  Q  S  P  R  N  K  V  A        
ATGGGCTCCAGGCTCTTCTTCGTGCTCTCCAGTCTCCTGTGTTCACACATGGAGGCTGCAGTCACCCAAAGCCCAAGAAACAAGGTGGCA 
 
 V  T  G  G  K  V  T  L  S  C  N  Q  T  N  N  H  N  N  M  Y  W  Y  R  Q  D  T  G  H  G  L          
GTAACAGGAGGAAAGGTGACATTGAGCTGTAATCAGACTAATAACCACAACAACATGTACTGGTATCGGCAGGACACGGGGCATGGGCTG 
 
 R  L  I  H  Y  S  Y  G  A  G  S  T  E  K  G  D  I  P  D  G  Y  K  A  S  R  P  S  Q  E  N          
AGGCTGATCCATTATTCATATGGTGCTGGCAGCACTGAGAAAGGAGATATCCCTGATGGATACAAGGCCTCCAGACCAAGCCAAGAGAAC 
 
 F  S  L  I  L  E  L  A  T  P  S  Q  T  S  V  Y  F  C  A  S  G  S  G  T  T  N  T  E  V  F          
TTCTCCCTCATTCTGGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCTGTGCCAGCGGCTCCGGGACAACAAACACAGAAGTCTTC 
 
 F  G  K  G  T  R  L  T  V  V  E  D  L  R  N  V  T  P  P  K  V  S  L  F  E  P  S  K  A  E          
TTTGGTAAAGGAACCAGACTCACAGTTGTAGAGGATCTGAGAAATGTGACTCCACCCAAGGTCTCCTTGTTTGAGCCATCAAAAGCAGAG 
 
 I  A  N  K  Q  K  A  T  L  V  C  L  A  R  G  F  F  P  D  H  V  E  L  S  W  W  V  N  G  K          
ATTGCAAACAAACAAAAGGCTACCCTCGTGTGCTTGGCCAGGGGCTTCTTCCCTGACCACGTGGAGCTGAGCTGGTGGGTGAATGGCAAG 
 
 E  V  H  S  G  V  S  T  D  P  Q  A  Y  K  E  S  N  Y  S  Y  C  L  S  S  R  L  R  V  S  A          
GAGGTCCACAGTGGGGTCAGCACGGACCCTCAGGCCTACAAGGAGAGCAATTATAGCTACTGCCTGAGCAGCCGCCTGAGGGTCTCTGCT 
 
 T  F  W  H  N  P  R  N  H  F  R  C  Q  V  Q  F  H  G  L  S  E  E  D  K  W  P  E  G  S  P         
ACCTTCTGGCACAATCCTCGCAACCACTTCCGCTGCCAAGTGCAGTTCCATGGGCTTTCAGAGGAGGACAAGTGGCCAGAGGGCTCACCC 
 
 K  P  V  T  Q  N  I  S  A  E  A  W  G  R  A  D  C  G  I  T  S  A  S  Y  Q  Q  G  V  L  S          
AAACCTGTCACACAGAACATCAGTGCAGAGGCCTGGGGCCGAGCAGACTGTGGGATTACCTCAGCATCCTATCAACAAGGGGTCTTGTCT 
 
 A  T  I  L  Y  E  I  L  L  G  K  A  T  L  Y  A  V  L  V  S  T  L  V  V  M  A  M  V  K  R          
GCCACCATCCTCTATGAGATCCTGCTAGGGAAAGCCACCCTGTATGCTGTGCTTGTCAGTACACTGGTGGTGATGGCTATGGTCAAAAGA 
 





TRBV5*03 chain sequence 303 AA 909 bp (Leader-V-D-J-Constant) 
(http://www.nature.com/nature/journal/v316/n6028/pdf/316517a0.pdf)  
BW5147 TCR selected for its non-immunosuppressive characteristics. 
 
 M  S  C  R  L  L  L  Y  V  S  L  C  L  V  E  T  A  L  M  N  T  K  I  T  Q  S  P  R  Y  L        
ATGAGCTGCAGGCTTCTCCTCTATGTTTCCCTATGTCTTGTGGAAACAGCACTCATGAACACTAAAATTACTCAGTCACCAAGATATCTA 
 
 I  L  G  R  T  N  K  S  L  E  C  E  Q  H  L  G  H  N  A  M  Y  W  Y  K  Q  S  A  E  K  P          
ATCCTGGGAAGAACAAATAAGTCTTTGGAATGTGAGCAACATCTGGGACATAATGCTATGTACTGGTATAAACAGAGCGCTGAGAAGCCG 
 
 P  E  L  M  F  L  Y  N  L  K  Q  L  I  R  N  E  T  V  P  S  R  F  I  P  E  C  P  D  S  S         
CCAGAGCTCATGTTTCTCTACAATCTTAAACAGTTGATTCGAAATGAGACGGTGCCCAGTCGTTTTATACCTGAATGCCCAGACAGCTCC 
 
 K  L  L  L  H  I  S  A  V  D  P  E  D  S  A  V  Y  F  C  A  S  S  Q  I  T  S  N  Q  D  T          
AAGCTACTTTTACATATATCTGCCGTGGATCCAGAAGACTCAGCTGTCTATTTTTGTGCCAGCAGCCAGATAACTAGTAACCAAGACACC 
 
 Q  Y  F  G  P  G  T  R  L  L  V  L  E  D  L  R  N  V  T  P  P  K  V  S  L  F  E  P  S  K          
CAGTACTTTGGGCCAGGCACTCGGCTCCTCGTGTTAGAGGATCTGAGAAATGTGACTCCACCCAAGGTCTCCTTGTTTGAGCCATCAAAA 
 
 A  E  I  A  N  K  Q  K  A  T  L  V  C  L  A  R  G  F  F  P  D  H  V  E  L  S  W  W  V  N          
GCAGAGATTGCAAACAAACAAAAGGCTACCCTCGTGTGCTTGGCCAGGGGCTTCTTCCCTGACCACGTGGAGCTGAGCTGGTGGGTGAAT 
 
 G  K  E  V  H  S  G  V  S  T  D  P  Q  A  Y  K  E  S  N  Y  S  Y  C  L  S  S  R  L  R  V          
GGCAAGGAGGTCCACAGTGGGGTCAGCACGGACCCTCAGGCCTACAAGGAGAGCAATTATAGCTACTGCCTGAGCAGCCGCCTGAGGGTC 
 
 S  A  T  F  W  H  N  P  R  N  H  F  R  C  Q  V  Q  F  H  G  L  S  E  E  D  K  W  P  E  G          
TCTGCTACCTTCTGGCACAATCCTCGAAACCACTTCCGCTGCCAAGTGCAGTTCCATGGGCTTTCAGAGGAGGACAAGTGGCCAGAGGGC 
 
 S  P  K  P  V  T  Q  N  I  S  A  E  A  W  G  R  A  D  C  G  I  T  S  A  S  Y  H  Q  G  V   
       
TCACCCAAACCTGTCACACAGAACATCAGTGCAGAGGCCTGGGGCCGAGCAGACTGTGGAATCACTTCAGCATCCTATCATCAGGGGGTT 
 
 L  S  A  T  I  L  Y  E  I  L  L  G  K  A  T  L  Y  A  V  L  V  S  G  L  V  L  M  A  M  V          
CTGTCTGCAACCATCCTCTATGAGATCCTACTGGGGAAGGCCACCCTATATGCTGTGCTGGTCAGTGGCCTGGTGCTGATGGCCATGGTC 
 








Figure B.1: Diagram of the expression vectors generated for this study 
The constructs generated for this surface display study included fluorescent protein fusions 
with EGFP, CFP, YFP, and mCherry. Vectors with resistance genes were formed from 
vectors (A) pEGFP-N1 (B) and pIRESPURO3 with G418 and puromycin antibiotic 
resistance genes respectively. The backbone vectors were a gift from the Poenie lab. 
B.2.3: IRES Format creation 
Enzyme Site Location 
EcoRI GAATTC 5’ kozak sequence 
BsiWI CGTACG First protein junction 
BglII AGATCT 5’ of Second protein, end of IRES 
SalI GTCGAC Second protein junction 
NheI GCTAGC 3’ of First protein, start of IRES 
XhoI CTCGAG 3’ of Second protein 
BssHII GCGCGC 3’ EcoRI site 
Table B.5: IRES cloning sites  
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B.2.4: 2A Peptide Construct 
Gene 1– RAKRGSGVKQTLNFDLLKLAGDVESNPGP177,178 – Gene 2 Signal sequence 
 
L  N  S  T  M  G  S  R  L  F  F  V  L  S  S  L  L  C  S  K  H  M  E  A  A  V  T  Q  S  P   
TTGAATTCCACCATGGGCTCCAGGCTCTTCTTCGTGCTCTCCAGTCTCCTGTGTTCAAAACACATGGAGGCTGCAGTCACCCAAAGCCCA 90 
R  N  K  V  A  V  T  G  E  K  V  T  L  S  C  N  Q  T  N  N  H  N  N  M  Y  W  Y  R  Q  D   
AGAAACAAGGTGGCAGTAACAGGAGAGAAGGTGACATTGAGCTGTAATCAGACTAATAACCACAACAACATGTACTGGTATCGGCAGGAC 180 
T  G  H  G  L  R  L  I  Y  Y  S  Y  G  A  G  S  T  E  K  G  D  I  P  D  G  Y  K  A  S  R   
ACGGGGCATGGGCTGAGGCTGATCTACTATTCATATGGTGCTGGCAGCACTGAGAAAGGAGATATCCCTGATGGATACAAGGCCTCTAGA 270 
P  S  R  E  N  F  S  L  T  L  E  S  A  T  P  S  Q  T  S  V  Y  F  C  A  S  G  S  G  T  T   
CCAAGCCGAGAGAACTTCTCCCTCACTCTGGAGTCGGCTACCCCCTCTCAGACATCAGTGTACTTCTGTGCCAGCGGCTCCGGGACAACA 360 
N  T  E  V  F  F  G  K  G  T  R  L  T  V  V  E  D  L  R  N  V  T  P  P  K  V  S  L  F  E   
AACACAGAAGTCTTCTTTGGTAAAGGAACCAGACTCACAGTTGTAGAGGACTTGAGAAATGTGACTCCACCCAAGGTCTCCTTGTTTGAG 450 
P  S  K  A  E  I  A  N  K  Q  K  A  T  L  V  C  L  A  R  G  F  F  P  D  H  V  E  L  S  W   
CCATCAAAAGCAGAGATTGCAAACAAACAAAAGGCTACCCTCGTGTGCTTGGCCAGGGGCTTCTTCCCTGACCACGTGGAGCTGAGCTGG 540 
W  V  N  G  K  E  V  H  S  G  V  S  T  D  P  Q  A  Y  K  E  S  N  Y  S  Y  C  L  S  S  R   
TGGGTGAATGGCAAGGAGGTCCACAGTGGGGTCAGCACGGACCCTCAGGCCTACAAGGAGAGCAATTATAGCTACTGCCTGAGCAGCCGC 630 
L  R  V  S  A  T  F  W  H  N  P  R  N  H  F  R  C  Q  V  Q  F  H  G  L  S  E  E  D  K  W   
CTGAGGGTCTCTGCTACCTTCTGGCACAATCCTCGAAACCACTTCCGCTGCCAAGTGCAGTTCCATGGGCTTTCAGAGGAGGACAAGTGG 720 
P  E  G  S  P  K  P  V  T  Q  N  I  S  A  E  A  W  G  R  A  D  C  G  I  T  S  A  S  Y  H   
CCAGAGGGCTCACCCAAACCTGTCACACAGAACATCAGTGCAGAGGCCTGGGGCCGAGCAGACTGTGGAATCACTTCAGCATCCTATCAT 810 
Q  G  V  L  S  A  T  I  L  Y  E  I  L  L  G  K  A  T  L  Y  A  V  L  V  S  G  L  V  L   
CAGGGGGTTCTGTCTGCAACCATCCTCTATGAGATCCTACTGGGGAAGGCCACCCTATATGCTGTGCTGGTCAGTGGCCTGGTGCTGATG 900 
A  M  V  K  K  K  N  S  R  A  K  R  G  S  G  V  K  Q  T  L  N  F  D  L  L  K  L  A  G  D   
GCCATGGTCAAAAAAAAAAATTCCAGAGCCAAAAGGGGATCCGGCGTGAAGCAGACACTCAACTTCGACCTGCTGAAGCTTGCGGGCGAC 990 
V  E  S  N  P  G  P  G  E  Q  V  E  Q  L  P  S  I  L  R  V  Q  E  G  S  S  A  S  I  N  C   
GTGGAATCTAACCCTGGCCCTGGCGAGCAGGTGGAGCAGCTTCCTTCCATCCTGAGAGTCCAGGAGGGATCCAGTGCCAGCATCAACTGC 1080 
T  Y  E  N  S  A  S  N  Y  F  P  W  Y  K  Q  E  P  G  E  N  P  K  L  I  I  D  I  R  S  N   
ACTTATGAGAACAGTGCCTCCAACTACTTCCCTTGGTATAAGCAAGAACCTGGAGAGAATCCTAAGCTCATCATTGACATTCGTTCAAAT 1170 
M  E  R  K  Q  T  Q  G  L  I  V  L  L  D  K  K  A  K  R  F  S  L  H  I  T  D  T  Q  P  G   
ATGGAAAGAAAGCAGACCCAAGGACTCATCGTTTTACTGGATAAGAAAGCCAAACGCTTCTCCCTGCACATCACAGACACCCAGCCTGGA 1260 
D  S  A  M  Y  F  C  A  A  S  P  N  Y  N  V  L  Y  F  G  S  G  T  K  L  T  V  E  P  N  I   
GACTCAGCCATGTACTTCTGTGCTGCAAGTCCTAATTACAACGTGCTTTACTTCGGATCTGGCACCAAACTCACTGTAGAGCCAAACATC 1350 
Q  N  P  E  P  A  V  Y  Q  L  K  D  P  R  S  Q  D  S  T  L  C  L  F  T  D  F  D  S  Q  I   
CAGAACCCAGAACCTGCTGTGTACCAGTTAAAAGATCCTCGGTCTCAGGACAGCACCCTCTGCCTGTTCACCGACTTTGACTCCCAAATC 1440 
N  V  P  K  T  M  E  S  G  T  F  I  T  D  K  T  V  L  D  M  K  A  M  D  S  K  S  N  G  A   
AATGTGCCGAAAACCATGGAATCTGGAACGTTCATCACTGACAAAACTGTGCTGGACATGAAAGCTATGGATTCCAAGAGCAATGGGGCC 1530 
I  A  W  S  N  Q  T  S  F  T  C  Q  D  I  F  K  E  T  N  A  T  Y  P  S  S  D  V  P  C  D   
ATTGCCTGGAGCAACCAGACATCCTTCACCTGCCAAGATATCTTCAAAGAGACCAACGCCACCTACCCCAGTTCAGACGTTCCCTGTGAT 1620 
A  T  L  T  E  K  S  F  E  T  D  M  N  L  N  F  Q  N  L  S  V  M  G  L  R  I  L  L  L  K   
GCCACGTTGACTGAGAAATCCTTTGAAACAGATATGAACCTAAACTTTCAAAACCTGTCAGTTATGGGACTCCGAATCCTCCTGCTGAAA 1710 





 L  N  S  T  M  G  W  S  C  I  I  L  F  L  V  A  T  A  T  G  V  H  S  E  A  A  V  T  Q  S   
TTGAATTCCACCATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACACTCGGAGGCTGCAGTCACCCAAAGC 90 
 P  R  N  K  V  A  V  T  G  E  K  V  T  L  S  C  N  Q  T  N  N  H  N  N  M  Y  W  Y  R  Q   
CCAAGAAACAAGGTGGCAGTAACAGGAGAGAAGGTGACATTGAGCTGTAATCAGACTAATAACCACAACAACATGTACTGGTATCGGCAG 180 
 D  T  G  H  G  L  R  L  I  Y  Y  S  Y  G  A  G  S  T  E  K  G  D  I  P  D  G  Y  K  A  S   
GACACGGGGCATGGGCTGAGGCTGATCTACTATTCATATGGTGCTGGCAGCACTGAGAAAGGAGATATCCCTGATGGATACAAGGCCTCT 270 
 R  P  S  Q  E  N  F  S  L  T  L  E  S  A  T  P  S  Q  T  S  V  Y  F  C  A  S  G  S  G  T   
AGACCAAGCCAAGAGAACTTCTCCCTCACTCTGGAGTCGGCTACCCCCTCTCAGACATCAGTGTACTTCTGTGCCAGCGGCTCCGGGACA 360 
 T  N  T  E  V  F  F  G  K  G  T  R  L  T  V  V  G  G  G  G  S  G  G  G  G  S  G  G  G  G   
ACAAACACAGAAGTCTTCTTTGGTAAAGGAACCAGACTCACAGTTGTAGGTGGAGGCGGTTCAGGCGGAGGTGGCTCCGGAGGCGGTGGT 450 
 S  G  G  G  G  S  E  Q  V  E  Q  L  P  S  I  L  R  V  Q  E  G  S  S  A  S  I  N  C  T  Y   
TCTGGAGGAGGAGGATCCGAGCAGGTGGAGCAGCTTCCTTCCATCCTGAGAGTCCAGGAGGGATCCAGTGCCAGCATCAACTGCACTTAT 540 
 E  N  S  A  S  N  Y  F  P  W  Y  K  Q  E  P  G  E  N  P  K  L  I  I  D  I  R  S  N  M  E   
GAGAACAGTGCCTCCAACTACTTCCCTTGGTATAAGCAAGAACCTGGAGAGAATCCTAAGCTCATCATTGACATTCGTTCAAATATGGAA 630 
 R  K  Q  T  Q  G  L  I  V  L  L  D  K  K  A  K  R  F  S  L  H  I  T  D  T  Q  P  G  D  S   
AGAAAGCAGACCCAAGGACTCATCGTTTTACTGGATAAGAAAGCCAAACGCTTCTCCCTGCACATCACAGACACCCAGCCTGGAGACTCA 720 
 A  M  Y  F  C  A  A  S  P  N  Y  N  V  L  Y  F  G  S  G  T  K  L  T  V  E  P  I  E  F  M   
GCCATGTACTTCTGTGCTGCAAGTCCTAATTACAACGTGCTTTACTTCGGATCTGGCACCAAACTCACTGTAGAGCCAATTGAGTTCATG 810 
 Y  P  P  P  Y  L  D  N  E  R  S  N  G  T  I  I  H  I  K  E  K  H  L  C  H  T  Q  S  S  P   
TACCCTCCGCCTTACCTAGACAACGAGAGGAGCAATGGAACTATTATTCACATAAAAGAGAAACATCTTTGTCATACTCAGTCATCTCCT 900 
 K  L  F  W  A  L  V  V  V  A  G  V  L  F  C  Y  G  L  L  V  T  V  A  L  C  V  I  W  T  N   
AAGCTGTTTTGGGCACTGGTCGTGGTTGCTGGAGTCCTGTTTTGTTATGGCTTGCTAGTGACAGTGGCTCTTTGTGTTATCTGGACAAAT 990 
 S  R  R  N  R  L  L  Q  S  D  Y  M  N  M  T  P  R  R  P  G  L  T  R  K  P  Y  Q  P  Y  A   
AGTAGAAGGAACAGACTCCTTCAAAGTGACTACATGAACATGACTCCCCGGAGGCCTGGGCTCACTCGAAAGCCTTACCAGCCCTACGCC 1080 
 P  A  R  D  F  A  A  Y  R  P  S  R  A  K  F  S  R  S  A  E  T  A  A  N  L  Q  D  P  N  Q   
CCTGCCAGAGACTTTGCAGCGTACCGCCCCAGCAGAGCAAAATTCAGCAGGAGTGCAGAGACTGCTGCCAACCTGCAGGACCCCAACCAG 1170 
 L  Y  N  E  L  N  L  G  R  R  E  E  Y  D  V  L  E  K  K  R  A  R  D  P  E  M  G  G  K  Q   
CTCTACAATGAGCTCAATCTAGGGCGAAGAGAGGAATATGACGTCTTGGAGAAGAAGCGGGCTCGGGATCCAGAGATGGGAGGCAAACAG 1260 
 Q  R  R  R  N  P  Q  E  G  V  Y  N  A  L  Q  K  D  K  M  A  E  A  Y  S  E  I  G  T  K  G   
CAGAGGAGGAGGAACCCCCAGGAAGGCGTATACAATGCACTGCAGAAAGACAAGATGGCAGAAGCCTACAGTGAGATCGGCACAAAAGGC 1350 
 E  R  R  R  G  K  G  H  D  G  L  Y  Q  G  L  S  T  A  T  K  D  T  Y  D  A  L  H  M  Q  T   
GAGAGGCGGAGAGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGCACTGCCACCAAGGACACCTATGATGCCCTGCATATGCAGACC 1440 





AbVec Signal sequence, (MGWSCIILFLVATATGVHS) 
SH2 binding site, Tyr can become phosphorylated (PYAP) 
ITAMS YXX(I/L)X(6-8)YXX(I/L)  
HindIII (AAGCTT) 
NotI (GCGGCCGC) 
Approximate size: 1460 bp, 485 AA, 53.5 kDa 
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AbVec	SS.	 MGWSCIILFLVATATGVHS   
TCR	consensus	 MLMGTRLLCWVALCLLGAGHV   









mCD3γ	 MEQRKGLAGLFLVISLLQ IGTISGFIFAEVISIFFLALGVYLIAG 
mCD3δ	 MEHSGILASLILIAVLPQ GVIFIDLIATLLLALGVYCFA 
mCD3ε	 MRWNTFWGILCLSLLAV DLTAVAIIIIVDICITLGLLMVIYYW 
mCD3ζ	 MKWKVSVLACILHVRFPGAE LCYLLDGILFIYGVIITALY 
mCD4	 MCRAISLRRLLLLLLQLSQL VFLACVLGGSFGFLGFLGLCILC 
mCD8	α	 MASPLTRFLSLNLLLLGESIILGSGEA IWAPLAGICVAPLLSLII 
mCD8	β	 MQPWLWLVFSMKLAALWS LSLLVVCILLLLAFLGVAVYFY 
mCD28	 MTLRLLFLALNFFSVQVT FWALVVVAGVLFCYGLLVTVALCVIW 
hCD8	α	 MALPVTALLLPLALLLHAARP IYIWAPLAGTCGVLLLSLVIT 
hCD8	β	 MRPRLWLLLAAQLTVLHGNSV ITLGLLVAGVLVLLVSLGVAI 
Gaussia	Luciferase	 MGVKVLFALICIAVAEA   
Table B.6: Sample signal sequences in immune-proteins 
Consensus signal sequences for antibodies and TCRs generated using all functional v-
region signal sequences and ClustalΩ. 
C: CANONICAL AND  HTS SQL PROGRAM SCRIPTS 
 Program scripts for the canonical loop structural analysis are located in the separate 
supplemental materials file due to their length.  
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Glossary 
2A: self-cleaving peptidase peptide signal 
APC: antigen presenting cell 
CAR: chimeric antigen receptor 
CD: cluster of differentiation 
CDR: complementarity determining region 
FACS: fluorescence-activated cell sorting 
FR: framework residue 
HTS: high-throughput sequencing 
IL-2: interleukin 2 
IMGT: Immuno-genetics Database 
IRES: internal ribosome entry site 
OVA: chicken-ovalbumin 
PDB: Protein Data Bank 
pMHC: peptide-major histocompatibility complex 
RT: Room temperature 
RT-PCR: Reverse transcription polymerase chain reaction 
SPR: surface plasmon resonance 
scTCR: single-chain T-cell receptor 
TCR: T-cell receptor 
TM: transmembrane 
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